Please can you provide the following information for financial years FY2016/17, FY2017/18, FY2018/19, FY2019/20, FY2020/21, current financial year to date (FY2021/22 YTD):
1) Please provide the top 5 ON framework 3rd Party providers for nursing staff, by name, used by your trust for each of the listed financial years
2) Please provide the total annual expenditure for each of the top 5 ON framework 3rd Party providers, for nursing staff, used by your trust for each of the listed financial years
3) Please provide the top 5 OFF framework 3rd Party providers for nursing staff, by name, used by your trust for each of the listed financial years
4) Please provide the total annual expenditure for each of the top 5 OFF framework 3rd Party providers, for nursing staff, used by your trust for each of the listed financial years

3rd Party Temporary Staffing Providers. 110222.docx

1. The amount spent on employing agency, temporary and/or locum doctors in A&E departments in each month in 2019 and 2020.
2. The number of FTE roles in A&E departments covered by agency, temporary and/or locum doctors in each month in 2019 and 2020.
3. The total number of FTE doctors (including agency, temporary and/or locum and permanent staff) working in A&E departments in each month in 2019 and 2020.

Download response A&E agency staff and cost. 141021.docx

All questions are shown as received by the Trust.
1. In the period 1st July 2024 to 30th September 2024 please provide a breakdown of:
a. Total trust spend with framework agencies for locum nurses
Please provide a further breakdown for locum nurses by:
b. Spend per band
c. Spend per agency name
2. In the period 1st July 2024 to 30th September 2024 please provide a breakdown of:
a. Total trust spend with off framework agencies for locum nurses
Please provide a further breakdown for locum nurses by:
b. Spend per band
c. Spend per agency name
3. In the period 1st July 2024 to 30th September 2024 please provide a breakdown of:
a. Total trust spend with the internal trust bank or associated external provider for locum nurses
Please provide a further breakdown for locum nurses by:
b. Spend per band
c. Spend per agency name

4. Please confirm the total number of nursing shifts booked during this period (1st July 2024 to 30th September 2024)
5. Please confirm the total number of nursing shifts booked above NHSE capped rates during this period (1st July 2024 to 30th September 2024)

Agency and Bank nursing spend.311024.docx

All questions are shown as received by the Trust.
In the period 1st February 2024 to 30th April 2024 please provide a breakdown of:
1. Total trust spend with framework agencies for locum doctors
Please provide a further breakdown for locum doctors by:
a. Spend per grade
b. Spend per specialty
c. Spend per agency name

In the period of 1st February 2024 to 30th April 2024 please provide a breakdown of:
2. Total trust spend with off-framework agencies for locums doctors
Please provide a further breakdown for locum doctors by:
a. Spend per grade
b. Spend per specialty
c. Spend per agency name

In the period of 1st February 2024 to 30th April 2024 please provide a breakdown of:
3. Total trust spend with the internal trust bank or associated external provider for locum doctors
Please provide a further breakdown for locum doctors by:
a. Spend per grade
b. Spend per specialty
c. Spend per internal or associated external provider

4. Please confirm your allocated budget for agency locum doctors for the period 1st February 2024 to 30th April 2024.

Agency and Bank spend.070624.docx

1. The total amount spent on agency temporary staff for the year 2021/22 (April ’21 to March ‘22) and between 31/10/2021 to 31/10/2022 for the following categories:
• Doctors
• Nurses
• AHP (all categories)
• Health Care Assistants
2. Bank Spend – Total amount spent on bank staff for the year 2021/22 (April ’21 to March ‘22) and between 31/10/2021 and 31/10/2022 year split into the Trusts’ staff groups (E.g. Medical, Nursing, Admin, AHP etc.) and speciality/grade (E.g. Consultants, GP, ICU Nurse, Acute Nurse, Occupational therapists, Pharmacists, Health Care Assistants, etc.) depending on how this is reported within the Trust.
3. Confirmation on whether the trust bank is currently operated by the trust themselves or by a private provider. If the latter please confirm the name of the provider.
The names and contact information of the individual divisional directors of Surgery covering the following treatment areas:
• General Surgery
• Urology
• Trauma and Orthopaedic
• Ear, Nose and Throat
• Ophthalmology
• Oral Surgery
• Neurosurgical Service
• Cardiothoracic
• Cardiology Service
• Dermatology Service
• Respiratory Medicine Service
• Gynaecology Service
• Rheumatology Service

Agency and Bank staff.100223.docx

Q1: Please can you confirm what percentage of your wage bill is spent on
(a) Agency staff?
(b) Bank staff?
Q2: What does the answer to Q1 (a) equate to in Pounds Sterling (£)?
Q3: What percentage of all your medical and clinical patient facing shifts are filled with staff that are paid above the ‘break glass’ ceiling rate (above the agency rules pay cap)?

Agency and Bank Staff costs.290623.docx

1)The total amount spent by the Trust on bank staff in 2021/22
2) The total amount spent by the Trust on agency staff in 2021/22
3) The total amount spent by the Trust on bank nurses in 2021/22
4) The total amount spent by the Trust on agency nurses in 2021/22
5) The largest amount spent by the Trust on a single agency nurse shift in 2021/22

Agency and Bank staff spend.181022.docx

1. Please provide agency spend for the staff group for the Financial Year 2021-22 (please specify your start and end date used) Financial Year indicating what percentage is on and off-framework (for example, “£4,650,000 – c80% framework / 20% off-framework”).
2. Please provide bank spend for the staff group for Financial Year 2021-22 (please specify your start and end date used)
3. Please confirm which model you have in place for managing agency within the staff group: Email to preferred supplier List, a Master Vendor, a Neutral Vendor, or a Software cascade to a preferred supplier list
4. Please confirm what percentage of bookings over the last 6 months have been within the NHSI agency caps (an approximation based on NHSI data submissions is fine)
5. Please confirm which provider manages your direct engagement process, the fee for the service and the date on which this contract expires (no this is not relevant for Nursing)
6. Please confirm what percentage of bookings are processed with a VAT savings by your direct engagement (DE) provider (average for last 3 months –December, January and February)
7. Is your bank managed by an external bank provider (e.g., NHS Professionals, Bank Partners) or in-house? Please confirm who is the external bank provider and when the contract expires if relevant
8. Is your bank managed via software? If so, please confirm which software.
9. Is the Trust likely to undertake any procurement activity over the next 18 months related to provision or bank or agency services or software for the relevant staff group?
10. If you have a managed service, master vendor or neutral vendor in place for Agency medics/Agency doctors please confirm who this contract is with and the date on which this contract expires
11. If you have a managed service, master vendor or neutral vendor in place for Agency Nurses please confirm who this contract is with and the date on which this contract expires

Agency and Bank staffing and spend.150822.docx

1. What is the total value of spend by your NHS Trust with on-framework and off-framework recruitment agencies by staff group (see staff groups below) on a temporary basis? Please provide this information for the following years (please fill in the tables below).
Note: Please provide total spend inclusive of salaries and agency margin / fees.
Note: If cannot provide split of spend by on- vs off- framework agencies, please provide total spend.
2. Do you use insourcing providers?
Note: Insourcing definition: Insourcing of Clinical Services – NHS SBS
3. If yes to previous question (use of insourcing providers), what is the total value of spend, listed by speciality and insourcing provider used for Apr-22 to Mar-23?
Note: If an insourcing provider covers multiple specialities, please list that provider multiple times (one row for each speciality).

Agency and insourcing spend.260723.docx

1.) A) Last financial year agency locum spend
B) Please break down into Specialty and Grade
2.) A) The retention rates for permanent and fixed term staff – Doctors and Nurses only
B) Please break down into Specialty and Grade
3.) A) Please provide the Names of agencies used to fill vacancies
B) how much each agency charges
4.) Please provide your trust wide budgeted establishment per specialty and grade for Doctors
– Name of Speciality / Division or Directorate
– Consultants, Locum Consultant Contract and Associate Specialists
– CT/ST3 – CT/ST7, Specialty Doctors, Senior Clinical Fellows, CESR Fellow or Middle Grade Level
– FY1-ST2, Trust Grade, Junior Clinical Fellow or SHO level
5.) Please what is your actual current establishment for Doctor
– Name of Speciality / Division or Directorate
– Consultants, Locum Consultant Contract and Associate Specialists
– CT/ST3 – CT/ST7, Specialty Doctors, Senior Clinical Fellows, CESR Fellow or Middle Grade Level
– FY1-ST2, Trust Grade, Junior Clinical Fellow or SHO level

Agency and Staff details.260423.docx

How much have you spent on agency staff during days in which industrial action was taken by staff in your trust since 1st December 2022?

Agency costs during industrial action.030823.docx

All questions are shown as received by the Trust.
How much have you spent on agency staff during days in which industrial action was taken by staff in your trust since 1st December 2022?

Agency costs during industrial action.170823.docx

1. The Trust’s spend on agency workers (both on-framework and off-framework);
2. By role type;
3. With which provider/s and how much the Trust spends;
4. and when the current contract ends with your agency staffing provider.

Agency details.230623.docx

You asked: All questions are shown as received by the Trust.
1. How much have you spent on agency midwives each of the last five years?

2. What was the most expensive agency midwife shift over the last five years?

Agency midwives.140923.docx

All questions are shown as received by the Trust.
1.
(a) Who is the head of procurement that is responsible for approving Nursing agency usage?
(b) Secondly, who is the temporary / flexible staffing lead responsible for the management of this service ?
2. Please can you provide the contact number and email address in relation to both question 1 (a) and (b)
3.
(a) Can you please confirm the names of all OFF-Framework agencies currently supplying to your trust for the following staffing groups: Registered General Nurses (RGNs) & Registered Mental-health Nurses (RMNs), Accident & Emergency (A&E)/Intensive Therapy Unit (ITU) Nurses, Prison nurses and Theatre Nurses
(b) Secondly, Can you please confirm the volume of supply, by number of shifts filled and & shift type, by each OFF-Framework agency during October 1st 2023 – February 29th 2024
4. How much was your OFF-Framework agency spend for each of the following staff groups between January 2024 – April 2024
(a) RGN’s
(b) Chemotherapy Nurses
(c) RMN
(d) ITU Nurse
(e) A&E nurse
(f) Prison Nurses
(g) Theatre nurses
(h) Neonatal nurses

Agency nurses.250424.docx

Could you provide me with a breakdown of spend on agency nurses and midwives between May 2022 and May 2023 as below
1. Number of shifts invoiced by each provider trust has used for agency nursing
2. Framework spend on agency nursing and midwifery broken down to spend per Framework provider
3. Off-framework spend on agency nursing and midwifery broken down to spend per off-framework provider

Agency nurses and midwives.240523.docx

All questions are shown as received by the Trust.
Please can you confirm how much was spent on agency nursing between the period April 1st 2023 and 31st June 2023?

Further to this, please can you confirm how much of this total was spent with Off-framework agencies?

Agency nursing.160823.docx

Please could you answer the following questions in relation to the trusts agency nursing usage in financial year 2022-2023
1. How much in total did the trust spend on agency nursing supply?
2. How was that total split between Community/ Acute/ Mental Health Nursing (please delete as appropriate)?
3. Of the total spend, how much of it was spent with off-framework agencies?
4. Who within the trust is responsible for reporting on off-framework usage?

Agency Nursing.200723.docx

All questions are shown as received by the Trust.
Please answer all questions with the relevant data for the month of March 2023 ( 1st to the 31st March ) for your nursing – inclusive of Adult, Mental Health, Critical, Community and District where applicable for both frameworks and off frameworks Agencies.
Information requested :
1. The total number and spend of nursing shifts sent to agencies to fill ( frameworks and off frameworks ) Please provide these totals separately
2. The total number and spend of nursing shifts filled by agencies ( frameworks and off frameworks ) Please provide these totals separately
3. The total number and spend of critical banded nursing shifts sent to agencies to fill. ( frameworks and off frameworks ) Please provide these totals separately
4. The total number and spend of critical banded nursing shifts filled by agencies. ( frameworks and off frameworks ) Please provide these totals separately
5. The total number and spend of ‘breaches’ for filling a shift with agency nurses (Registered Nurses) not within the NHSI capped charge rates.
6. Please provide a list of all frameworks agencies that are currently ‘breaching’ ‘breaches’ when filling a shift with agency nurses (Registered Nurses) not within the NHSI capped charge rates.
7. Please provide a list of all frameworks agencies which supply the trust with nursing staff.
8. Please provide a list of off framework agencies which have supplied (from 1st January 2023 to 31st March 2023) into the trust with nursing staff across all sites.
9. From 1st March 2023 to 31st March 2023, please list the wards/ departments you have requested shifts for off framework agencies.

Agency Nursing.230823.docx

All questions are shown as received by the Trust.
For nursing registered and unregistered please could you share the below agency data:
1. For registered Nursing
a. How many hours were used in the last year?
b. What is your spend over the corresponding period?
2. For unregistered Nursing
a. How many hours were used in the last year?
b. What is your spend over the corresponding period?
Please could you also confirm if you have a:
3. Master vendor and their contract end date?
4. Neutral vendor and their contract end date?

Agency Nursing, Master Vendor and Neutral Vendor.160823.docx

1) How many agency nursing shifts have your Trust used SNG or Thornbury Nursing Services for between 1st December 2021 and 10th February 2022
2) Please provide a breakdown of the number of shifts per ward or department where SNG or Thornbury Nursing Services were used between 1st December 2021 and 10th February 2022
3) How many agency nursing shifts have your Trust used Nutrix, MED GEN, Greenstaff for between 1st December 2021 and 10th February 2022?
4) Please provide a breakdown of the number of shifts per ward or department where Nutrix, or Greenstaff were used between 1st December 2021 and 10th February 2022
5) Please name any other OFF CONTRACT SUPPLIERS who have been utilised by the Trust between 1st December 2021 and 10th February 2022
6) If for any reason you are unable to supply data up until 10th February please provide the data until 31st January 2022

Agency nursing shifts. 210222.docx

1. Can you confirm names of all agencies supplying into the trust directly or via the NHS Professionals platform for nursing staff specifically for both Band 2 and Band 5 requirements, including off-framework agencies.
a. With the above information, can this be broken down by
• Volume of supply (per month for the last 12 months)
• Total trust spend per agency (per month for the last 12 months)
• By AfC banding of shift request and speciality of nurse
2. Please can you confirm how many shifts have been filled by agencies supplying Band 5 Registered Nursing staff at or below NHSI agency capped rates within the last 12 month period?
3. Please can you confirm how many shifts have been filled by agencies supplying Band 5 Registered Nursing staff above NHSI agency capped rates within the last 12 month period?
4. For the same 12 month period, can you confirm the average charge rate per hour for Band 5 Nursing agency staff across:
Week Days:
Night Shift/Saturday shifts:
Sunday shift/Bank Holiday:
5. Lastly can you confirm the highest agency nurse hourly charge rate, and their speciality?

Agency Nursing Spend.260822.docx

All questions are shown as received by the Trust.
In the period 1st January 2024 to 30th June 2024 please provide a breakdown of:
1. Total trust spend with framework agencies for locum nurses
Please provide a further breakdown for locum nurses by:
2. Spend per band
3. Spend per agency name
In the period 1st January 2024 to 30th June 2024 please provide a breakdown of:
4. Total trust spend with off framework agencies for locum nurses
Please provide a further breakdown for locum nurses by:
5. Spend per band
6. Spend per agency name
In the period 1st January 2024 to 30th June 2024 please provide a breakdown of:
7. Total trust spend with the internal trust bank or associated external provider for locum nurses
Please provide a further breakdown for locum nurses by:
8. Spend per band
9. Spend per agency name
10. Please confirm the total number of nursing shifts booked during this period (1st January 2024 to 30th June 2024)
11. Please confirm the total number of nursing shifts booked above NHSE capped rates during this period (1st January 2024 to 30th June 2024)

Agency nursing spend.290824.docx

Please can I have the following information under The Freedom of Information Act (FOIA)
Total Spend on Temporary Locums broken down into the following specialties and sites of the Trust – From April 2022 – April 2023
Medicine
Surgery
Trauma & Orthopaedics
Paediatrics
A&E
Anaesthetics
Obstetrics & Gynaecology

Agency spend.300623.docx

All questions are shown as received by the Trust.
1. Total Spend on Temporary Locums broken down into the following specialties and sites of each Trust belonging to NHS England – From April 2023 – May 2024

Surgery – Breast
Surgery – Cardiothoracic
Surgery – Colorectal
Surgery – ENT
Surgery -General Surgery
Surgery – Lower GI
Surgery – Max Fax
Surgery – Neurosurgery
Surgery – Ophthalmology
Surgery – Plastic
Surgery – Upper GI
Surgery – Vascular
Surgery – Trauma & Orthopaedics
Paediatrics
Neonates
A&E
Anaesthetics
Obstetrics & Gynaecology

2. Locum Agency providers – Please can you advise which locum agencies you use to fill the following areas.

Surgery – Breast
Surgery – Cardiothoracic
Surgery – Colorectal
Surgery – ENT
Surgery -General Surgery
Surgery – Lower GI
Surgery – Max Fax
Surgery – Neurosurgery
Surgery – Ophthalmology
Surgery – Plastic
Surgery – Upper GI
Surgery – Vascular
Surgery – Trauma & Orthopaedics
Paediatrics
Neonates
A&E
Anaesthetics
Obstetrics & Gynaecology

3. Department contact’s – Please can you provide name and email address of the following departments,

Surgery – Breast
Rota Coordinator
Service Manager
Clinical Lead

Surgery – Cardiothoracic
Rota Coordinator
Service Manager
Clinical Lead

Surgery – Colorectal
Rota Coordinator
Service Manager
Clinical Lead

Surgery – ENT
Rota Coordinator
Service Manager
Clinical Lead

Surgery -General Surgery
Rota Coordinator
Service Manager
Clinical Lead

Surgery – Lower GI
Rota Coordinator
Service Manager
Clinical Lead

Surgery – Max Fax
Rota Coordinator
Service Manager
Clinical Lead

Surgery – Neurosurgery
Rota Coordinator
Service Manager
Clinical Lead

Surgery – Ophthalmology
Rota Coordinator
Service Manager
Clinical Lead

Surgery – Plastic
Rota Coordinator
Service Manager
Clinical Lead

Surgery – Upper GI
Rota Coordinator
Service Manager
Clinical Lead

Surgery – Vascular
Rota Coordinator
Service Manager
Clinical Lead

Surgery – Trauma & Orthopaedics
Rota Coordinator
Service Manager
Clinical Lead

Paediatrics
Rota Coordinator
Service Manager
Clinical Lead

Neonates
Rota Coordinator
Service Manager
Clinical Lead

A&E
Rota Coordinator
Service Manager
Clinical Lead

Anaesthetics
Rota Coordinator
Service Manager
Clinical Lead

Obstetrics & Gynaecology
Rota Coordinator
Service Manager
Clinical Lead

Agency Spend, Agency Locums, Department Contacts.240624.docx

All questions are shown as received by the Trust.
Please can I have the following information under The Freedom of Information Act (FOIA) – There are three separate points,
1. Total Spend on Temporary Locums (Agency – Doctors Only NOT BANK LOCUMS) broken down into the following specialties and sites of each Trust belonging to NHS England – From January 2024 – August 2024
Anaesthetics
ICU
2. Locum Agency providers – Please can you advise which locum agencies you use to fill the following areas.
Anaesthetics
ICU
3. Department contact’s – Please can you provide name or email address of the following departments,
Anaesthetics
Rota Coordinator
Service Manager
Clinical Lead
ICU
Rota Coordinator
Service Manager
Clinical Lead

Agency spend and staffing.290824.docx

I would like to request the following information:

The trusts total temp agency spend for the financial year 22/23 broken down by Doctors, Nursing and AHP spend.

Agency spend for 2022-2023.210623.docx

The total amount spent on agency temporary staff between January 21 – December 21 for the following categories:
Doctors
Nurses
AHP’s

Agency Spend for Doctors, Nurses and Allied Health Professionals. 070222.docx

I would like to request the below information from the trust for year 2021/2022.
1. What was your agency spend for nursing and midwifery for the year April 2021- April 2022?
2. How much of the spend was above the NHSI rate caps April 2021- April 2022?
3. Have you used off-framework in the last 6 months?
4. If so, what was the total spend?
5. Which off-framework agencies have you used?
6. How many unfilled shifts have you had for:
a. A&E
b. ITU
c. General
d. Theatres
e. Mental Health
f. CPN
g. Midwifery
h. Paediatrics
i. Neonatal
j. HCA
7. If this cannot be provided via speciality, please could I have an over-all number?
8. How many vacancies do you have for band 5/6 nurses in the following areas?
a. A&E
b. ITU
c. General
d. Theatres
e. Mental Health
f. CPN
g. Midwifery
h. Paediatrics
i. Neonatal
j. HCA
9. How many incident/critical incidents have been declared as a result of staffing?
10. Who is the nurse bank/temporary staffing manager?
11. What are the contact details for the Nurse Bank / Temporary Staffing Manager?

Agency spend for nursing and midwifery.211122.docx

All questions are shown as received by the Trust.
1. How much have you spent on agency staff each of the last five years?
a. What was the most expensive agency midwife shift last year?
b. How much on bank midwives each of the past five years?

Agency staff.040923.docx

Please can you provide the following information regarding use of agency staff in your NHS Trust.
Please note there are three parts to this request.
1. Please can you provide the total spend on agency staff in your NHS Trust in the financial year ending April 2022
2. Please can you provide the total spend on agency staff in your NHS Trust in the financial year ending April 2019
3. Please can you provide the total spend on agency staff in your NHS Trust in the financial year ending April 2017

Agency Staff.100822.docx

1. What was your trust spend on agency for the period 1 January 2022 to 31 December 2022 inclusive for the following staff groups: –
a. Registered nurse (RN)
b. Health care support workers/healthcare assistants/nursing associates?

2. What was your trust spend on agency for the period 1 January 2021 to 31 December 2021 inclusive for the following staff groups: –
a. Registered nurse (RN)
b. Health care support workers/healthcare assistants/nursing associates?

3. What was your trust spend on agency for the period I January 2020 to 31 December 2020 inclusive for the following staff groups: –
a. Registered nurse (RN)
b. Health care support workers/healthcare assistants/nursing associates?

Agency Staff.210323.docx

Nurses:
1. Total number of hours of agency nurses used by the Trust in the month of February 2023
2. Of the total number of agency nurse hours used, the number of hours procured ‘off-framework’
3. Of the total number of agency nurse hours used, the number of hours procured at ‘break glass’ or rates above the NHSI rate caps.
4. Of the total number of agency nurse hours used, the number of hours procured at an increased AFC banding i.e. band 5 offered band 6 as an incentive
Healthcare Assistants:
1. Total number of hours of agency healthcare assistants used by the Trust in the month of February 2023
2. Of the total number of agency healthcare assistants hours used, the number of hours procured ‘off-framework’
3. Of the total number of agency healthcare assistants hours used, the number of hours procured at ‘break glass’ or rates above the NHSI rate caps.
Pharmacy Staff:
1. Total number of hours of agency pharmacy staff used by the Trust in the month of February 2023
2. Of the total number of agency pharmacy staff hours used, the number of hours procured ‘off-framework’
3. Of the total number of agency pharmacy staff hours used, the number of hours procured at ‘break glass’ or rates above the NHSI rate caps.

Agency Staff.210823.docx

For Hospitals
1. Hospitals in trust
2. Names of off-framework agencies used between 2021- to date
3. Names of on-framework agencies used between 2021- to date
4. Do you have a master vendor in place?
5. If yes, please provide your account manager’s email
6. Temporary agency staff manager full name
7. Temporary agency staff manager email
8. Temporary agency staff manager telephone
9. Permanent agency staff manager full name
10. Permanent agency staff manager email
11. Permanent agency staff manager telephone
12. Off-framework agency spend between Feb 2021-date
13. Framework agency spend between Feb 2021 – date
14. Total agency shift cancelations Feb 2021-date
For Urgent Care Centres/Walk-in Clinics
1. Urgent treatment / walk-in centres
2. Names of off-framework agencies used between 2021- to date
3. Names of on-framework agencies used between 2021- to date
4. Do you have a master vendor in place?
5. If yes, please provide your account manager’s email
6. Temporary agency staff manager full name
7. Temporary agency staff manager email
8. Temporary agency staff manager telephone
9. Permanent agency staff manager full name
10. Permanent agency staff manager email
11. Permanent agency staff manager telephone
12. Off-framework agency spend between Feb 2021-date
13. Framework agency spend between Feb 2021 – date
14. Total agency shift cancelations Feb 2021-date

Agency Staff Bank.250322.docx

The total amount spent on agency temporary staff for the year 2021/22 (April ’21 to March ‘22) and between 31/10/2021 to 31/10/2022 for the following categories:
• Doctors
• Nurses
• AHP (all categories)
• Health Care Assistants

Agency Staff costs.101122.docx

All questions are shown as received by the Trust.
1. From 1st January 2024 to 1st March 2024, within your Emergency Medicine Departments, how many locum agency doctors were employed by the trust at Middle grade level (ST3 – ST8 level)?
2. From 1st January 2024 to 1st March 2024, within your Emergency Medicine Departments, how much money was spent on agency locum doctors working in the Middle grade (ST3 – ST8 level)?
3. From 1st January 2024 to 1st March 2024, within your Emergency Medicine Departments, how much money was spent on bank doctors covering vacant shifts within the department?

Agency staff in Emergency Medicine.100524.docx

All questions are shown as received by the Trust.
For the most recent month available please provide your usage in terms of financial spend of agency staff for the job types below. Where the information is available, indicate the percentages ‘on-framework’ and ‘off-framework’.

The job types are:
1. Nursing
2. HCAs
3. Pharmacists
4. Pharmacy Technicians

Agency staff spend.050224.docx

All questions are shown as received by the Trust.
For the most recent month available please provide your usage in terms of financial spend of agency staff for the job types below.

Agency staff spend.100524.docx

All questions are shown as received by the Trust.
1. The total (£) spent by the trust on agency nurses and healthcare staff in April 2023 – April 2024?
2. Of the amount spent above, how much was the total (£) spent within Mental Health services?
3. Which agencies have the highest agency spend for temporary nurses?
4. What is the current model for dealing with agency staff, such as NHSP / temporary staffing or other such as master or neutral vendor?
5. If the Trust does have a master or neutral vendor agreement in place for the supply of qualified nursing, when does this end?
6. The total off framework agency spend on temporary nurses and healthcare assistant staff in April 2023 – April 2024.

Agency staffing.070624.docx

All questions are shown as received by the Trust.
1. The total Trust expenditure on framework agencies for the provision of Registered General Nurses, Registered Mental Health Nurses, and Health Care Assistants from 1st January 2024 to 30th June 2024.
2. The total Trust expenditure on off-framework agencies for the provision of Registered General Nurses, Registered Mental Health Nurses, and Health Care Assistants for the same period.
3. The total Trust expenditure through the internal Trust bank from 1st January 2024 to 30th June 2024.
4. The total number of Nursing and Health Care Assistant shifts booked during this period.
5. The total number of Nursing and Health Care Assistant shifts booked above NHSE capped rates during this period.
6. The number of agencies currently assigned to tier 1, tier 2, and tier 3 under Lot 1.

Agency staffing.151024.docx

All questions are shown as received by the Trust.
1. What type of agency arrangement / agreement do you currently have in place for the provision of AHP’s, Doctor’s and Nursing i.e. Preferred Supplier List / Master Vend:
a. AHP – arrangement / agreement type
b. Doctor – arrangement / agreement type
c. Nursing – arrangement / agreement type
2. Who is the arrangement / agreement in place with:
a. AHP – Provider Name(s)
b. Doctor – Provider Name(s)
c. Nursing – Provider Name(s)
3. For each of the above staffing categories, when is the arrangement / agreement up for renewal and how do you intend to come to market:
a. AHP – Renewal Date / Route to Market
b. Doctor – Renewal Date / Route to Market
c. Nursing – Renewal Date / Route to Market

Agency staffing.160724.docx

All questions are shown as received by the Trust.
Question 1: Please provide us with a spend report for Agency Band 5 and Band 6 Nurses from 1st Jan 2024 – 30th June 2024.
Question 2: Can you please provide us with a break down per month of hours filled with Agency workers both Band 5 and Band 6 between 1st Jan 2024 and end of 30th June 2024
Question 3: Can you please provide us with a break down of money spent on off framework agency nurses from 1st Jan 2024-June2024.
Question 4: can you please confirm your top 5 agencies by spend for Band 5 and Band 6 Nurses for the period 1st Jan 2024-30th June 2024.

Agency staffing.180724.docx

All questions are shown as received by the Trust.
1. Does the Trust have a Managed Service (MSP) or MV or an external Bank supplier for the recruitment of agency staff? Please break this down into Doctors, Nursing & AHP if appropriate.
2. If yes, who is that contract with and when does it end?
3. If yes, how did the Trust review whether the supplier followed ethical business practices, what ethical insights did they gather?
4. What steps do the Trust take to ensure suppliers are paying their fair share of taxes and acting with integrity.
5. Who is responsible within the Trust, for ensuring that suppliers follow ethical business practices?

Agency Supply and Ethical Business Practices.190324.docx

I would like to request the following information regarding your agency nurse spend for the months of March, April, and May 2024, specifically for “Band 2 HCAs” and separately for “all other Nursing & Midwifery roles”:
1.Top 10 Nurse Agencies by Spend:
a. Please provide a list of your top 10 nurse agencies by spend for the months of March, April, and May 2024.
b. For each agency, specify whether they are on-framework or off-framework.
c. Provide this information separately for “Band 2 HCAs” and “all other Nursing & Midwifery roles”.
2. On-Framework vs Off-Framework Spend:
a. Provide the total spend for the months of March, April, and May 2024.
b. Break down the spend into on-framework and off-framework categories.
c. Provide this information separately for “Band 2 HCAs” and “all other Nursing & Midwifery roles”.
3. Compliance with NHS England Rate Caps:
a. Specify the number of agency shifts in May 2024 that were compliant with NHS England Rate Caps.
b. Provide this information separately for “Band 2 HCAs” and “all other Nursing & Midwifery roles”.
4. Compliance with Agency Spend Ceiling:
a. Total agency spend (all staff groups, including Nursing & Midwifery (and HCAs), Medical and Dental, Non-Medical Non-Clinical, and any others) between 1st January and 31st May 2024.
b. What does this figure represent as a percentage of the Trust’s total pay bill for the same period.

Agency usage and spend.181124.docx

1. Who is the head of procurement responsible for approving agency usage for Physiotherapy, Occupational Therapy, Pharmacy, Radiography, Speech and Language Therapy and Sterile Services?
2. Who are the managers responsible for agency usage (on and off framework) for the following departments at all hospitals associated with the Trust:
(a) Physiotherapy
(b) Occupational Therapy
(c) Pharmacy
(d) Radiography
(e) Sterile Services
(d) Speech and Language Therapy
3. Please can you provide the contact number and email addresses for the managers listed in relation to question 1 and 2?
4. Have you used off-framework agency staff between March 2021 – March 2022 in the following departments:
(a) Physiotherapy
(b) Occupational Therapy
(c) Pharmacy
(d) Radiography
(e) Sterile Services
(d) Speech and Language Therapy
5. How much was your Off-Framework agency spend for each of the following staff groups between March 2021 – March 2022?
(a) Physiotherapy
(b) Occupational Therapy
(c) Pharmacy
(d) Radiography
(e) Sterile Services
(d) Speech and Language Therapy
6. How many unfilled agency roles did you have between March 2021 – March 2022 for each of the departments outlined in question 5?

Agency usage for Physiotherapy, Occupational Therapy, Pharmacy, Radiography, Speech and Language Therapy and Sterile Services.220422.docx

1. Who is the person in charge for approving agency usage for the Decontamination department at your trust?
2. Who is responsible for agency usage (on and off framework) in the Decontamination department at all hospitals associated with the Trust?
3. If the decontamination service is not managed by the trust, please confirm which company runs your decontamination service.
4. Please can you provide the contact number and email address for the manager(s) in question 1 and 2.
5. Have you used off-framework agency staff between March 2022 – March 2023 in Decontamination and endoscopy?
6. How much was your Off-Framework agency spend for Decontamination and Endoscopy from March 2022 – March 2023?

Agency usage for the Decontamination department.200723.docx

1. Who is the head of procurement responsible for approving agency usage for the Physiotherapy department?
2. Who is responsible for agency usage (on and off framework) in the Physiotherapy department at all hospitals associated with the Trust for the following areas within Physiotherapy?
– Musculoskeletal
– Community
– Rehabilitation
– Neurology
– Paediatrics
– Trauma and Orthopaedics
– Acute Medical/Surgical/inpatient
– Respiratory
3. Please can you provide the contact number and email address for the manager(s) in question 1 and 2.
4. How much was your Off-Framework agency spend for Physiotherapy from June 2022-June2023
5. What agencies were providing the Off-Framework services.

Agency usage for the Physiotherapy department.040823.docx

1. Who is the head of procurement responsible for approving agency usage for the Sonography/Ultrasound department at your trust?
2. Who is responsible for agency usage (on and off framework) in the Sonography/Ultrasound department at all hospitals associated with the Trust? 3. Please can you provide the contact number and email address for the manager(s) in question 1 and 2. 4. Have you used off-framework agency staff between March 2022 – March 2023 in Sonography/Ultrasound?
5. How much was your Off-Framework agency spend for Sonography/Ultrasound from March 2022 – March 2023?

Agency usage for the Sonography and Ultrasound department.310323.docx

I am writing to request specific information regarding your trust’s agency workforce spend for the period of January 2023 to December 2023.

1. Please provide the agency workforce spend for the specified period, broken down into the following categories:

• Medical Staff
• Nursing Staff
• Allied Health Professionals (AHP)

2. Additionally, could you provide the percentage of the total workforce is agency in each of the mentioned categories?

Agency Workforce Spend (January 1st -December 31st 2023).080524.docx

All questions are shown as received by the Trust.
I. The total amount spent by the Trust on bank and agency doctors in each of the last 5 financial years (including 2023/24 so far)
II. The total amount spent by the Trust on bank and agency nurses in in each of the last 5 financial years (including 2023/24 so far)
III. The largest amount spent by the Trust on a single agency nurse shift in 2023/24
IV. The largest amount spent by the Trust on a single agency doctor’s shift in 2023/24

Bank and agency costs.070324.docx

Please disclose the information listed in the below table rows for each of the 4 staff groups in the table columns by return email within 20 days as per the Freedom of Information Act 2000.
1. Please provide agency spend for the staff group for the year 2022.
2. Please provide bank spend for the staff group for the year 2022.
3. Please confirm which model you have in place for managing the staff group: Email to preferred supplier List, a Master Vendor, a Neutral Vendor, or a Software cascade to a preferred supplier list.
4. If you have a master vendor or neutral vendor in place, please confirm who this contract is with and the date on which this contract expires.
5. Please confirm what percentage of bookings over the last 6 months have been within the NHSI/E agency caps (an approximation based on NHSI data submissions is fine).
6. Please confirm which provider manages your direct engagement process, the fee for the service and the date on which this contract expires (no this is not relevant for Nursing).
7. Please confirm what percentage of bookings are processed with a VAT savings by your direct engagement provider
8. Is your bank managed by an external bank provider (eg. NHS Professionals, Bank Partners) or in-house? Please confirm who is the external bank provider and when the contract expires if relevant.
9. Is your bank managed via software? If so, please confirm which software.
10. Please confirm what the percentage is on framework (for example, “£6,650,000 – 99% framework /20% off-framework”) for the year 2022.
11. Please confirm what percentage is off-framework (for example, “£6,650,000 – 99% framework /20% off-framework”) for the year 2022.
12. Please confirm the direct engagement- DE% uptake for the year 2022.
13. Please confirm the direct engagement- DE provider.
14. Please confirm the direct engagement- DE contract end date.

Bank and Agency spend.050423.docx

1. Please confirm which model is in place for managing each staff group: preferred supplier list, master vendor or neutral vendor
Locum
Nurse
Allied Health Professionals
Non-medical/non-clinical
2. If you have a master vendor or neutral vendor in place, please confirm who this contract is with
3. Please confirm the contract end date with the provider
4. Is your bank managed by an external bank provider (e.g., NHS Professionals,
Bank Partners).
5. Please confirm who is the external bank provider and when the contract expires if relevant
6. Is your bank managed via software? If so, please confirm which software.

Bank and agency systems.080323.docx

All questions are shown as received by the Trust.
Rostering
For each of the staff group categories:
1 Does your Trust use an E-Rostering provider? (YES/NO)
2 What is the name of your current E-Rostering provider?
3 What is the contract start date for your e-rostering software? (dd/mm/yyyy)
4 What is the contract end date for your e-rostering software? (dd/mm/yyyy)
5 How many licenses is your contract for?
Bank
For each of the staff group categories:
1 Do you have an in- house temporary staffing team to manage your bank OR is this outsourced to a company? (In-house/Outsourced)
2 If outsourced, what is the name of this company?
3 What was the start date for the contract with this outsourced provider? (dd/mm/yyyy)
4 What is the expiry date for the contract with this outsourced provider? (dd/mm/yyyy)
For each of the staff group categories:
5 Does your organistion use digital technology/software to manage it’s staff bank? (YES/NO)
6 If the response was YES to question 1, what is the name of your digital staff bank technology (e.g. Allocate, Patchwork, Locum’s Nest)?
7 What was the contract start date for the provider you currently use for your Digital staff bank? (dd/mm/yyyy)
8 What is the contract expiry date for the provider you currently use for your Digital staff bank? (dd/mm/yyyy)

Bank and Rostering.170624.docx

1. Bank Spend – Total amount spent on bank staff for the year 2021/22 (April ’21 to March ‘22) and between 31/10/2021 and 31/10/2022 year split into the Trusts’ staff groups (E.g. Medical, Nursing, Admin, AHP etc.) and speciality/grade (E.g. Consultants, GP, ICU Nurse, Acute Nurse, Occupational therapists, Pharmacists, Health Care Assistants, etc.) depending on how this is reported within the Trust.
2. Confirmation on whether the trust bank is currently operated by the trust themselves or by a private provider. If the latter please confirm the name of the provider.

Bank Staff costs.101122.docx

We would like to understand how much money MTW have spent with Cloud21 Broken Down for each financial year
16/17
17/18
18/19
19/20
20/21
21/22

Cloud21. 120422.docx

Please could you tell me how much money your trust spent on bank and/or agency and/or locum staff – and/or non-contractual rates to consultants or other medical staff employed by the trust – to cover junior doctors’ shifts during industrial action by the British Medical Association on:
A) March 13-15 2023
and
B) April 11-15 2023
Please provide as much detail as possible on the staff category (i.e. agency or bank), department of the hospital and the day(s) of employment.

Cost of strike cover.120523.docx

All questions are shown as received by the Trust.
1) Since the beginning of the calendar year 2023, how much has the trust spent on external management/business consultants, including commitments that cover the rest of the calendar year?
2) Since the beginning the calendar year 2023, how much has the trust spent fees to recruitment agencies, including commitments that cover the rest of the calendar of the calendar year?

External management, business consultants and recruitment agency fees.060224.docx

Question 1 – For the timescale from the 1st April 2023 until 30th April 2023, details of the lowest, highest and average fee paid to agencies providing HCA’s for band 5, 6 and 7.

Question 2 – For the single week of the 16th July 2023 until 22nd July 2023, details only of the average fee paid to agencies providing HCA’s for band 5, 6 and 7.

HCA agency fees.180823.docx

All questions are shown as received by the Trust.
1. Please confirm the name and email address of the relevant contact within the trust who is responsible for agency hires for the following categories:
Facilities
Estates
Administrative / Clerical
Ambulance / Patient Transport

2. Please confirm whether the trust utilises a 3rd party vendor or tech system for the hiring of the following agency staff categories. If so, please confirm the name of the vendor / tech provider:
Facilities
Estates
Administrative / Clerical
Ambulance / Patient Transport

Hiring of agency staff.301024.docx

1) Please could you confirm the names of the top 5 locum agencies you have the most spend with within AHP/HSS there at the trust from the calendar year of 2021?
2. Please could you state the utilisation rate for each agency that has been achieved? This should amount to the total value of AHP locum spend supplied by each agency during the 2021 calendar year as a percentage of total AHP locum spend in the same period.
3) Please can you breakdown the total spend on AHP/HSS agency staff during the calendar year of 2021?
4) Please can break down the total spend on AHP/HSS agency staffing during the calendar year 2021 for the specialisms below:
AHP
Sonographers
Radiographers
Radiotherapists
Clinical Physiologists
Physiotherapists
Occupational Therapists
Speech and Language Therapists
Audiologists
Dieticians
Podiatrists
Clinical Psychologists
Theatre Practitioners
HSS
Biomedical Scientists
Mortuary/Pathology Technicians
Pharmacy Services Staff
Orthoptists & Optometrists

Locum agencies.010622.docx

1. How many agencies are used to supply Locum agency doctors?
2. Of these agencies, how many are off framework?
3. What is your highest capped commission rates for each grade?
4. When is your PSL up for renewal?
5. Which Framework does your trust use for Locum Doctors?
6. How many Locum Bookings are paid over the framework or capped rates at your trust in the last 12 months?
7. Please confirm what percentage of bookings over the last 6 months have been within the NHSI agency caps (an approximation based on NHSI data submissions is fine)
8. Please confirm which provider manages your direct engagement process, the fee for the service and the date on which this contract expires
9. Is your bank managed by an external bank provider (e.g., NHS Professionals, Bank Partners) or in-house? Please confirm who is the external bank provider and when the contract expires if relevant
10. Please confirm what percentage of bookings are processed with a VAT savings by your direct engagement (DE) provider
11. Please confirm % of locums working non-Direct Engagement and % outside IR35
12. What is the grade & speciality of all locums paid outside IR35?
13. Please confirm which services in the hospital are currently utilising insourcing contacts, who is supplying the insourcing service and when the contract is up for renewal.
14. Does your Trust utilise a payment portal to process Locum Doctors Pay?
15. What grade & speciality is your highest paid Locum agency doctor, what is their speciality and their hourly charge?
16. What grade & speciality is your highest paid bank doctor, what is their speciality and their hourly charge?
17. Please outline you spend per agency, broken down by grade and speciality of doctor over the past 12 months?
18. Please outline spend per doctors’ specialty, broken down by grade and speciality of doctor over the past 12 months from your internal Bank?
19. What grade & speciality is your highest paid Locum agency doctor, what is their speciality and their hourly charge?
20. Please confirm the name, job title and email of the head of department & manager for the following services:
• General Surgery
• Urology Service
• Trauma and Orthopaedic Service
• Ear, Nose and Throat Service
• Ophthalmology Service
• Neurology Service
• Cardiology Service
• Cancer Services
• Endocrinology Service
• Respiratory Medicine
• Dermatology Service
• Gastroenterology
• Acute Medicine
• Geriatrics
• Stroke Medicine
• Palliative Care
• Radiology
• Anaesthetics
• Maxillofacial Surgery
• Pathology Services
Locum agency doctors.230823.docx

All questions are shown as received by the Trust.
Could you please break down your spend on agency staff and locum doctors over the past three financial years (2023-24, 2022-23, 2021-22)?

Please could you split the spend up into:
• Agency & locum nurses
• Agency & locum doctors
• Other agency staff (not doctors or nurses)

Locum and agency staff spend.271124.docx

All questions are shown as received by the Trust.
1. In the period 1st May 2024 to 31st July 2024 please provide a breakdown of:
• Total trust spend with framework agencies for locum doctors
Please provide a further breakdown for locum doctors by:
• Spend per grade
• Spend per specialty
• Spend per agency name
2. In the period 1st May 2024 to 31st July 2024 please provide a breakdown of:
• Total trust spend with off-framework agencies for locums doctors
Please provide a further breakdown for locum doctors by:
• Spend per grade
• Spend per specialty
• Spend per agency name
3. In the period 1st May 2024 to 31st July 2024 please provide a breakdown of:
• Total trust spend with the internal trust bank or associated external provider for locum doctors
Please provide a further breakdown for locum doctors by:
• Spend per grade
• Spend per specialty
• Spend per internal or associated external provider
4. Please confirm your allocated budget for agency locum doctors for the period 1st May 2024 to 31st July 2024.

Locum doctors.290824.docx

All questions are shown as received by the Trust.
how much was spent on locum and agency doctors during the walkouts held by both consultants and junior doctors over the past 12 months.
Please provide answers for each timeframe and separate each one clearly in your response.
These timeframes are:
(A) Junior doctor strike – 13, 14 and 15 March 2023
(B) Junior doctor strike – 11, 12, 13, 14 and 15 April
(C) Junior doctor strike – 14, 15, 16 and 17 June
(D) Junior doctor strike – 13, 14, 15, 16, 17 and 18 July
(E) Junior doctor strike – 11, 12, 13, 14 and 15 August
(F) Consultant strike – 20 and 21 July
(G) Consultant strike – 24, 25 and 26 August

For each given timeframe could you please provide the following information.
1. How many staff walked out as a result of industrial action over each period and what percentage of your junior doctor/consultant staff did this equate to. IE – 150 junior doctor staff walked out during 13, 14 and 15 March dates out of 200 junior doctor staff would be 75%.
2. How much did the trust spend on locum/agency workers during each period specifically as a result of industrial action. If this specific figure is not held, please provide the locum and agency spend for the previous year for each relevant timeframe. IE 13, 14 and 15 March 2023 vs 13, 14 and 15 March 2022.
3. Did the Trust allow doctors who were taking part in industrial action to take on locum shifts at the same trust during strike periods when they were not scheduled to work?
4. If the answer to the above question was yes, (a) How many doctors did this during each period and (b) How much did the Trust spend on paying its own doctors for these shifts during each period?

Locum shifts during industrial action.311023.docx

Total spend for the LFY on off-framework supply?

Number of hours filled?

Broken down by grade/specialty?

Off-framework agencies used during this period including the total spend for each agency?

Highest off-framework charge rate (including detail of grade/specialty)?

Average off-framework charge rates per grade/specialty (if available)?

Medical Locum off-framework expenditure.260723.docx

Please may you provide me with:
1. Confirmation if the trust works under, Non-Clinical Temporary and Fixed Term Staff CCS Framework RM6160 and the new CCS Non-Clinical Staffing Framework Agreement RM6277.
2. If the trust works under, these frameworks, please can you provide a list of agencies that have supplied you with non-clinical staff and a breakdown of agency spend by bands between May 2022 and April 2023.
3. Can you also please provide the contact details of the person/persons responsible for agreeing non-clinical staffing call-off contracts, for roles which would fall under Lot 2 (Corporate Functions) and Lot 6 (Estates, Facilities Management & Ancillary Staff).
4. Lastly please can you provide organisational charts with names and jobs titles for the Estates, Facilities Management and Corporate Functions departments.

Non-Clinical Temporary and Fixed Term Staff.160823.docx

Please provide the total agency spend on your Trust, for the last 8- month period (May to December 2021), for Non-Framework and Clinical Services Insourcing, for the following staff Categories.
1. Total hours Non-Framework
2. Total Spend Non-Framework
3. Total hours Clinical Services Insourcing
4. Total Spend Clinical Services Insourcing
Staffing Provision
a. General nursing
b. ITU
c. A&E
d. Theatres (Nursing)
e. Healthcare Assistants
f. RMN’s (where applicable)
g. Doctors all specialisms
h. Endoscopy

Download response Non-Framework and Clinical Services Insourcing. 280122.docx

1.
(a) Who is the head of procurement at your trust responsible for approving Nursing agency usage?
(b)Secondly, who is the temporary / flexible staffing lead responsible for the management of this service.
2. Please can you provide the contact information in relation to both question 1 (a) and (b)
3. Please can you outline your Off-Framework agency spend for each of the following staff groups between Dec 2021 – May 2022:
(a) RGN’s
(b) RCN’s
(c) RN’s
(d) HealthCare Assistants
(e) RMN
(f) Specialist RN (ITU)
4. Following the same breakdown of staff groups in Question 3, how many Off-framework shifts have been unfilled between Dec 2021 – Present
5. Since the start of January 2022 – present, please provide the current charge rates from your Off Framework, Nursing providers, providing a clear breakdown between the workers pay rate and agency commission
6. Based on the above information, who are your current Nursing Off-Framework agencies and how many shifts have been booked for each month from January 2022 – Present

Nursing agency usage.260822.docx

All questions are shown as received by the Trust.
1. A list of nursing agencies currently utilized for nursing and care staff at Maidstone and Tunbridge Wells NHS Trust.
2. Spend data for nursing and care agencies across all areas of the Trust for qualified staff for the period from April 2023 to April 2024.
3. Information on any off-framework agencies that supplied nursing staff between April 2023 and April 2024, along with the associated spend data.

Nursing Agency Usage and Spend.151024.docx

1. What has been the agency spend so far this year?
2. How much of this is for nursing/Health Care Assistants?
3. How much was spent on break-glass/off-framework nursing shifts?
4. How many break-glass/off-framework agencies have you used?
5. Which break-glass/off-framework agencies have you used?
6. How many unfilled shifts have you had?
7. Do you use agency to supply associate physicians?
8. If yes, what has the agency spend for associate physicians so far this year been?
9. Do you use agency to supply dental nurses?
10. If yes, what has the agency spend for dental nurses so far this year been?

Download response Nursing and HCA agency staffing. 110122.docx

All questions are shown as received by the Trust.
1. What is the average charge for both RMN’s and RGN’s from ON framework agencies?
2. Which ON framework agencies is the trust currently utilising for Nursing vacancies and what is the spend on these agencies October 2023 to date?
3. Who at director level is responsible for patient safety and staffing levels and could you provide me with their contact details?
4. Who at temporary staffing is responsible for onboarding new agencies and could you provide me with their contact details?
5. What is the temporary staffing generic email address?

Nursing Temporary Staffing.080524.docx

All questions are shown as received by the Trust.
1. A list of the OFF-framework agencies used by the trust in the past 12 months’
2. The average length of time a long-term agency placement is left vacant before being filled by the agencies who are ON framework in the past 12 months’
3. How many long-term bookings and individual shifts have been placed through OFF-framework agencies in the past 12 months’ (Please separate individual shifts and long-term placements)
4. Average cost per hour for Band 5, 6 and 7 agency workers paid to OFF-framework agencies in the past 12 months’
5. Who in the trust has authority to approve the use of off-framework agencies (name and job title)
6. If authority to use off-framework agencies in the trust lies with a specific department i.e., temporary staffing/staffing solutions/agency bookings/NHSP or equivalents, then who in the trust has the authority to override such decision made by that department (name and job title)

Off-framework agencies.061023.docx

1. What is the total Agency “Off Frame” spend from 27.01.2021 to date with your Trust?
2. The Names of the “Off Framework” agencies supplying to your Trust?
3. Which area within nurses has the highest spend, e.g. …RGN, Midwifery & A&E Nurses?

Off Framework Agencies. 080222.docx

1.) What is the total Agency “Off Frame” spend from 27.01.2021 to date.
2.) The Names of the agencies supplying Off Frame
3.) Which area within nurses has the highest spend, e.g. …RGN, Midwifery & A&E Nurses.

Off framework Agencies. 090222.docx

1. How many shifts has your trust used Thornbury Nursing Services for between 1st – 28th February 2023
2. Within this timeframe, please can you list the number of shifts filled by ward or department that Thornbury were used in.
3. Please name all other Off Framework agencies that were utilised within this timeframe (1st – 28th February 2023)
4. How many shifts were filled during this time frame by these agencies (1st – 28th February 2023)
5. Within this same timeframe, please list the number of shifts filled, by ward or department.
6. Please list all suppliers with a general band 5 day charge rate of £50 per hour
7. Please list all suppliers with a general band 5 night charge rate of £55 per hour.

Off Framework agencies.090323.docx

1. Who is responsible for managing the recruitment of temporary staff and what is their work email address
2. Could you please provide your total OFF-Framework agency spend between 1st of January 2022 to 31st of December 2022 for:
A) Nurses (all bands and specialties)
B) General Practitioners (please answer separately)
3. Could you please list individually which specialty of nurses hired through off-framework agencies that accumulated agency spend in excess of £100,000 between the 1st of January 2022 to 31st of December 2022.

Off-framework agencies.110823.docx

Please could you answer the below questions in relation to the trusts off framework usage in financial year 2021-2022;
1) Which off framework agencies did the trust use for HCA and Nursing vacancies and what was the spend on these agencies?
2) What was the average charge for both HCA’s and Nurses from off framework agencies?
3) How many HCA shifts were sent out to off framework agencies?
4) How many of these were filled?
5) How many Nursing shifts were sent out to off framework agencies?
6) How many of these were filled?

Off framework agencies.120822.docx

All questions are shown as received by the Trust.
1. From 1st April 2023- 15th May 2023 how many shifts has your Trust used Thornbury Nursing Services for?
2. Within this timeframe please list the number of shifts by ward or department that Thornbury was utilised in.
3. Please name all other ‘off contract agencies’ for nursing that were utilised by the Trust within this time frame. (01/04/2023- 15/05/2023) For the purpose of definition ‘off contract suppliers’ would be any non framework providers under Work Force Alliance or Health Trust Europe.
4. Within this same time frame please list all wards or departments that utilised these agencies.
5. Please list any suppliers with a general Band 5 day charge rate of over £50 per hour that have been booked for the Trust in this time period (01/04/2023- 15/05/2023)
6. Please list any suppliers with a general Band 5 night charge above £60 per hour that have been booked for the Trust in this time period (01/04/2023- 15/05/2023)

Off Framework agencies.160823.docx

1.
a) Who is the head of procurement at your Trust responsible for approving nursing healthcare workers agency use?
b) Who is the temporary/ flexible Staff only responsible for the management of this service?
2.
Please provide the contract information in relation to both question 1 a) and b)
3.
Please can you outline your Off-Framework agency spend for each of the following staff groups between September 05 2019 to July 11, 2021?
a) RGNs (ward nurse) band 5
b) RCNs band 5
c) Healthcare assistance band 2
d) RMNs band 5
e) specialist ITU nurses band 5 and 6
f) CPNs band 6
g) Scrub nurses band 5 and band 6
h) ODP band 5 and band 6
i) Physiotherapist
j) Speech Therapist
k) Paramedic band 5
4.
Following the same breakdown of staff groups in question three how many of framework shifts have been unfilled between September 05 2019 to July 11, 2021?
5.
Since the start of January 2019 to present please provide the current charge rate from Off Framework agencies nursing / healthcare worker providers a clear breakdown of the workers’ pay rate and agency commission?
6.
Based on the above information
a. who are your current Off Framework agencies and
b. how many shifts have been booked for each month from September 05 2019 to July 11, 2021?
7.
Can you please provide the charge rates for the below nursing / healthcare worker levels that Off Framework have been charging you since September 05 2019 to July 11, 2021?
a) RGNs (ward nurse) band 5
b) RCNs band 5
c) Healthcare assistance band 2
d) RMNs band 5
e) specialist ITU nurses band 5 and 6
f) CPNs band 6
g) Scrub nurses band 5 and band 6
h) ODP band 5 and 6
i) Physiotherapist
j) Speech therapist
k) Paramedic band 5

Off-Framework agencies.220422.docx

All questions are shown as received by the Trust.
1. Which off framework agencies are used for non-clinical vacancies?
2. On a month by month basis what was your off-framework agency spend for the last 12 months for nurses
3. On a month by month basis what was your off-framework agency spend for the last 12 months for doctors
4. On a month by month basis what was your off-framework agency spend for the last 12 months for band 8s
5. On a month by month basis what was your off-framework agency spend for the last 12 months for band 9s
6. On a month by month basis what was your off-framework agency spend for the last 12 months for very senior managers?
7. Which off frame work agencies supplied nurses in 2020, 2021 and 2022
8. What is the average length of a contract for a band 8 placed through an off framework agency
9. What is the average length of a contract for a band 9 placed through an off framework agency
10. Total off framework spend in 2020, 2021, and 2022 Finance to answer
11. Total agency spend for band 8s in 2020, 2021 and 2022 through framework
12. Total agency spend for band 9s in 2020, 2021 and 2022 through framework
13. Total agency spend for VSMs in 2020, 2021 and 2022 through framework
14. Who is responsible for approving the use of agencies for agency staff? Please provide their email address and contact number
15. What was your off-framework agency spend for fixed term contracts (not ad-hoc shifts) in 2020, 2021, and 2022 split between clinical and non-clinical
16. What is the process for recruiting interim very senior managers? Who is responsible for that recruitment?
17. What was the agency spend for VSMs for 2020, 2021 and 2022 N/A
18. Do you have an off-framework audit pack?
19. What are the compliance requirements for off-framework agencies – split between clinical and non-clinical

Off framework agencies.300124.docx

All questions are shown as received by the Trust.
1. From 1st October 2022 to 2nd December2022 how many shifts has your Trust used Thornbury Nursing Services for?
2. Within this timeframe please list the number of shifts by ward or department that Thornbury was utilised in.
3. Please name all other ‘off contract agencies’ for nursing that were utilised by the Trust within this time frame. (01/10/2022- 02/12/2022) For the purpose of definition ‘off contract suppliers’ would be any non framework providers under Work Force Alliance or Health Trust Europe.
4. Within this same time frame please list all wards or departments that utilised these agencies.
5. Please list any suppliers with a general Band 5 day charge rate of over £50 per hour that have been booked for the Trust in this time period (01/10/2022- 02/12/2022)
6. Please list any suppliers with a general Band 5 night charge above £60 per hour that have been booked for the Trust in this time period (01/10/2022- 02/12/2022)

Off Framework agencies.300823.docx

1. Does your trust utilise off-framework agencies for Nursing or Care, if so which agencies?
2. How many hours have been covered by off-framework agencies for Nursing and Care AUG 22-PRESENT?
3. Who at director level is responsible for patient safety and staffing levels?

Off-framework agencies for Nursing and Care.080323.docx

All questions are shown as received by the Trust.
1. Do you currently use any off framework agencies for Nursing, if so please include agency name?
2. Do you currently use any off framework agecnies for HCA/support workers, if so please include agency name?
3. Since May 2023 till now, how many shifts have been booked with off framework agency for nursing?
4. Since May 2023 till now, how many shifts have been booked with off framework agency for healthcare assisant/support workers?
5. Do you have any off framework agencies who currently charge £50+ per hour for nursing staff, if so who may they be?
6. Do you have any off framework agencies who currently charge £24+ per hour for healthcare assitant/support workers, if so who may they be?

Off-framework agency details.160823 2.docx

All questions are shown as received by the Trust.
1. From 1s January 2023- 28th February 2023 how many shifts has your Trust used Thornbury Nursing Services for?
2. Within this timeframe please list the number of shifts by ward or department that Thornbury was utilised in.
3. Please name all other ‘off contract agencies’ for nursing that were utilised by the Trust within this time frame. (01/01/2023-28/02/2023) For the purpose of definition ‘off contract suppliers’ would be any non-framework providers under WorkForce Alliance or Health Trust Europe.
4. Within this same time frame please list all wards or departments that utilised these agencies.
5. Please list any suppliers with a general Band 5-day charge rate of over £50 per hour that have been booked for the Trust in this time period (01/01/2023-28/02/2023)
6. Please list any suppliers with a general Band 5-night charge above £60 per hour that have been booked for the Trust in this time period (01/01/2023-28/02/2023)

Off-framework agency details.160823 3.docx

1.) What is the Agency spend for Off Framework” from 01.01.2022 to Present for your Trust ?
2.) What are the names of the “Off Framework” agencies supplying to your Trust?
3.) Which area in “ Off Framework” has the highest expenditure e.g…RGN, Midwife, & A&E including any other Nursing specialities?

Off-Framework Agency details.160823.docx

1. Could you please provide your total OFF-Framework agency spend between 1st of March 2020 to 31st of March 2021 for A. Nurses (all bands and specialties)
& B. General Practitioners, Nurse Practitioners (all types/seniorities). Please answer A & B individually
2. Same question as above but for between April 1st 2021 to Present day
3. Please provide the hourly charge rate for the below Staff Groups/Specialties supplied to your hospital/trust by OFF-Framework recruitment agencies between the beginning of April 2021 to present day. Please answer individually and specify if the charge rate was for a Day, Night, Saturday or Sunday/Bank holiday shift.
A. Registered General Nurse (RGN)
B. Critical Care / ITU / ICU Nurses
C. A&E Nurses
D. Paediatric Nurses
E. Orthopaedic Nurses
F. Operating Department Practitioners (ODP)
G. Theatre Nurses
H. Midwives
I. Healthcare Assistant (HCA)
J. Registered Mental-Health Nurse (RMN)
K. Community Psychiatric Nurses (CPN)
L. General Practitioners (GP)
M. Nurse Practitioners / ANPs
4. Who is responsible for approving the use of Healthcare Recruitment agencies for temporary staff?
A. Please provide their work email address and work phone number (or extension if unable to provide a direct line)
5. Who is responsible for approving the use of Healthcare Recruitment agencies for permanent staff?
A. Please provide their work email address and work phone number (or extension if unable to provide a direct line)
6. Please can you confirm the total number of unfilled shifts between 1st of August 2020 to present day 2021 for:
A. Nurses (All Bands & Specialties)
B. Healthcare Assistants (HCA’s)
C. Doctors (All Bands & Specialties)
D. General Practitioners (GP’s), Advance Nurse Practitioners (ANP’s) & Nurse Practitioners

Download response Off-framework agency staffing. 070122.docx

1. How many RGN and HCA shifts have been filled using an “Off Framework” Agency between November 1st 2021 and January 31st 2022
2. Which “Off Framework” Nursing agencies have been used by the Trust between November 1st 2021 and January 31st 2022
3. Breakdown of shifts filled by each individual “Off Framework” Nursing Agencies between November 1st 2021 and January 31st 2022
4. Total Cost for each “Off Framework” Nursing Agency between November 1st 2021 and January 31st 2022

Off Framework Nursing Agencies.090222.docx

All questions are shown as received by the Trust.
1. Please can you confirm how many shifts have been released/allocated to ON framework agencies within the last 90 days?
2. In the last 90 days which wards, or departments were these ON framework requests for?
3. Please can you confirm how many nursing shifts have been filled by ON framework agencies within the last 90 days?
4. How many long term lines of work or block bookings are currently being supplied by ON framework agencies?
5. Which ON framework agencies is the trust currently utilising for Nursing vacancies and what is the spend on these agencies year to date?
6. Please can you confirm how many shifts have been released/allocated to OFF framework agencies within the last 90 days?
7. What is the average charge for both RMN’s and RGN’s from ON framework agencies?
8. Who at Temporary Staffing is responsible for onboarding new agencies and could you provide their email address and contact number?
9. What is the generic Nurse bank email address for staff bank?
10. How many shifts were cascaded to Thornbury Nursing within the last 90 days?

On and Off Framework Nursing agency usage.250424.docx

All questions are shown as received by the Trust.
1. Please can you confirm how many shifts have been released/allocated to ON framework agencies within the last 60 days?
2. In the last 60 days which wards, or departments were these ON framework requests for?
3. Please can you confirm how many nursing shifts have been filled by ON framework agencies within the last 60 days?
4. How many long term lines of work or block bookings are currently being supplied by ON framework agencies?
5. Which ON framework agencies is the trust currently utilising for Nursing vacancies and what is the spend on these agencies year to date?
6. What is the average charge for both RMN’s and RGN’s from ON framework agencies?
7. Who at temporary staffing is responsible for onboarding new agencies and could you provide me with their contact details?

ON framework agencies.261023.docx

All questions are shown as received by the Trust.
1. Who is the head of procurement responsible for approving agency usage for Physiotherapy and Occupational Therapy locums?
2. Who are the managers responsible for agency usage (on and off framework) for the following departments at all hospitals associated with the Trust:
(a) Physiotherapy
(b) Occupational Therapy
3. Please can you provide the contact number and email addresses for the managers listed in relation to question 1 and 2.
4.. How much was your Framework agency spend for each of the following staff groups since January 2023 – present?
(a) Physiotherapy
(b) Occupational Therapy
5. Please provide the names of the agencies currently used by the Trust to supply Physiotherapists and Occupational Therapists – please include the % of shifts filled by each agency since January 2023.
6. Do you use a direct engagement model to facilitate locum placements for Physiotherapists and Occupational Therapists, if so, which one?
7: What is the highest rate paid for Band 6 Physiotherapists and Band 6 Occupational Therapists since January 2023?

Physiotherapy and Occupational Therapy locums. 080524.docx

All questions are shown as received by the Trust.
In relation to your supply of locum Psychiatrists for each grade and sub-specialty per month, please could you provide the answers to the requests below for the following periods?
i. Financial year 2022/2023
ii. Financial year 2023/2024
iii. April – September 2024
1. Please confirm the total number of vacancy requirements given out to framework and non-framework agencies for each agency
2. Please confirm the total number of shifts given out to framework and non-framework agencies for each agency
3. Please confirm the total number of agency locum doctors working per month, for each agency supplier divided between on and off framework.
4. Please confirm the total number of hours worked by agency locum doctors per month, for each agency supplier divided between on and off framework.
5. Please confirm the total number of unfilled vacancies (excluding locum filled posts) per month.

Psychiatry Agency Locums.201124.docx

All questions are shown as received by the Trust.
In the last 12 months (the most recent that you have recorded):
1. Has your trust used agencies to recruit any of the AHP roles detailed below?
2. What was your monthly/quarterly agency spend on recruiting Radiographers?
3. What was your monthly/quarterly agency spend on recruiting Physiotherapists?
4. What was your monthly/quarterly agency spend on recruiting Occupational Therapists?
5. What was your monthly/quarterly agency spend on recruiting Speech and Language Therapists?
6. What was your monthly/quarterly agency spend on recruiting Biomedical Scientists?
7. What was your monthly/quarterly agency spend on recruiting Dieticians?
8. What was your monthly/quarterly agency spend on recruiting Podiatrists?

Recruitment agency spend.200824.docx

(i) How much money the Trust has spent on recruitment consultants in (a) 2021 and (b) in the year 2022 to date.
(ii) How much, if any, of this recruitment spending was related to recruitment for the new Integrated Care Boards

Recruitment consultants. 100822.docx

1. Does the Trust use or has the Trust ever used RMOs supplied by agencies?
2. If so, how many are being used currently? If you can’t answer this, could you please tell us how many contracted hours do RMOs provide for the trust per month or per year?
3. How many hours would an RMO be working in any given week and any given month? What is their shift pattern?
4. What are the departments within the trust where RMOs work (for example orthopaedic, mental health, general medicine, surgery etc).
5. How much does the trust pay to NES Healthcare Ltd (or any other NES company within NES Holdings (UK) Limited group) per hour per RMO? Please ideally break this down by grade and if it’s not possible tell us the average rate.
6. If the trust receives RMOs from agencies other than NES Healthcare Ltd please tell us the names of those agencies and rates paid to each per RMO per hour.
7. What was the Trust’s total spend on RMOs in 2020, 2021 and 2022? Please break this down by agencies suppling RMOs.
Resident Medical Officers [RMOs], Resident Doctors and/or Senior House Officers [SHOs]

Resident Medical Officers [RMOs], Resident Doctors and or Senior House Officers [SHOs].210722.docx

System: Rostering
For each of the staff group categories:
1. Does your Trust use an E-Rostering provider? (Yes/No – if No, have you previously tried to implement an e-rostering provider? Please name the provider).
2. What is the name of your E-Rostering provider?
3. When does the contract for the software you currently use for E-Rostering expire? (dd/mm/yyyy)
System: Bank
For each of the staff group categories:
1. Do you have a Digital staff bank provider?
2. What is the name of your Digital staff bank provider?
3. What is the contract expiry date for the provider you currently use for your Digital staff bank? (dd/mm/yyyy)
System: Vendor Management System (VMS) / Agency Management Software
For each of the staff group categories:
1. Do you use a VMS provider? (Yes/No/Not Applicable)
2. What is the name of your VMS Provider?
3. What is the contract expiry date for the provider you currently use? (dd/mm/yyyy)

Rostering, Bank and Vendor Management System.120822.docx

1. Do you use external providers/3rd parties to manage any of your Staff Banks?
If you have answered yes, please also provide answers to the following questions, otherwise please stipulate ‘N/A’
a. Who is the provider? If different providers are used for different staffing groups, please state all, and indicate which staffing group each is used for
b. When is the contract due to end? (per staffing group if applicable)
c. Was this contract awarded as a result of a tender process or via a direct award?
2. Do you use a third-party to provide Direct Engagement services to any staff group?
If you have answered yes, please also provide answers to the following questions, otherwise please stipulate ‘N/A’
a. Who is your Direct Engagement provider? If different providers are used for different staffing groups, please state all, and indicate which staffing group they are used for
b. When is the contract due to end? (per staffing group if applicable)
c. Was this contract awarded as a result of a tender process or via a direct award?

Staff Bank and Direct Engagement services.270722.docx

System: Rostering
For each of the staff group categories:
1. Does you Trust use an E-Rostering provider? (Yes/No – if No, have you previously tried to implement an e-rostering provider? Please name the provider).
2. What is the name of your E-Rostering provider?
3. If the software provider is not in the list – Please type
4. When was the contract for the software you currently use for E-Rostering signed?
5. When does the contract for the software you currently use for E-Rostering expire?
6. Was the e-rostering software procured through a framework?
7. What is the name of the framework the e-rostering software was procured using?
8. What was the Trust’s total spend on E-Rostering fees in 2020 – not incl. Implementation?
9. How many workers were actively E-Rostered at your Trust in 2020?
10. Does the rostering system integrate to ESR?
11. Does the rostering system integrate to PAS?
12. What system do you use for rota planning? E.g. eRota
13. Who is the Senior Responsible Officer for E-Rostering?
System: Bank
For each of the staff group categories:
1. Do you have a staff bank provider? (Yes/No – if No, please provide more details).
2. What is the name of your staff bank provider?
3. If the software provider is not in the list – Please type
4. Was the bank software procured through a framework?
5. What is the name of the framework the bank provider was procured using?
6. What was the contract signed date for the provider you currently use for your staff bank?
7. What was the contract expiry date for the provider you currently use for your staff bank?
8. What was the Trust’s spend on bank staff wages in 2020?
9. What was the Trust’s spend on agency staff wages in 2020?
10. What was the Trust’s spend on its Staff Bank provider fees in 2020?
System: Collaborative Bank
For each of the staff group categories:
1. Is your Trust part of a collaborative Bank? (Yes/No)
2. Who is the technology provider for the collaborative bank?
3. If the software provider is not in the list – Please type
4. What was the contract signed date of Trust joining the Collaborative Bank?
5. When does the contract for the Collaborative Bank expire?
System: Managed Service
For each of the staff group categories:
1. Do you use a third-party managed service provider to manage your temporary staff bank? (yes/no)
2. What is the name of your third-party Managed Service provider?
3. What was the contract signed date for the provider you currently use for your managed service?
4. What was the contract expiry date for the provider you currently use for your managed service?
5. What was the Trust’s spend on its Managed Service provider fees in 2020?
System: VMS
For each of the staff group categories:
1. Do you use a VMS provider? (Yes/No/Not Applicable)
2. What is the name of your VMS Provider?
3. What was the contract signed date for the provider you currently use?
4. What is the contract expiry date for the provider you currently use?
5. What was the Trust’s spend on its VMS provider fees in 2020?
System: DE
For each of the staff group categories:
1. Do you use an On Payroll Service Provider (Direct Engagement)? (Yes/No)
2. What is the name of your DE Provider?
3. If the software provider is not in the list – Please type
4. What was the contract signed date for the provider you currently use?
5. What is the contract expiry date for the provider you currently use?
6. What was the Trust’s spend on its DE provider fees in 2020?

Staffing system(s).300822.docx

All questions are shown as received by the Trust.
1. Neutral Vend (NV) or Master Vend (MV) Agency Supplier:
i. Medical
– Name of the NV or MV agency supplier
– Expiry date of contract with the NV or MV agency supplier?
ii. Allied Health Professionals (AHPs)
– Name of the NV or MV agency supplier
– Expiry date of contract with the NV or MV agency supplier
iii. Nursing
– Name of the NV or MV agency supplier
– Expiry date of contract with the NV or MV agency supplier
iv. Non-Medical, Non-Clinical (NMNC)
– Name of the NV or MV agency supplier
– Expiry date of contract with the NV or MV agency supplier
2. Direct Engagement (DE):
i. Medical
– Name of the DE provider
– Expiry date of contract with the DE provider
– % of DE currently achieved
ii. Allied Health Professionals (AHPs)
– Name of the DE provider
– Expiry date of contract with the DE provider
– % of DE currently achieved
iii. Non-Medical, Non-Clinical (NMNC)
– Name of the DE provider
– Expiry date of contract with the DE provider
– % of DE currently achieved
3. Financial Year 2022/2023 – spend figures on temporary agency staffing – (worker pay & agency commission only):
i. Medical
ii. Allied Health Professionals (AHPs)
iii. Nursing
iv. Non-Medical, Non-Clinical (NMNC)
4. Financial Year 2022/2023 – number of hours worked by temporary agency workers:
i. Medical
ii. Allied Health Professionals (AHPs)
iii. Nursing
iv. Non-Medical, Non-Clinical (NMNC)
5. Contact responsible for temporary agency staffing at the Trust:
i. Workforce Lead
– Name
– Job Title
ii. Procurement Lead
– Name
– Job Title
iii. Finance Lead
– Name
– Job Title

Temporary Agency Staffing.300823.docx

1. Do you currently receive a neutral vendor managed service, or master vendor managed service, for the supply of temporary agency staff?
Please provide the following information for each staffing group. If there is no service provider, please state this.
i. Medical / Dental
– Name of the managed service provider?
– Are they a neutral vendor or master vendor?
– Expiry date of contract with the managed service provider?
ii. Allied Health Professionals (AHPs) / Scientific, Therapeutic and Technical
– Name of the managed service provider?
– Are they a neutral vendor or master vendor?
– Expiry date of contract with the managed service provider?
iii. Nursing and Midwifery / Healthcare Assistants (HCAs)
– Name of the managed service provider?
– Are they a neutral vendor or master vendor?
– Expiry date of contract with the managed service provider?
iv. Non-Medical, Non-Clinical (NMNC)
– Name of the managed service provider?
– Are they a neutral vendor or master vendor?
– Expiry date of contract with the managed service provider?
2. Do you currently have a direct engagement (DE) provider in place, for VAT reclaim on agency spend?
Please provide the following information for each staffing group. If there is no service provider, please state this.
i. Medical / Dental
– Name of the DE provider?
– Expiry date of contract with the managed service provider?
ii. Allied Health Professionals (AHPs) / Scientific, Therapeutic and Technical
– Name of the DE provider?
– Expiry date of contract with the managed service provider?
iii. Non-Medical, Non-Clinical (NMNC)
– Name of the DE provider?
– Expiry date of contract with the managed service provider?
3. Please can you provide 2022 full calendar year (01/01/2022 – 31/12/2022) spend figures on temporary agency staff (agency throughput)?
Please provide the following information for each staffing group. If there is no agency spend, please state this.
i. Medical / Dental
– 2022 spend on temporary agency staff (excluding VAT)?
ii. Allied Health Professionals (AHPs) / Scientific, Therapeutic and Technical
– 2022 spend on temporary agency staff (excluding VAT)?
iii. Nursing and Midwifery / Healthcare Assistants (HCAs)
– 2022 spend on temporary agency staff (excluding VAT)?
iv. Non-Medical, Non-Clinical (NMNC)
– 2022 spend on temporary agency staff (excluding VAT)?
4. Please can you provide the name of the person who looks after temporary agency staffing at the Trust?
Please provide the following information for each staffing group. If multiple people lead this from different departments, please give the details of each person.
i. Medical / Dental
– Name
– Job Title
– Department
ii. Allied Health Professionals (AHPs) / Scientific, Therapeutic and Technical
– Name
– Job Title
– Department
iii. Nursing and Midwifery / Healthcare Assistants (HCAs)
– Name
– Job Title
– Department
iv. Non-Medical, Non-Clinical (NMNC)
– Name
– Job Title
– Department
5. Please can you provide the name of the person who leads temporary agency staffing at ICS level?
Please provide the following information for each staffing group. If multiple people lead this from different departments at ICS level, please give the details of each person.
i. Medical / Dental
– Name
– Job Title
– Department
ii. Allied Health Professionals (AHPs) / Scientific, Therapeutic and Technical
– Name
– Job Title
– Department
iii. Nursing and Midwifery / Healthcare Assistants (HCAs)
– Name
– Job Title
– Department
iv. Non-Medical, Non-Clinical (NMNC)
– Name
– Job Title
– Department

Temporary Agency Staffing in 2022.120423.docx

Please can you provide me with the following information for the most recent complete fiscal year:
1. Total number of temporary workers engaged by your organization, broken down by department or function, if possible.
2. Total annual expenditure on temporary workers, including a breakdown of costs by department or function, if possible.
3. Total number of agency suppliers (Preferred Suppliers/non-Preferred Suppliers) in your organisation’s labour supply chain
Details of any existing Managed Service Programme or Provider (MSP) and/or Vendor Management System (VMS) used to manage temporary workers:
4. Name of the MSP and VMS.
5. Date the contract was awarded.
6. Date of contract expiration.
7. Name of the government procurement framework through which the MSP and VMS were procured.
Details of any upcoming retendering or renewal processes related to your MSP and VMS contracts:
8. Anticipated date for the retendering or renewal process to commence.
9. Name and contact information of the person responsible for overseeing the retendering or renewal process.

Temporary labour usage.040523.docx

All questions are shown as received by the Trust.
Sourced Staffing Arrangements
1a. Do you have a master vendor (MV) or neutral vendor (NV) arrangement in place for sourcing agency staff? If so, please state which arrangement is in place
1b. What is the name of the MV/NV provider(s) and what staffing groups do they source? e.g. medical, nursing etc.
1c. As part of the arrangement, is any technology provided by the supplier to help manage the procurement of agency staff?
1d. Please provide the contract start and end date for the supplier (dd/mm/yy)
Direct Engagement
2a. Does the organisation use a third party to provide a Direct Engagement/Outsourced Employment Solution? (This is where the NHS organisation sources agency staff via a recruitment agency but hold a direct contract between the organisation and the worker – there is often VAT savings associated to this employment model)
2b. What is the name of the Direct Engagement (DE)/Outsourced Employment supplier (e.g 247Time/Allocate, PlusUs, Retinue, Liaison etc.)
2c. Under the DE/Outsourced Employment arrangement, which staffing groups are managed? For example; Medical, Admin, Scientific staff. Please list all applicable
2d. Please provide the contract start and end date for the DE supplier (dd/mm/yy)
2f. How much did the organisation pay the supplier in 22/23 (April 2022 to March 2023) for the provision of the direct engagement service?
Vendor Management System for Nurse Agency
3a. Does the organisation use a third-party Vendor Management System for the supply of nurse agency staff?
3b. Who supplies your Vendor Management System? E.g. Allocate, NHSP etc.
3c. Please provide the contract start and end date for this provider (dd/mm/yy)
Bank Management
4a. Please name the technology provider used to manage the supply of your bank staff, inclusive of any outsourced or managed arrangements (i.e. NHSP, Bank Partners, Allocate, Liaison, Patchwork, Locum’s Nest etc). If more than one supplier is used, please name all suppliers
4b. Please name the staffing group each provider is used for e.g. medical, nursing, AHPs, admin and clerical
4c. Please provide the contract start and end date for each bank supplier (dd/mm/yy)
4d. How much did the organisation pay the supplier(s) in 22/23 for the provision of the bank service?

Temporary Staff Management.080524.docx

Sourced Staffing Arrangements
1a. Do you have a master vendor (MV) or neutral vendor (NV) arrangement in place for sourcing agency staff? If so, please state which arrangement is in place
1b. What is the name of the MV/NV provider(s) and what staffing groups do they source? e.g. medical, nursing etc.
1c. As part of the arrangement, is any technology provided by the supplier to help manage the procurement of agency staff?
1d. Please provide the contract start and end date for the supplier (dd/mm/yy)
Direct Engagement
2a. Does the organisation use a third party to provide a Direct Engagement/Outsourced Employment Solution? (This is where the NHS organisation sources agency staff via a recruitment agency but hold a direct contract between the organisation and the worker – there is often VAT savings associated to this employment model)
2b. What is the name of the Direct Engagement (DE)/Outsourced Employment supplier (e.g 247Time/Allocate, PlusUs, Retinue, Liaison etc.)
2c. Under the DE/Outsourced Employment arrangement, which staffing groups are managed? For example; Medical, Admin, Scientific staff. Please list all applicable
2d. Please provide the contract start and end date for the DE supplier (dd/mm/yy)
2f. How much did the organisation pay the supplier in 21/22 (April 2021 to March 2022) for the provision of the direct engagement service?
Vendor Management System for Nurse Agency
3a. Does the organisation use a third-party Vendor Management System for the supply of nurse agency staff?
3b. Who supplies your Vendor Management System? E.g. Allocate, NHSP etc.
3c. Please provide the contract start and end date for this provider (dd/mm/yy)
Bank Management
4a. Please name the technology provider used to manage the supply of your bank staff, inclusive of any outsourced or managed arrangements (i.e. NHSP, Bank Partners, Allocate, Liaison, Patchwork, Locum’s Nest etc). If more than one supplier is used, please name all suppliers
4b. Please name the staffing group each provider is used for e.g. medical, nursing, AHPs, admin and clerical
4c. Please provide the contract start and end date for each bank supplier (dd/mm/yy)
4d. How much did the organisation pay the supplier(s) in 21/22 for the provision of the bank service?
Temporary staff management.100822.docx

All questions are shown as received by the Trust.
1. How much did the organisation spend on agency (non-contract) staff and internal bank staff for the financial year 22/23 (April 2022 – March 2023)? Please fill in the spend in the table below for each staffing group and total.
2. How much did the organisation spend on Waiting List Initiative (WLI) and Overtime payments to staff (WLI payments refers to any sessional payments made for additional time worked under a system called the Waiting List Initiative, used by trusts to reduce waiting lists and meet government targets. Overtime payments are defined as any payment for additional time beyond the standard FTE for the grade). Please fill in the spend and number of sessions/hours in the below table for each staffing group and total.

Temporary Staff Spend 2022-2023.271023.docx

All questions are shown as received by the Trust.
1. How much did the organisation spend on agency (non-contract) staff and internal bank staff for the financial year 23/24 (April 2023 – March 2024)? Please fill in the spend in the table below for each staffing group and total.

2. How much did the organisation spend on Waiting List Initiative (WLI) and Overtime payments to staff (WLI payments refers to any sessional payments made for additional time worked under a system called the Waiting List Initiative, used by trusts to reduce waiting lists and meet government targets. Overtime payments are defined as any payment for additional time beyond the standard FTE for the grade). Please fill in the spend and number of sessions/hours in the below table for each staffing group and total.

Temporary staff spend.240824.docx

All questions are shown as received by the Trust.
The name, email address, and contact number of the person(s) or department responsible for managing the supply of temporary staffing for Allied Health Professionals (AHP) and Health Science Services (HSS) within your trust.

Temporary staffing.271124.docx

All questions are shown as received by the Trust.
Please disclose how much (total £) the trust has spent on on-framework agency, off-framework agency, and bank staff in the past four full financial years (2020/21; 2021/22; 2022/23; and 2023/24).

In this instance, “on-framework” refers to organisations on NHS England’s list of approved staffing providers. “Off-framework” refers to those who are not on this list but still provide services to trusts.

The figures should pertain to totals in each financial year and overall since 1 April 2020 (i.e., the start of the 2020/21 financial year). If possible, please also disclose:
1. A breakdown by total for all three (i.e., £2m on “on-framework”, £800k for “off-framework”, £1.2m for bank) in each of the four financial years; and
2. If available, the top three specialties by spend in each of the four financial years (e.g., gynaecology, dermatology, cardiology).

Temporary staffing spend. 271124.docx

1. From 31st July 2021 to 31st August 2021 how many shifts has your Trust used Thornbury Nursing Services and Nutrix for?
2. Within this timeframe please list the number of shifts by ward or department that Thornbury and Nutrix was utilised in.
3. Please name all other ‘off contract agencies’ for nursing that were utilised by the Trust within this time frame. (31st July 2021 to 31st August 2021) For the purpose of definition ‘off contract suppliers’ would be any non-framework providers under Work Force Alliance or Health Trust Europe.
4. Within this same time frame please list all wards or departments that utilised these agencies and break the amount of shifts down per non framework supplier.
5. How many theatre shifts have been filled by all nursing agencies in the month of August 2021? Please break these down by agency (framework and non-framework)
6. What percentage of operations have been completed this year 31st July 2021 to 31st August 2021 compared to the same time frame last year.

Download response Thornbury and Nutrix nursing services. 081121.docx

All questions are shown as received by the Trust.
Please confirm the amount of total hours utilised by the Trust for Thornbury Nursing Services on a month by month basis for every month from January 2023 to December 2024.

Thornbury Nursing Services.140324.docx

1. From 1st July 2022 to 3oth September 2022 how many shifts has your Trust used Thornbury Nursing Services for?
2. Within this timeframe please list the number of shifts by ward or department that Thornbury was utilised in.
3. Please name all other ‘off contract agencies’ for nursing that were utilised by the Trust within this time frame. (1/7/22- 30/9/22) For the purpose of definition ‘off contract suppliers’ would be any non framework providers under Work Force Alliance or Health Trust Europe.
4. Within this same time frame please list all wards or departments that utilised these agencies.
5. Please list any suppliers with a general Band 5 day charge rate of over £50 per hour that have been booked for the Trust in this time period (1/7/22- 30/9/22)
6. Please list any suppliers with a general Band 5 night charge above £60 per hour that have been booked for the Trust in this time period (1/7/22-30/9/22)

Thornbury Nursing Services.230323.docx

All questions are shown as received by the Trust.
1) Over the past 3 months, how many shifts have Thornbury Nursing Services been utilised for supplying agency nurses to your trust?
2) Over the past 3 months, how many shift requests have been sent to Thornbury Nursing Services?
3) Over the past 3 months, which clinical areas have you requested shifts from Thornbury Nursing Services (ITU,A&E,PICU, NICU,WARD, Mental Health)? [Please break down numbered shift requests for each area.]
4) Over the past 3 months, how many nursing shifts were sent out to off-framework suppliers?
5) Which off Framework suppliers are currently supplying your Trust with agency nurses?

Thornbury Nursing Services.250424.docx

All questions are shown as received by the Trust.
1. From 1st January 2024 until 1st March 2024 how many shifts has your Trust or Health Board utilised Thornbury Nursing services for?
2. Within this same time frame (1st January 2024 until 1st March 2024) please list all wards or departments that utilised this agency and display the number of shifts in each.
3. Within this same time frame (1st January 2024 until 1st March 2024) please list all other off contract agencies utilised by the Trust or Health Board for nursing and break down a list of each ward or department and total number of shifts for each off contract agency.
4. Please list any suppliers with a general Band 5 day charge rate of over £50 per hour that have been booked for the Trust or Health Board in this time period (01/01/2024- 01/03/2024)
5. Please list any suppliers with a general Band 5 night charge above £60 per hour that have been booked for the Trust or Health Board in this time period (01/01/2024- 01/03/2024)
6. Please list any suppliers with a critical day rate charge (Band 5 or 6) ITU/A&E/Theatre or any other Speciality above the rate of £60 per hour that have been utilised in this time period
7. Please list any suppliers with a critical night rate charge (Band 5 or 6) ITU/A&E/Theatre or any other Speciality above the rate of £70 per hour that have been utilised in this time period

Thornbury Nursing services and agency suppliers.080524.docx

All questions are shown as received by the Trust.
1. From 1st May 2023- 31st July 2023 how many shifts have your Trust used Thornbury Nursing Services for?
2. Within this timeframe, please list the number of shifts by ward or department that Thornbury was utilised in.
3. Please name all other ‘off-contract agencies’ for nursing that were utilised by the Trust within this time frame. (01/05/2023-31/07/2023) For the purpose of definition ‘off-contract suppliers’ would be any non-framework providers under Workforce Alliance or Health Trust Europe.
4. Please list all wards or departments that utilised these agencies within this same time frame.
5. Please list any suppliers with a general Band 5-day charge rate of over £50 per hour that have been booked for the Trust in this time period (01/05/2023-31/07/2023)
6. Please list any suppliers with a general Band 5-night charge above £60 per hour that have been booked for the Trust in this time period (01/05/2023-31/07/2023)

Thornbury Nursing Services and off-framework agencies.300823.docx

All questions are shown as received by the Trust.
1. What are the vacancies within the trust for:
a. Registered Nurses
b. Nursing associates
c. HCA’s
d. AHP’s
2. What is your agency spend within the trust from year to date (by month if possible please)?
3. How many failure to fill shifts did you have for nursing posts in August and September 2023?
4. Who is the current supplier for international nurse recruitment?

Vacancies and Agency Nursing.311023.docx

All questions are shown as received by the Trust.
Query 1
Please provide the total agency workforce spend for the specified period, broken down into the following categories for the period of 1st of January 2024 – 31st of June 2024.
• Medical Staff
• Nursing Staff
• Allied Health Professionals (AHP)
Query 2
Please provide the total agency workforce spend for the period of 1st of January 2023 – 31st of December 2023 broken down into the following categories:
• Medical Staff
• Nursing Staff
• AHP Staff
Query 3
I would also like to request spend per agency, broken down by category (Medical, Nursing and AHP) if possible as above for the period of 1st of January 2024 until 31st of June 2024

Workforce Agency Spend.150824.docx

Workforce Managed Service Provider:
1. Do you have a workforce managed service provider (MSP) Including neutral or master vendor? If yes, please specify:
2. What services do they cover?
3. When does the contract with the MSP end?
4. What are the annual service fees for the MSP?
Agency Spend:
5. How much did your trust spend on agency staffing in the last financial year?
Bank Workforce:
6. How much did your trust spend on bank workforce staffing in the last financial year?
Temporary Staffing Agencies:
7. How many temporary staffing agencies does your trust currently use?

Workforce Managed Service Provider, agency spend and staffing agencies.170624.docx

1. Please can you provide the average number of FTE vacancies for each year from FY2016/17 to FY2020/21 for the following 3 specialties. Please can you also state what the vacancy rate was as a percentage of the total FTEs in each staffing category:
a. Consultant Anaesthetists
b. Consultant Obstetricians
c. Consultant Radiologist
2. Please provide the spend for your Trust for each year from FY2016/17 to FY2020/21 for bank staffing for the following categories:
a. Consultant Anaesthetists
b. Consultant Obstetricians
c. Consultant Radiologist
3. Please provide the volume of bank staff for your Trust for each year from FY2016/17 to FY2020/21 for the following categories:
a. Consultant Anaesthetists
b. Consultant Obstetricians
c. Consultant Radiologist
4. Please provide the spend for your Trust for each year from FY2016/17 to FY2020/21 for agency staffing for the following staffing categories. If possible, please split between on-framework and off-framework agency staff spending:
a. Consultant Anaesthetists
b. Consultant Obstetricians
c. Consultant Radiologist
5. Please provide the volume of agency staff for your Trust for each year from FY2016/17 to FY2020/21 for the following staffing categories. If possible, please split between on-framework and off-framework agency staff volume:
a. Consultant Anaesthetists
b. Consultant Obstetricians
c. Consultant Radiologist

Download response Yearly staffing vacancy rates and spending on bank and agency staffing. 091221.docx

1. Please can you provide the average number of FTE vacancies for each year from FY2016/17 to FY2020/21 for the following 4 specialties. Please can you also state what the vacancy rate was as a percentage of the total FTEs in each staffing category:
a. Anaesthetists
b. Mental Health nurses
c. Midwives
d. Obstetricians
2. Please provide the spend for your Trust for each year from FY2016/17 to FY2020/21 for bank staffing for the following categories:
a. Anaesthetists
b. Mental Health nurses
c. Midwives
d. Obstetricians
3. Please provide the spend for your Trust for each year from FY2016/17 to FY2020/21 for on-framework agency staffing for the following staffing categories:
a. Anaesthetists
b. Mental Health nurses
c. Midwives
d. Obstetricians
4. Please provide the spend for your Trust for each year from FY2016/17 to FY2020/21 for off-framework agency staffing for the following staffing categories:
a. Anaesthetists
b. Mental Health nurses
c. Midwives
d. Obstetricians

Download response Yearly staffing vacancy rates and spending on bank and agency staffing. 221121.docx

All questions are shown as received by the Trust.
We seek to request that your trust shares any FOI responses where your organisation(s) indicated an adverse event due to an Electronic Patient Record System issue.

Adverse event due to an Electronic Patient Record System issue.100624.docx

All questions are shown as received by the Trust.
Under the FOI Act I would like to request the amount of times nurses working for the trust were a) assaulted and b) sexually assaulted in each of the last three years (2021, 2022 and 2023).

Assaults on nursing staff.250624.docx

1. The amount of money ordered to be paid by an Employment Tribunal to victims of sexual assault at your NHS trust for each of the last three financial years?
2. The number of people sexually assaulted at your NHS trust for each of the last three financial years?

Sexual Assault and Employment Tribunals.301023.docx

1) How many patients have reported being sexually assaulted by another patient to the Trust between 1 January 2018 and 30 June 2023?
Please can you break down the figure by year (i.e 2018, 2019, 2020, 2021, 2022 and 2023).
2) How many patients have reported being sexually assaulted by a Trust staff member between 1 January 2018 and 30 June 2023.
Please can you break down the figure by year (i.e 2018, 2019, 2020, 2021, 2022 and 2023).

Sexual assaults.160823.docx

All questions are shown as received by the Trust.
I am writing to make a request under the Freedom of Information Act for the Trust’s official policy for a) reporting and b) recording of sexual safety incidents, including sexual abuse, sexual harassment or sexual assault through the National Reporting and Learning System (NRLS) or any other relevant system.

Sexual safety incidents.081123.docx

All questions are shown as received by the Trust.
Total sexual safety incidents

1. How many sexual safety incidents did the trust record? (This includes incidents by all alleged perpetrators against all alleged victims: staff, patients, visitors, members of the public)
1.1 in 2022/23 financial year
1.2 in 2023/24 financial year

Sexual safety incidents by staff against patients
2. How many sexual safety incidents allegedly perpetrated by staff against patients did the trust record?
2.1 in 2022/23 financial year
2.2 in 2023/24 financial year

Sexual violence and misconduct by patients against other patients
3. How many sexual safety incidents allegedly perpetrated by patients against other patients did the trust record?
3.1 in 2022/23 financial year
3.2 in 2023/24 financial year

Sexual safety incidents by patients against staff
4. How many sexual safety incidents allegedly perpetrated by patients against staff did the trust record?
4.1 in 2022/23 financial year
4.2 in 2023/24 financial year

Sexual safety incidents by staff against other staff
5 How many sexual safety incidents allegedly perpetrated by staff against other staff did the trust record?
5.1 in 2022/23 financial year
5.2 in 2023/24 financial year

Age of alleged victims
6. How many of the sexual safety incidents did the trust record where the victim was a patient:
6.1 Under 18 (this includes under 16 and under 13)
6.2 Under 16 (this includes under 13)
6.3 Under 13

Please provide figures for the 2022/23 and 2023/24 financial years.
7. How many incidents of physical violence perpetrated by patients against staff did the trust record?
7.1 in 2022/23 financial year
7.2 in 2023/24 financial year

Terminology:
Sexual safety incidents include any behaviour of a sexual nature that is unwanted, or makes another person feel uncomfortable or afraid. This covers:
• sexual assault: when a person is coerced or physically forced to engage in sexual activity against their will, or when a person (of any gender) touches another person sexually without their consent.
• sexual harassment: any behaviour that is characterised by inappropriate sexual remarks, gestures or physical advances which are unwanted and make a person feel uncomfortable, intimidated or degrade their dignity.
• Other sexual incidents: where an individual may have witnessed or experienced something of a sexual nature that does not fit in to the categories of sexual harassment or assault, and which made the person feel uncomfortable and/or sexually unsafe.

Sexual safety incidents.170924.docx

All questions are shown as received by the Trust.
I would like to make another freedom of Information request to ask how many other people were frozen and if their families have been told that they were frozen as is your legal obligation. And if not why not?

Mortuary data.250724.docx

All questions are shown as received by the Trust.
Please could you kindly send me any information you may hold relating to persons who have died with no known next of kin (*defined as blood relatives, this would include patients who have listed next of kin but where such persons are friends or non blood relatives) since 1/8/2024 to the day of your reply (or as close as possible).
I confirm that this is a new request for new data only.
Please include:
1. full names of deceased persons,
2. dates of death,
3. marital status,
4. maiden surnames of married or widowed females,
5. dates of birth or ages at death,
6. last known addresses,
7. estimated value of estates,
8. dates when the information was passed (or information that is about to be or likely to be passed) to any third party, if so to whom, or confirmation that this will not be happening and the reason why.

If your authority holds this information on your website, please confirm whether or not your website information is up to date and provide a link to this. If it is not please provide full details of any unpublished cases, as per the questions above.

Persons who have died with no known blood relative next of kin.241024.docx

All questions are shown as received by the Trust.
1. Please state what percentage of your total discharges from the Acute Medical Unit are discharged home/to usual place of residence without support
2. For those patients, what was the average length of stay in the Acute Medical Unit?
3. Please state what percentage of all admitted patients from A&E waited more than 12 hours from decision to admit to actual admission (12hr+ trolley waits)
4. Please state what percentage of cancelled elective operations for non-clinical reasons were due to:
a. unavailable ward beds: b. unavailable surgeon
c. unavailable anaesthetist: d. unavailable theatre staff

Acute Medical Unit, A&E waits and cancelled elective operations.250624.docx

1. How many cancer operations have been cancelled by your NHS Trust in each of the past four financial years:
a. 2022/23
b. 2021/22
c. 2020/21
d. 2019/20
2. Please could you provide a breakdown for the reasons these operations were cancelled e.g. lack of staff, lack of beds, or equipment issues, again broken down by the financial years:
a. 2022/23
b. 2021/22
c. 2020/21
d. 2019/20

Cancelled cancer operations.061223.docx

All questions are shown as received by the Trust.
1. How many cancer operations have been cancelled by your NHS Trust in each of the past four financial years:
a. 2022/23
b. 2021/22
c. 2020/21
d. 2019/20
2. The highest number of times a patient’s operation has been cancelled at your NHS Trust since the start of 2022.
3. Please could you provide a breakdown for the reasons these operations were cancelled e.g. lack of staff, lack of beds, or equipment issues.
a. 2022/23
b. 2021/22
c. 2020/21
d. 2019/20

Cancelled Cancer operations.290224.docx

You asked: All questions are shown as received by the Trust.
1. The number of children (under 18s) who have an operation cancelled or delayed at your trust for non-clinical reasons, in each of the past five calendar years (2022, 2021, 2020, 2019, 2018).
2. For each of these years, please could you provide figures broken down by the reason behind the cancellation or delay, e.g. lack of staff, lack of bed capacity, or lack of equipment.
3. Please could you provide figures on the five longest waits for an operation currently faced by under-18s at your trust, e.g. 118 days, 116 days, 113 days. For each of these waits, please could you provide a summary of the surgical procedure in question, e.g. heart surgery.

Cancelled children’s operations.140323.docx

Question 1
How many booked elective invasive procedures (this includes but is not limited to procedures being performed in operating theatres, interventional radiology or other radiology suites, cardiac catheter labs, endoscopy and any other site not mentioned involving an invasive procedure, whether under local anaesthetic, general anaesthetic, spinal or epidural anaesthetic, peripheral nerve block, or sedation) did your trust cancel in the calendar years:
a. 2017
b. 2018
c. 2019
d. 2020
e. 2021
Question 2
How many booked elective invasive procedures (this includes but is not limited to procedures being performed in operating theatres, interventional radiology or other radiology suites, cardiac catheter labs, endoscopy and any other site not mentioned involving an invasive procedure, whether under local anaesthetic, general anaesthetic, spinal or epidural anaesthetic, peripheral nerve block, or sedation) did your trust cancel at the date of this request in this calendar year?

Cancelled elective procedures.270722.docx

a) How many elective operations were cancelled for a non-clinical reason at the Trust in 2021/22, broken down by reason for cancellation?
b) Of the total elective operations cancelled for a non-clinical reason at the Trust in 2021/22, how many were:
i. urgent surgery
ii. paediatric surgery
iii. surgical oncology

Cancelled operations.021222.docx

All questions are shown as received by the Trust.
Please can you provide me with information on medical equipment at your Trust.
The number of procedures that were cancelled by your NHS Trust due to issues with defective diagnostic equipment in each of the calendar years
a) 2019, b) 2020, c) 2021, d) 2022, e) 2023

Cancelled operations.050624.docx

All questions are shown as received by the Trust.
1. Please could you provide me with information for each of the financial years 2023/24, 2022/23
2. How many elective operations were cancelled last minute for non clinical reasons?
3. How many of those patients were not treated within 28 days of the last minute elective cancellation?
4. How many patients had their elective operation cancelled last minute on more than 5 occasions?
5. How many patients had their elective operation cancelled last minute on more than 10 occasions?
6. In the financial years above – what was the highest number of occasions that a patient had an elective operation cancelled at the last minute?

Cancelled operations.080424.docx

1. Please can you tell me the number of last minute elective operations cancelled for non clinical reasons at your trust or board for each month of 2020 and 2021 to date.
2. Please can you tell me the number of urgent operations cancelled for non-medical reasons during each month.
If giving the full data requested would be likely to exceed the costs cap, please provide data for the most recent month and then as many months as possible working backwards until the limit is reached.
3. If possible, please let me know how many of the cancelled elective operations had still not been carried out 28 days later.
4. If possible, please let me know how many of the cancelled urgent operations had still not been carried out 28 days later.

Download response Cancelled operations. 131021.docx

1. The number of people who have had an operation cancelled or delayed at your trust for non-clinical reasons, in each of the past five calendar years (2022, 2021, 2020, 2019, 2018).
2. For each of these years, please could you provide figures broken down by the reason behind the cancellation or delay, e.g. lack of staff, lack of bed capacity, or lack of equipment.
3. Please could you provide figures on the five longest waits for an operation currently faced by under-18s at your trust, e.g. 110 days, 98 days, 200 days. For each of these waits, please could you provide a summary of the surgical procedure in question, e.g. heart surgery.

Cancelled operations.140323.docx

1. The number of elective operations scheduled. I would like this information for January 2022 to end of December 2022 broken down by week i.e. the total number of elective operations that were planned for Week 1, January 2022, Week 2 etc.
2. The number of elective operations performed. January 2022 to end of December 2022 broken down by week i.e. the total number of elective operations that were planned for Week 1, January 2022, Week 2, etc
3. The number of elective operations cancelled at the “last minute”, as defined by the NHS when providing data on cancelled elective operations. I would like this information for January 2022 to end of December 2022 broken down by week i.e. the total number of elective operations planned for Week 1, January 2022, Week 2 etc.
4. The total number of elective operations cancelled, regardless of how long cancellations were made before scheduled operation times, if this information is also collected. I would like this information for January 2022 to the end of December 2022 broken down by week i.e. the total number of elective operations planned for Week 1, January 2022, Week 2 etc.

Cancelled operations.2. 140323.docx

All questions are shown as received by the Trust.
How many elective operations were cancelled for a non-clinical reason at the Trust in 2021/22, broken down by reason for cancellation?

Cancelled operations 2021-2022.110624.docx

All questions are shown as received by the Trust.
a) How many elective operations were cancelled for a non-clinical reason at the Trust in 2022/23, broken down by reason for cancellation?

Cancelled operations 2022-2023.110624.docx

All questions are shown as received by the Trust.
a) How many elective operations were cancelled for a non-clinical reason at the Trust in 2023/24, broken down by reason for cancellation?

Cancelled operations 2023-2024.110624.docx

1. Please can you provide figures on the total number of patients who have had their operation cancelled for a second time. I would like these figures broken down by year for each of the past five years:
a. 2022,
b. 2021,
c. 2020,
d. 2019,
e. 2018.
For context, I am looking for incidents where the surgery was cancelled for non-clinical reasons (i.e. staff shortages, equipment problems, lack of theatre capacity) and also not at the request of the patient.
2. In addition, please can you provide the largest number of times that a single patient has had their operation cancelled for non-clinical reasons, over the past five years.
a. Please could you name the operation in question (e.g. hip replacement),
b. The year that the last cancellation took place (e.g. 2022).

Cancelled operations.280923.docx

I have been looking on the MTW website for your “2 week urgent referral policy”. I have not been able to locate this or a leaflet. Would you please be able to email me a copy of this?

Download response 2-week urgent referral policy. 031121.docx

All questions are shown as received by the Trust.
Please see below a Freedom of Information request made by OPEN Health. Please answer the questions with regards to NHS patients, i.e., excluding patients that received treatment as part of clinical trials or private healthcare.
1. Do you treat patients with acute myeloid leukaemia (AML) in your Trust?
If yes, please proceed to Question 3, if no, please answer Question 2
2. Where do patients diagnosed with AML in your Trust receive treatment?
3. Please complete the table below with how many newly diagnosed patients with AML have started first-line treatment with each of the following therapies during the 6-month period October 2023 to March 2024?
• Azacitidine monotherapy
• Low dose cytarabine (LoDAC) monotherapy
• Venetoclax + azacitidine
• Venetoclax + LoDAC
• Ivosidenib
• Intensive chemotherapy-based regimen
o Examples include: cytarabine and daunorubicin, idarubicin, fludarabine, mitoxantrone, etoposide (VP-16), 6-thioguanine (6-TG), methotrexate (MTX) or 6-mercaptopurine (6-MP), gemtuzumab ozogamicin with daunorubicin cytarabine, or FLAG-Ida (fludarabine, cytarabine, granulocyte-colony stimulating factor and idarubicin)
• Best supportive care
• Other
o Do not include prophylactic therapies such as GCSF, anti-fungals, antihistamines, anti-nauseants

Note: this should only include patients with AML who have started first-line treatment during the 6-month window.

Acute myeloid leukaemia (AML).100524.docx

All questions are shown as received by the Trust.
1. Please complete the table below with how many newly diagnosed patients with AML have started first-line treatment with each of the following therapies during the 6-month period February 2024 to July 2024?
• Azacitidine monotherapy
• Low dose cytarabine (LoDAC) monotherapy
• Venetoclax + azacitidine
• Venetoclax + LoDAC
• Ivosidenib
• Intensive chemotherapy-based regimen
O Examples include: cytarabine and daunorubicin, idarubicin, fludarabine, mitoxantrone, etoposide (VP-16), 6-thioguanine (6-TG), methotrexate (MTX) or 6-mercaptopurine (6-MP), gemtuzumab ozogamicin with daunorubicin cytarabine, or FLAG-Ida (fludarabine, cytarabine, granulocyte-colony stimulating factor and idarubicin)
• Best supportive care
• Other
O Do not include prophylactic therapies such as GCSF, anti-fungals, antihistamines, anti-nauseants

Acute myeloid leukaemia (AML).220824.docx

All questions are shown as received by the Trust.
Patients with acute myeloid leukaemia (AML)
1. How many patients with AML, in total, have been treated with the following therapies during the last 6 months, irrespective of start date or line of therapy?
• Azacitidine monotherapy
• Low dose cytarabine (LoDAC) monotherapy
• Venetoclax + azacitidine
• Venetoclax + LoDAC
• Ivosidenib
• Intensive chemotherapy-based regimen
• Other
2. How many newly diagnosed patients with AML have started first-line treatment with the following therapies during the last 6 months?
• Azacitidine monotherapy
• Low dose cytarabine (LoDAC) monotherapy
• Venetoclax + azacitidine
• Venetoclax + LoDAC
• Ivosidenib
• Intensive chemotherapy-based regimen
• Other
3. (a) Of the patients with AML treated with venetoclax (venetoclax + azacitidine or venetoclax + LoDAC) in the last 6 months, how many are approved for treatment via Blueteq?
Patients with chronic lymphocytic leukaemia (CLL)
4. How many patients with CLL have received treatment with venetoclax in the past 6 months (including venetoclax monotherapy, venetoclax + rituximab, venetoclax + obinutuzumab or venetoclax + ibrutinib)?
5. How many patients with CLL who were new to all lines of treatment received venetoclax in the past 6 months (including venetoclax monotherapy, venetoclax + rituximab, venetoclax + obinutuzumab or venetoclax + ibrutinib)?

Acute myeloid leukaemia (AML) and chronic lymphocytic leukaemia (CLL).171123.docx

Please note the questionnaire refers only to Adult Haematology services.
1) Does your Trust have a Clinical Haematology service for Adults?
Yes / No (delete as appropriate)
If No, please return the questionnaire at this stage – there are no further questions that need to be answered.
2) If Yes, please complete the staffing table below:
3) If you have Haematology Clinical Nurse Specialists, please advise on how their jobs are split, for example 1.0WTE Myeloma CNS, 0.8WTE BMT CNS etc.
4) Which of the below haematological services does your Haematology service cover?
5) In the last 3 years, how many ‘New’ patients were seen by your Clinical Haematology Team?
6) If you have a BMT service, how many patients do you treat on average per year?

Adult Haematology services.190522.docx

1) In the past 3 months, how many advanced/metastatic breast cancer patients have the status of;
a) HR+ and HER2+ [Hormone receptor-positive and human epidermal growth factor 2-positive]
b) HR- and HER2+ [Hormone receptor-negative and human epidermal growth factor 2-positive]
2) In the past 3 months, how many breast cancer patients were treated with:
a. Abemaciclib (Verzenios) + aromatase inhibitor *
b. Abemaciclib (Verzenios) + Fulvestrant
c. (Faslodex) Alpelisib (Piqray) + Fulvestrant (Faslodex)
d. Atezolizumab (Tecentriq)**
e. Bevacizumab (Avastin)
f. Eribulin (Halaven)
g. Everolimus (Afinitor) + Exemestane
h. Fulvestrant (Faslodex) as a single agent
i. Gemcitabine + paclitaxel
j. Lapatinib (Tyverb)
k. Neratinib (Nerlynx)
l. Olaparib (Lynparza)
m. Palbociclib (Ibrance) + aromatase inhibitor*
n. Pertuzumab (Perjeta) + trastuzumab + docetaxel
o. Ribociclib (Kisqali) + aromatase inhibitor*
p. Ribociclib (Kisqali) + Fulvestrant (Faslodex)
q. Talazoparib (Talzenna)
r. Trastuzumab + paclitaxel Trastuzumab as a single agent
s. Trastuzumab emtansine (Kadcyla)
t. Trastuzumab Deruxtecan (Enhertu)
u. Tucatinib + Trastuzumab + Capecitabine (Tukysa)
v. Other active systemic anti-cancer therapy ** *aromatase inhibitor e.g. Anastrozole, Exemestane or Letrozole **e.g. docetaxel, vinorelbine or capecitabine as a single agent

Advanced breast cancer.041122.docx

Q1. How many patients have been diagnosed with advanced hepatocellular carcinoma (Stage 3b and 4) in the last 6 months?
Q2. How many hepatocellular carcinoma patients (any stage) have been treated in the last 6 months with the following treatments:
a. Lenvatinib
b. Sorafenib
c. Regorafenib
d. Atezolizumab + Bevacizumab
Q3. In the last 6 months, how many patients has your trust treated (for any condition) with the following treatments:
a. Avatrombopag
b. Eltrombopag
c. Fostamatinib
d. Romiplostim
Q4. In the last 6 months, how many patients has your trust treated for Immune thrombocytopenia (ICD10 code D69.3) ONLY with the following treatments:
a. Avatrombopag
b. Mycophenolate mofetil
c. Rituximab
d. Surgery (splenectomy)
Q5. Does your trust participate in any clinical trials for the treatment of hepatocellular carcinoma? If so, can you please provide the name of each trial and the number of patients taking part.

Advanced hepatocellular carcinoma (Stage 3b and 4).230522.docx

All questions are shown as received by the Trust.
I should be grateful if you could inform me of the number of ALK-positive lung cancer patients that your Trust is currently treating. Would it be possible to separate out NHS and private patients?

ALK-positive lung cancer.150923.docx

1. The number of Autoclaves commissioned and commissioned date.
2. The departments where Autoclaves are used.

Autoclaves.130223.docx

All questions are shown as received by the Trust.
I would be grateful if you could please provide the following information with regards to patients treated with Durvalumab (Imfinzi) and Nivolumab.

Where the specified Nov 23 – March 24 timeframe is not possible to provide, could you please provide the latest 5 months of data you have, and specify which timeframe this covers.

1. How many unique total patients were treated in the last 5 months (Nov 23 – March 24) with Durvalumab for the following indications?
A) Biliary Tract Cancer
B) Non-Small Cell Lung Cancer
2. How many unique total patients were treated in the last 5 months (Nov 23 – March 24) with Nivolumab for early stage (resectable) non-small cell lung cancer (Stages 1 – 3b).
3. How many unique total patients were treated last month (March 24) with Durvalumab for the following indications?
C) Biliary Tract Cancer
D) Non-Small Cell Lung Cancer

4. How many patients received their first treatment in the last 5 months (Nov 23 – March 24) with Durvalumab for the following indications?
E) Biliary Tract Cancer
F) Non-Small Cell Lung Cancer

Biliary Tract and Non-Small Cell Lung Cancer Treatment.240424.docx

All questions are shown as received by the Trust.
1. In the last 12 months, how many individual patients were treated for biliary tract cancer with the following Diagnosis Codes:
A) C22.1 Intrahepatic Bile Duct Cardinoma
B) C23 Malignant Neoplasm of Gallbladder
C) C24 Malignant Neoplasm of unspecified biliary tract (If possible, could this please be further split to C24.0 Extrahepatic bile duct, C24.8 Overlapping lesion of Biliary Tract, C24.9 Biloary Tract, Unspecified).

Could you please also provide a total unique patient number for all of the diagnosis codes above, in case they have been coded multiple times.
2. In the last 12 months, how many patients were treated for Oesophagus Oesophagogastric Junction Cancer? (C16.7)

Biliary tract cancer.281223.docx

All questions are shown as received by the Trust.
In the past three months, how many patients have been treated for Bladder cancer with the below:
a) Avelumab
b) Atezolizumab
c) Carboplatin with Gemcitabine
d) Carboplatin single or in any other combination
e) Cisplatin with Gemcitabine
f) Cisplatin single or in any other combination
g) Nivolumab
h) Pembrolizumab
i) Any other systemic anti-cancer therapy
j) Palliative care only

Bladder cancer.081223.docx

Please provide details of the type (manufacturer and model), quantity, department, site where they are located and age of all Blood Gas Analysers listed on your trust’s asset register (or equivalent).

Blood Gas Analysers.111022.docx

1. How many patients have been treated for glioblastoma brain cancer in the last 12 months, in your trust/ health board?
2. Which consultant is the nominated medical lead for the treatment or referral of glioblastoma brain cancer?
3.Does your trust/ health board treat all referred glioblastoma brain cancer cases, or are they referred to different centre’s? If so, which treatment centre(s) are they referred to?

Brain Cancer Treatment.051022.docx

Q1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:
a. Abemaciclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole)
b. Abemaciclib + Fulvestrant
c. Alpelisib + Fulvestrant
d. Anthracycline (e.g. doxorubicin or epirubicin) as a single agent
e. Atezolizumab +Nab-paclitaxel/Paclitaxel
f. Capecitabine as a single agent
g. Eribulin as a single agent or in combination
h. Everolimus + Exemestane
i. Fulvestrant as a single agent
j. Lapatinib
k. Neratinib
l. Parp Inhibitors (Olaparib/Talazoparib)
m. Palbociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole)
n. Palbociclib + Fulvestrant
o. Pembrolizumab
p. Platinum (e.g. carboplatin or cisplatin) as a single agent
q. Ribociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole)
r. Ribociclib + Fulvestrant
s. Sacituzumab Govitecan
t. Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent
u. Taxane and/or Anthracycline in combination
v. Trastuzumab as a single agent or in combination
w. Trastuzumab emtansine
x. Transtuzumab deruxtecan
y. Any other active systemic anti-cancer therapy

Breast cancer.021123.docx

Q1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:
a. Abemaciclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole)
b. Abemaciclib + Fulvestrant
c. Alpelisib + Fulvestrant
d. Anthracycline (e.g. doxorubicin or epirubicin) as a single agent
e. Atezolizumab +Nab-paclitaxel/Paclitaxel
f. Capecitabine as a single agent
g. Eribulin as a single agent or in combination
h. Everolimus + Exemestane
i. Fulvestrant as a single agent
j. Lapatinib
k. Neratinib
l. Parp Inhibitors (Olaparib/Talazoparib)
m. Palbociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole)
n. Palbociclib + Fulvestrant
o. Pembrolizumab
p. Platinum (e.g. carboplatin or cisplatin) as a single agent
q. Ribociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole)
r. Ribociclib + Fulvestrant
s. Sacituzumab Govitecan
t. Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent
u. Taxane and/or Anthracycline in combination
v. Trastuzumab as a single agent or in combination
w. Trastuzumab emtansine
x. Transtuzumab deruxtecan
y. Any other active systemic anti-cancer therapy
Q2. Does your trust participate in any clinical trials for the treatment of breast cancer? If so, please provide the name of each trial and the number of patients taking part.

Breast Cancer.030723.docx

Q1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:
a. Abemaciclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole)
b. Abemaciclib + Fulvestrant
c. Alpelisib + Fulvestrant
d. Anthracycline (e.g. doxorubicin or epirubicin) as a single agent
e. Atezolizumab + Nab-paclitaxel/Paclitaxel
f. Capecitabine as a single agent
g. Eribulin as a single agent or in combination
h. Everolimus + Exemestane
i. Fulvestrant as a single agent
j. Lapatinib
k. Neratinib
l. Parp Inhibitors (Olaparib/Talazoparib)
m. Palbociclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole)
n. Palbociclib + Fulvestrant
o. Pembrolizumab
p. Platinum (e.g. carboplatin or cisplatin) as a single agent
q. Ribociclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole)
r. Ribociclib + Fulvestrant
s. Sacituzumab Govitecan
t. Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent
u. Taxane and/or Anthracycline in combination
v. Trastuzumab as a single agent or in combination
w. Trastuzumab emtansine
x. Transtuzumab deruxtecan
y. Any other active systemic anti-cancer therapy

Q2. Of the patients treated for breast cancer with Abemaciclib + Aromatase Inhibitor in the past the 3 months, please provide the number of patients with:
a. early/locally advanced breast cancer (Stages 1 to 3B)
b. advanced/metastatic breast cancer (Stages 3C and 4)

Breast cancer.090323.docx

1. In the past 3 months, how many Breast Cancer patients (any stage) were treated with:
a. Abemaciclib monotherapy
b. Aromatase inhibitor monotherapy (e.g. anastrazole, exemestane, letrozole)
c. Tamoxifen monotherapy
d. Abemaciclib + Tamoxifen
e. Abemaciclib + Tamoxifen + Goserelin
f. Abemaciclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) + Goserelin
g. Aromatase inhibitor + Goserelin
h. Tamoxifen+ Goserelin
2. How many patients have been treated for Triple-Negative Breast Cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:
a. Anthracycline (e.g. doxorubicin or epirubicin) as a single agent
b. Atezolizumab +Nab-paclitaxel/Paclitaxel
c. Pembrolizumab
d. Sacituzumab Govitecan
e. Parp Inhibitors (Olaparib/Talazoparib)
f. Eribulin as a single agent or in combination
g. Capecitabine as a single agent
h. Platinum (e.g. carboplatin or cisplatin) as a single agent
i. Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent
j. Taxane and/or Anthracycline in combination
k. Any other active systemic anti-cancer therapy

Breast cancer.090922.docx

Q1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of June 2023 and end of August 2023?
Please provide data for the latest 3-month period, if Jun to Aug is not available yet
1.1 Abemaciclib (Verzenios)
1.2 Alpelisib (Piqray)
1.3 Fulvestrant (fulvestrant or Faslodex)
1.4 Palbociclib (Ibrance)
1.5 Ribociclib (Kisqali)
Q2. How many patients received abemaciclib (Verzenios) for early breast cancer in the 3 months between the start of June 2023 and end of August 2023?
Please provide data for the latest 3-month period, if Jun to Aug is not available yet
Q3. How many patients received abemaciclib (Verzenios) as adjuvant treatment for early breast cancer in the 3 months between the start of June 2023 and end of August 2023?
Please provide data for the latest 3-month period, if Jun to Aug is not available yet
Q4. How many patients received abemaciclib (Verzenios) with the following treatment intent in the 3 months between the start of June 2023 and end of August 2023?
Please provide data for the latest 3-month period, if Jun to Aug is not available yet
4.1 Curative
4.2 Palliative
4.3 Not known / stated
Q5. How many patients were treated with the following medicines in combination in the 3 months between the start of June 2023 and end of August 2023?
Please provide data for the latest 3-month period, if Jun to Aug is not available yet
5.1 Abemaciclib (Verzenios) + Fulvestrant (fulvestrant or Faslodex)
5.2 Abemaciclib (Verzenios) + an aromatase inhibitor (anastrozole, letrozole or exemestane)
5.3 Abemaciclib (Verzenois) + tamoxifen
5.4 Abemaciclib monotherapy
5.5 Alpelisib (Piqray) + Fulvestrant (fulvestrant or Faslodex)
5.6 Palbociclib (Ibrance) + Fulvestrant (fulvestrant or Faslodex)
5.7 Palbociclib (Ibrance) + an aromatase inhibitor (anastrozole, letrozole or exemestane)
5.8 Ribociclib (Kisqali) + Fulvestrant (fulvestrant or Faslodex)
5.9 Ribociclib (Kisqali) + an aromatase inhibitor (anastrozole, letrozole or exemestane)

Breast Cancer.151223.docx

1. In the past 3 months, how many Breast Cancer patients (at any stage) were treated with:
a. Abemaciclib monotherapy
b. Aromatase inhibitor monotherapy (e.g. anastrazole, exemestane, letrozole)
c. Tamoxifen monotherapy
d. Abemaciclib + Tamoxifen
2. In the past 3 months, how many early/locally advanced Breast Cancer (Stages 1 to 3B) patients were treated with:
a. Abemaciclib + Aromatase inhibitor (e.g. anastrazole, exemestane, letrozole)
b. Taxane and/or Anthracycline (monotherapy or in combination)
c. Any other active systemic anti cancer therapy
3. How many patients have been treated for Triple Negative Breast Cancer (any stage) in the past 3 months with the following systemic anti cancer therapies:
a. Anthracycline (e.g. doxorubicin or epirubicin) as a single agent
b. Atezolizumab +Nab-paclitaxel/Paclitaxel
c. Pembrolizumab
d. Sacituzumab Govitecan
e. Parp Inhibitors (Olaparib/Talazoparib)
f. Eribulin as a single agent or in combination
g. Capecitabine as a single agent
h. Platinum (e.g. carboplatin or cisplatin) as a single agent
i. Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent
j. Taxane and/or Anthracycline in combination
k. Any other active systemic anti-cancer therapy

Breast Cancer.181122.docx

All questions are shown as received by the Trust.
Q1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:
a. Abemaciclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole)
b. Abemaciclib + Fulvestrant
c. Alpelisib + Fulvestrant
d. Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide
e. Aromatase Inhibitor as a single agent
f. Atezolizumab
g. Capecitabine as a single agent
h. Carboplatin + Paclitaxel
i. Eribulin as a single agent or in combination
j. Everolimus + Exemestane
k. Fulvestrant as a single agent
l. Palbociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole)
m. Palbociclib + Fulvestrant
n. Parp Inhibitors (Olaparib/Talazoparib)
o. Pembrolizumab
p. Ribociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole)
q. Ribociclib + Fulvestrant
r. Sacituzumab Govitecan
s. Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent
t. Transtuzumab deruxtecan
u. Trastuzumab as a single agent or in combination
v. Trastuzumab emtansine
w. Any other active systemic anti-cancer therapy
Q2. Does your trust participate in any clinical trials for breast cancer? If so, please provide the name of each trial, and the number of patients taking part.

Breast Cancer.231024.docx

Q1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the systemic anti-cancer therapies listed below?
a. Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole) as a single agent
b. Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)
c. Abemaciclib + Fulvestrant
d. Anthracycline (e.g. doxorubicin or epirubicin) as a single agent
e. Atezolizumab +Nab-paclitaxel/Paclitaxel
f. Capecitabine as a single agent
g. Carboplatin or Cisplatin as a single agent
h. Eribulin as a single agent or in combination
i. Everolimus + Exemestane
j. Fluorouracil
k. Fulvestrant as a single agent
l. Goserelin
m. Lapatinib
n. Neratinib
o. Olaparib
p. Palbociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole)
q. Palbociclib + Fulvestrant
r. Pertuzumab + Trastuzumab + Docetaxel
s. Platinum (e.g. carboplatin or cisplatin) as a single agent
t. Ribociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole)
u. Ribociclib + Fulvestrant
v. Talazoparib
w. Tamoxifen
x. Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent
y. Transtuzumab as a single agent
z. Trastuzumab emtansine
aa. Transtuzumab deruxtecan
bb. Any other active systemic anti-cancer therapy

Q2. In the past 3 months, how many early/locally advanced (Stages I to IIIc) breast cancer patients were treated with an Aromatase Inhibitor (anastrozole, exemestane, Letrozole) as a single agent?

Download response Breast cancer. 251021.docx

Breast Cancer.

You asked: All questions are shown as received by the Trust.
1) In the past 3 months, how many advanced/metastatic breast cancer patients have the status of;
a) HR+ and HER2+ [Hormone receptor-positive and human epidermal growth factor 2-positive]
b) HR- and HER2+ [Hormone receptor-negative and human epidermal growth factor 2-positive]
c) The total number of Metastatic breast cancer patients of any type.

2) In the past 3 months, how many metastatic breast cancer patients were treated with:
a) Trastuzumab + Pertuzumab + paclitaxel
b) Trastuzumab + paclitaxel Trastuzumab as a single agent
c) Trastuzumab emtansine
d) Trastuzumab Deruxtecan
e) Tucatinib + Trastuzumab + Capecitabine

Breast Cancer.270224.docx

All questions are shown as received by the Trust.
Q1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:
a. Abemaciclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole)
b. Abemaciclib + Fulvestrant
c. Alpelisib + Fulvestrant
d. Anthracycline (e.g. doxorubicin or epirubicin) as a single agent
e. Atezolizumab +Nab-paclitaxel/Paclitaxel
f. Capecitabine as a single agent
g. Eribulin as a single agent or in combination
h. Everolimus + Exemestane
i. Fulvestrant as a single agent
j. Lapatinib
k. Neratinib
l. Parp Inhibitors (Olaparib/Talazoparib)
m. Palbociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole)
n. Palbociclib + Fulvestrant
o. Pembrolizumab
p. Platinum (e.g. carboplatin or cisplatin) as a single agent
q. Ribociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole)
r. Ribociclib + Fulvestrant
s. Sacituzumab Govitecan
t. Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent
u. Taxane and/or Anthracycline in combination
v. Trastuzumab as a single agent or in combination
w. Trastuzumab emtansine
x. Transtuzumab deruxtecan
y. Any other active systemic anti-cancer therapy
Q2. Does your trust participate in any clinical trials for breast cancer? If so, please provide the name of each trial, and the number of patients taking part.

Breast cancer.280224.docx

Q1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the latest three months for which you have data?
Name of medicine
1.1 Abemaciclib (Verzenios)
1.2 Alpelisib (Piqray)
1.3 Anastrozole (anastrozole or Arimidex)
1.4 Exemestane (exemestane or Aromasin)
1.5 Fulvestrant (fulvestrant or Faslodex)
1.6 Letrozole (letrozole or Femara)
1.7 Palbociclib (Ibrance)
1.8 Ribociclib (Kisqali)
Q2. How many patients received abemaciclib (Verzenios) as adjuvant treatment for early breast cancer in the latest three months for which you have data?
If you do not have data on early breast cancer, please state how many patients received abemaciclib (Verzenios) as adjuvant treatment.
Q3. How many patients received abemaciclib in combination with an aromatase inhibitor (anastrozole or exemestane or letrozole) for early breast cancer and locally advanced or metastatic breast cancer in the latest three months for which you have data?
3.1 Abemaciclib + aromatase inhibitor (anastrozole or exemestane or letrozole)
3.2 Abemaciclib + aromatase inhibitor (anastrozole or exemestane or letrozole)
Q4. How many patients received Olaparib (Lynparza) as adjuvant treatment for early breast cancer in the latest three months for which you have data?
If you do not have data on early breast cancer, please state how many patients received Olaparib (Lynparza) as adjuvant treatment.
Q5. How many patients were treated with the following medicines in combination in the latest three months for which you have data?
Name of combination
4.1 Abemaciclib (Verzenios) + Fulvestrant (fulvestrant or Faslodex)
4.2 Abemaciclib (Verzenios) + Anastrozole (anastrozole or Arimidex)
4.3 Abemaciclib (Verzenios) + Exemestane (exemestane or Aromasin)
4.4 Abemaciclib (Verzenios) + Letrozole (letrozole or Femara)
4.7 Alpelisib (Piqray) + Fulvestrant (fulvestrant or Faslodex)
4.8 Palbociclib (Ibrance) + Fulvestrant (fulvestrant or Faslodex)
4.9 Palbociclib (Ibrance) + Anastrozole (anastrozole or Arimidex)
4.10 Palbociclib (Ibrance) + Exemestane (exemestane or Aromasin)
4.11 Palbociclib (Ibrance) + Letrozole (letrozole or Femara)
4.12 Ribociclib (Kisqali) + Fulvestrant (fulvestrant or Faslodex)
4.13 Ribociclib (Kisqali) + Anastrozole (anastrozole or Arimidex)
4.14 Ribociclib (Kisqali) + Exemestane (exemestane or Aromasin)
4.15 Ribociclib (Kisqali) + Letrozole (letrozole or Femara)
Q5. How many patients were treated with Olaparib (Lynparza) as monotherapy for locally advanced or metastatic breast cancer in the latest three months for which you have data?
Q6. Which of these protocols does your Trust follow when issuing prescriptions for aromatase inhibitors (anastrozole or exemestane or letrozole) prescribed in combination with CDK4/6 inhibitors (abemaciclib or palbociclib or ribociclib)?
6.1 Aromatase inhibitors and CDK4/6 inhibitors are issued together To Take Out at the hospital
6.2 Aromatase inhibitors and CDK4/6 inhibitors are issued separately. The CDK4/6 inhibitors (abemaciclib or palbociclib or ribociclib) are issued To Take Out at the hospital. The aromatase inhibitors (anastrozole or exemestane or letrozole) are issued as an FP10 to the patient or a request is sent to the GP to issue in the community
6.3 Both protocols above

Breast Cancer.310323.docx

Q1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:
a. Abemaciclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole)
b. Abemaciclib + Fulvestrant
c. Anthracycline (e.g. doxorubicin or epirubicin) as a single agent
d. Atezolizumab +Nab-paclitaxel/Paclitaxel
e. Capecitabine as a single agent
f. Eribulin as a single agent or in combination
g. Everolimus + Exemestane
h. Fulvestrant as a single agent
i. Lapatinib
j. Neratinib
k. Parp Inhibitors (Olaparib/Talazoparib)
l. Palbociclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole)
m. Palbociclib + Fulvestrant
n. Pembrolizumab
o. Platinum (e.g. carboplatin or cisplatin) as a single agent
p. Ribociclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole)
q. Ribociclib + Fulvestrant
r. Sacituzumab Govitecan
s. Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent
t. Taxane and/or Anthracycline in combination
u. Trastuzumab as a single agent or in combination
v. Trastuzumab emtansine
w. Transtuzumab deruxtecan
x. Any other active systemic anti-cancer therapy
Q2. In the past 3 months, how many early/locally advanced breast cancer (Stages 1 to 3B) patients were treated with:
a. Abemaciclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole)
b. Taxane and/or Anthracycline (monotherapy or in combination)
c. Any other active systemic anti-cancer therapy

Breast cancer treatment.110722.docx

1. How many cancer operations have been cancelled by your NHS Trust in each of the past four financial years:
a. 2022/23
b. 2021/22
c. 2020/21
d. 2019/20
2. Please could you provide a breakdown for the reasons these operations were cancelled e.g. lack of staff, lack of beds, or equipment issues, again broken down by the financial years:
a. 2022/23
b. 2021/22
c. 2020/21
d. 2019/20

Cancelled cancer operations.061223.docx

All questions are shown as received by the Trust.
1. How many cancer operations have been cancelled by your NHS Trust in each of the past four financial years:
a. 2022/23
b. 2021/22
c. 2020/21
d. 2019/20
2. The highest number of times a patient’s operation has been cancelled at your NHS Trust since the start of 2022.
3. Please could you provide a breakdown for the reasons these operations were cancelled e.g. lack of staff, lack of beds, or equipment issues.
a. 2022/23
b. 2021/22
c. 2020/21
d. 2019/20

Cancelled Cancer operations.290224.docx

All questions are shown as received by the Trust.
1. The number of (a) first consultant appointments after an urgent referral, (b) first definitive cancer treatments, and (c) subsequent cancer treatments, that were cancelled or rescheduled by your trust in financial year 2022/23:
(i) once
(b) twice
(c) three times or more
2. The most amount of times the date was changed on a single one of the above cancer appointments by your trust in FY 2022/23.

Cancer appointments.081223.docx

1) How many PALS enquiries and official complaints your Trust has received from patients concerned about
a) the impact of the coronavirus pandemic and your Trust’s response on their or their family member’s access to cancer treatment
b) and access to cancer testing – including tests to find out whether their or their family member’s cancer has spread, returned or occurred for the first time
2) For the five most recent PALS enquiries/official complaints received, please provide me with
a) a summary of the complaint (e.g. a patient with stage 4 lung and breast cancer has contacted PALS to complain about their chemotherapy being postponed for a month)
b) the exact wording of the complaint, with redactions to remove potentially identifying information
c) what action the Trust took in response

Download response Cancer complaints. 021121.docx

All questions are shown as received by the Trust.
1. How many fatalities have been due to cancer wrong diagnosis or failure/delay diagnosis in the last three years (Between 2021-up to and including any data held for 2024)?

For example: The number of incidents where the Primary Cause is ‘Wrong Diagnosis’ or ‘Failure/Delay Diagnosis’ and where both injury codes ‘Cancer’ and ‘Fatality’ are recorded?

Cancer diagnosis.190424.docx

All questions are shown as received by the Trust.
The number of patients diagnosed with cancer, broken down between 2018 and 2023, where:
o The source of referral for the cancer diagnosis was listed as ‘Following A&E Attendance’.
o Attendances at A&E where the presenting complaint indicated that the patient was already known to have cancer or was undergoing cancer treatment were excluded.

Cancer diagnosis via A&E.190424.docx

1. How many patients are currently on your trust’s waiting list for a cancer diagnostic test?
2. How many patients were on your trust’s waiting list for a cancer diagnostic test 12 months ago?
3. What is the longest time a patient has had to wait for a cancer diagnostic test in the last 12 months?
4. How many cancer diagnostic tests have been cancelled by your trust for non-clinical reasons in the last 12 months?
5. What is the highest number of times a cancer diagnostic test for one patient has been cancelled by your trust for non-clinical reasons in the last 12 months?

Cancer diagnostic tests.021123.docx

All questions are shown as received by the Trust.
“The total amount of your Trusts budget in pounds-sterling (£) that is allocated for all cancer funding in each of the financial years a) 2023-2024, b) 2023-2022, c) 2022-2021, d) 2021-2020, e) 2020-2019
The percentage of your Trusts total budget that is allocated for all cancer funding in each of the financial years a) 2023-2024, b) 2023-2022, c) 2022-2021, d) 2021-2020, e) 2020-2019”

Cancer funding.140324.docx

All questions are shown as received by the Trust.
1. The number of people at your trust currently receiving treatment for cancer?
2. The number of people at your trust currently waiting to receive treatment for cancer?
3. How long has the person who has waited the longest been waiting?
4. The number of people waiting to start cancer treatment, as measured from the date of urgent referral, who have waited longer than:
a. 62 days,
b. 3 months,
c. 4 months
d. 6 months,
e. 12 months.
5. The single longest wait to start cancer treatment, as measured from the date of the urgent referral, for each of the last three years?

Cancer – Longest Wait.310823.docx

1. How many patients on the cancer pathway started treatment within the 62 days and over 62 days, from urgent GP referral to starting treatment in each month of 2020 and 2021.
2. How many patients referred under the 2 weeks wait pathway were seen within 14 days in each month of 2020 and 2021.
3. How many patients started cancer treatment in each month of:
a. 2019
b. 2020
c. 2021

Download response Cancer pathway and treatment. 270821.docx

1. Over all how many Cancer trackers are employed by your Trust (WTE)?
2. Over all how many cancer MDT co-ordinators are employed by your Trust (WTE)?
3. Please provide the split of cancer tracker WTE by each tumour site of responsibility
a. Lung
b. Breast
c. Head & Neck
d. Lower GI
e. Upper GI
f. Gynaelogical
g. Children’s
h. Acute leukaemia
i. Haematological malignancies (excluding acute leukaemia)
j. Testicular
k. Urological
4. Please provide the split of cancer MDT co-coordinators WTE by each tumour site of responsibility
a. Lung
b. Breast
c. Head & Neck
d. Lower GI
e. Upper GI
f. Gynaelogical
g. Children’s
h. Acute leukaemia
i. Haematological malignancies (excluding acute leukaemia)
j. Testicular
k. Urological
5. What cancer PAS system is used by your organisation? I.e. Somerset, Infoflex other. If other please specify.

Cancer services.180522.docx

All questions are shown as received by the Trust.
1) Over the last 6 months, how many patients were treated with a combination of Dabrafenib + Trametinib for the following diseases:
A) Metastatic Melanoma
B) Adjuvant Melanoma
C) BRAF mutated Lung Cancer

2) Over the last 6 months, how many patients were treated with a combination of Encorafenib (Braftovi) + Binimetnib (Mektovi) for the following diseases:
A) Metastatic Melanoma
B) Colorectal Cancer
C) Any other indications

Cancer Treatment.101023.docx

All questions are shown as received by the Trust.
1) In the past 6 months, what was the number of patients treated with a combination of Dabrafenib + Trametinib for the following conditions:
A) Metastatic Melanoma
B) Adjuvant Melanoma
C) BRAF mutated Lung Cancer
2) In the past 6 months, what was the number of patients treated with a combination of Encorafenib (Braftovi) + Binimetnib (Mektovi) for the following conditions:
A) Metastatic Melanoma
B) Colorectal Cancer

Cancer treatment using specified products.250624.docx

1. Within your health trust, how many patients have been treated in the past 3 months for head and neck cancer (squamous cell carcinoma) with the following agents?
a. Carboplatin (monotherapy or in combination with 5-FU)
b. Cisplatin (monotherapy or in combination with 5-FU)
c. Cetuximab with/without chemotherapy
d. Cetuximab with radiotherapy
e. Pembrolizumab monotherapy
f. Pembrolizumab with chemotherapy
g. Nivolumab
h. Docetaxel (monotherapy or in combination with 5-FU)
i. Fluorouracil (5FU)
j. Radiotherapy only
k. Other
2. For the patients treated in the past 3 months for head and neck cancer (squamous cell carcinoma) with the therapies listed in the first question, please provide:
a. Total number of head and neck cancer patients
b. Number of locally advanced head and neck cancer patients
c. Number of recurrent and/or metastatic head and neck cancer patients
3. Within your health trust, how many patients have been treated in the past 3 months with the following agents for colorectal cancer [CRC]?
a. Aflibercept
b. Bevacizumab
c. Capecitabine
d. CAPIRI
e. CAPOX (XELOX)
f. Cetuximab in combination with FOLFIRI
g. Cetuximab in combination with FOLFOX
h. Cetuximab not in combination with FOLFIRI or FOLFOX
i. Irinotecan only
j. FOLFIRI
k. FOLFOX
l. Fluorouracil (5FU) only
m. Oxaliplatin only
n. Panitumumab in combination with FOLFIRI
o. Panitumumab in combination with FOLFOX
p. Panitumumab not in combination with FOLFIRI or FOLFOX
q. Pembrolizumab
r. Nivolumab
s. Raltitrexed
t. Ramucirumab
u. Regorafenib
v. Sorafenib
w. Other SACT

Download response Cancer treatments. 051121.docx

All questions are shown as received by the Trust.
1) in the past 6 months, how many patients were treated with a combination of both Encorafenib (Braftovi) + Binimetnib (Mektovi) for the following diseases:

A) Metastatic Melanoma
B) Colorectal Cancer
C) Any other indications

2) In the past 6 months, how many patients were treated with a combination of Dabrafenib + Trametinib for the following diseases:
A) Metastatic Melanoma
B) Adjuvant Melanoma
C) BRAF mutated Lung Cancer

Cancer treatments.270224.docx

All questions are shown as received by the Trust.
I writing to request, under the Freedom of Information Act, the number of cancer treatments started at each cancer stage in each of the last five years in your trust.

Cancer treatments.270923.docx

Please can you let me know what your success rate in meeting the cancer two week wait referral is? What % of patients referred are actually seen within the two weeks?

Cancer two week wait referral.110822.docx

Q1. Does your trust provide SACT (systemic anti-cancer therapy) treatments for the following conditions?
a. Cervical cancer
b. Endometrial cancer
In case you do not provide SACT treatments for either of the above conditions, which other trust do you refer patients to for these treatments?
Q2. How many patients were treated for cervical cancer in the past 6 months with the following treatments:
a. Paclitaxel in combination with Platinum and/or Bevacizumab
b. Pembrolizumab in combination with Platinum and/or Bevacizumab
c. Platinum standalone or in combination with Bevacizumab
d. Toptecan in combination with Platinum and/or Bevacizumab
e. Any other SACT
Q3. How many patients were treated for endometrial cancer in the past 6 months with the following treatments:
a. Dostarlimab
b. Hormone therapy (Progesterone or Letrozole)
c. Pembrolizumab in combination with Lenvatinib
d. Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide)
e. Any other SACT
Q4. How many endometrial cancer patients received the following therapies as 1st Line treatment in the past 6 months:
a. Hormone therapy (Progesterone or Letrozole)
b. Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide)
c. Any other SACT
Q5. Does your trust participate in any clinical trials for the treatment of cervical cancer? If so, can you please provide the name of each trial and the number of patients taking part.
Q6. Does your trust participate in any clinical trials for the treatment of endometrial cancer? If so, can you please provide the name of each trial and the number of patients taking part.

Cervical cancer and Endometrial cancer.171022.docx

We are seeking information for both general advice relevant to all chemotherapies and anything specific to carboplatin.
As part of this guidance and information we are seeking data including but not limited to:
1. The % and number of patients having the kidney function tests before chemo has begun and after it has begun, with associated outcomes, including mortality rates, split by chemo cycle stage undertaken.
2. The % and number of patients whose GFR tests taken prior to chemo starting, have indicated their kidneys were not functioning sufficiently to enable progression of chemotherapy.
3. It would then be helpful to understand which of those patients guided chemo cannot be progressed, did not progress and those that did (going against doctors wishes if that is possible to do?) and their outcomes.
It needs to reflect a time pre covid that is representative of more ‘normal’ time in treatment of cancers patients and also post pandemic peak when hospitals have been ramping up recovery.
We’d therefore be looking at two periods of data 1) 12 rolling months, February 2018 to Feb 2019 and then 5 months May 2021 to September 2021.
In addition to our questions below we’d like:
4. The specific data on number of patients during those periods who did not have a kidney function test prior to the first chemo cycle e.g total patients given chemo and not given chemo and the numbers of those that had gfr test before and those that did not.
5. For those patients that did not, also confirm of any subsequent kidney failure experienced and at what stage of chemo it was experienced.
6. To make a fair comparison, we’d welcome data of those who experienced kidney failure from chemo and at what stage chemo this happened – who undertook a gfr test prior and whose kidneys were deemed fit enough to withstand chemo treatment.

Chemotherapies and anything specific to carboplatin. 170322.docx

All questions are shown as received by the Trust.
Please answer the questions with regards to NHS patients, i.e., excluding patients that received treatment as part of clinical trials or private healthcare.

1. How many newly diagnosed patients with chronic lymphocytic leukaemia (CLL) have started first-line treatment in your Trust or Centre during the 6-month period February 2024 to July 2024?
2. How many of these newly diagnosed patients with CLL received chemoimmunotherapy (CIT) as first-line treatment?
CITs include fludarabine + cyclophosphamide + rituximab (FCR), fludarabine + rituximab (FR), bendamustine + rituximab (BR), bendamustine monotherapy, rituximab + cyclophosphamide + doxorubicin + vincristine + prednisolone (R-CHOP), obinutuzumab ± chlorambucil, rituximab + chlorambucil and ofatumumab
3. Please complete the table below with how many newly diagnosed patients with CLL have started first-line treatment with each of the following CITs during the 6-month period February 2024 to July 2024
a. FCR (fludarabine + cyclophosphamide + rituximab)
b. FR (fludarabine + rituximab)
c. BR (bendamustine + rituximab)
d. Bendamustine monotherapy
e. RCHOP (Rituximab + cyclophosphamide + doxorubicin + vincristine + prednisolone)
f. Obinutuzumab ± chlorambucil
g. Rituximab + chlorambucil
h. Ofatumumab
i. Other – please specify

Note: this should only include newly diagnosed patients with CLL who have started first-line treatment during the 6-month window

Chronic lymphocytic leukaemia.251024.docx

A list of the current medical imaging equipment held by the Trust across all hospital sites, providing the following information:
Q1: What is your overall spend on medical imaging products and services for the current year?
Q2: How much do you spend on each modality requested below for the current year:
a) Computed Tomography (CT)
b) Magnetic Resonance Imaging (MRI)
c) Ultrasound
d) Fluoroscopy
e) Mammography
f) Nuclear
g) Mobile X-ray
h) Static X-ray
Q3: A list of the current equipment held by the Trust across all hospital sites for each of the following:
a) Supplier
b) Product
c) Contract start date
d) Contract expiry date
e) Number of devices
f) Age of product
Example Response: 3 x Siemens Acuson SC2000, Initial cost £ 29,000, Contract start date 10/02/2022 Contract end date 10/02/2026, 6 years old
Q4: Annual cost of maintenance of equipment
Q5: What percentage of your imaging equipment has an element of Artificial Intelligence?

Clinical Imaging Equipment. 150322.docx

1. Do you insource clinical services and if so, which ones?
2. Do you have any current contracts in place with a company for these insourced services, and if so which services?
3. How much have you spent on insourcing clinical services per annum for the past 3 years?
4. Do you outsource clinical services and if so, which ones?
5. Do you have any current contracts in place with a company for these outsourced services, and if so which services?
6. How much have you spent on outsourcing clinical services per annum for the past 3 years?

Download response Clinical Insourcing and Outsourcing. 111121.docx

All questions are shown as received by the Trust.
Name of person completing out this form:
Full name of the hospital or NHS Trust (specify):
Your role at the hospital:
Your involvement in oncology clinical trials:
Is your hospital/ NHS Trust a Cancer Unit, Cancer Centre or Centre of Excellence in Cancer Care?
1.Ia What tumour groups do you treat with systemic anti-cancer therapy at your centre?
1.Ib Since 2010, for what tumour groups has your organisation had clinical trials involving systemic anti-cancer therapy? Select all that apply.
1.Ic In TOTAL, how many clinical trials (interventional Phase 0 – III) involving novel or novel combination or novel way of administering systemic anti-cancer therapies for solid cancers did you have in the Oncology department on 31 Dec in each year (provide a snapshot number) since 2010?
1.Id Of the total number of clinical trials you reported in 1.Ic, how many were solely funded by the NHS and NIHR (thus excluding trials funded by charity, government research councils like MRC, academic institutions and commercial companies)?
1.Ie Of the total number of clinical trials you reported in 1.Ic, how many were PHASE 1 trials?
1.If Of the total number of clinical trials you reported in 1.Ic, how many were PHASE 2 trials?
1.Ig Of the total number of clinical trials you reported in 1.Ic, how many were PHASE 3 trials?
1.Ih On a separate note, how many Phase IV trials did you conduct in each year at your hospital/ Trust?
1.Ii Of the total number of clinical trials you reported in 1.Ic, how many involved another procedure such as surgery or radiotherapy in combination with the trialled systemic anti-cancer therapy within the trial?
1.Ij Provide the total number of adult patients enrolled in phase I – III solid-cancer systemic anti-cancer therapy trials on 31 Dec of each year at your hospital/ Trust:
1.Ik In each year, how many new Phase I – III clinical trials did you open for recruitment?
2.I Post-BREXIT, what regulatory changes have had the greatest impact on the initiation of oncology trials at your centre?
2.II Post-BREXIT, what regulatory changes have had the greatest impact on the conduct/ continuation of oncology trials at your centre?
2.IIIa Post-BREXIT, have you observed any specific challenges related to regulatory compliance for initiating new oncology trials at your centre?
2.IIIb If yes, please specify the regulatory challenges encountered:
2.IVa Have there been any notable changes in the regulatory reporting requirements for ongoing oncology trials post-BREXIT?
2.IVb If yes, please elaborate on the changes and their impact on trial conduct:
2.Va Have there been any changes in the timeline for regulatory approvals post-BREXIT for initiating new oncology trials?
2.Vb If yes, please specify the nature of delays and their impact on trial initiation:
2.VI How has the communication and coordination with regulatory authorities changed post-BREXIT in the context of oncology trials?
2.VIa Have there been any new documentation or compliance requirements introduced post-BREXIT for ongoing oncology trials?
2.VIb If yes, please provide examples of the additional documentation or compliance measures introduced:
2.VII How has the training and education of clinical trial staff in your centre been impacted by regulatory changes post-BREXIT?
2.VIIIa Have there been any changes in the requirements for informed consent processes for oncology trials post-BREXIT?
2.VIIIb If yes, please specify the nature of changes and their impact on the informed consent process:
2.IX How has the interpretation and implementation of Good Clinical Practice (GCP) guidelines evolved post-BREXIT in your centre?
2.Xa Where staff updated or educated on regulatory changes post- BREXIT?
2.Xb If yes, explain how:
2.Xc If no, explain why not:
3.I In each year, how many Phase 0 – IV clinical trials did you have to discontinue due to a lack of funding? Comment on the funding sources affected:
3.II Name all organisations, including your own, that sponsored and/or funded solid- cancer systemic-anticancer therapy trials at your centre in each year:
3.III How has the funding landscape for oncology pharmaceutical trials at your centre changed post-BREXIT?
3.IV If there has been a change, please describe the main factors contributing to the shift in funding availability:
3.V How has the change in funding impacted the continuity of ongoing oncology pharmaceutical trials at your centre?
3.VI Are there specific types of trials more affected by funding challenges (e.g., Phase 1, investigator-initiated trials, certain types of systemic anti-cancer drugs, combination therapies, for certain tumour groups)?
3.VII How has the uncertainty surrounding BREXIT impacted the willingness of funding organisations to support oncology trials?
3.VIII Answering on behalf of your organisation, are there any specific policy changes that would enhance funding opportunities for oncology trials post-BREXIT?
3.IXa Have you explored alternative funding sources or strategies to mitigate potential funding challenges post-BREXIT?
3.IXb If yes, please share details of any successful strategies or approaches implemented:
3.X To what extent have patient advocacy groups played a role in supporting or influencing funding for oncology trials post-BREXIT in or for your organisation?
3.XIa Have there been any changes in the criteria or preferences of funding organisations when considering proposals for oncology trials post-BREXIT?
3.XIb If yes, please elaborate on the key changes in criteria or preferences:
4.I Comment on collaborative challenges that affected or caused disruptions in the initiation or running of solid-cancer systemic anti- cancer therapy drugs:
4.IIa Have there been challenges in maintaining international collaborations for oncology trials post-BREXIT?
4.IIb If yes, please identify the main collaborative challenges faced:
4.IIIa Have changes in regulatory requirements impacted international partnerships in oncology trials?
4.IIIb If yes, please elaborate on the specific regulatory aspects causing challenges:
4.IVa In your experience, have collaborative challenges affected the timeline and efficiency of oncology trials?
4.IVb If yes, please provide examples or instances where collaboration challenges led to disruptions in trial initiation or conduct:
4.Va At your current NHS hospital, have there been challenges in aligning international ethical standards and practices for oncology trials post-BREXIT?
4.Vb If yes, please elaborate on the specific ethical challenges faced and their impact on collaborative efforts:
4.VI How has the exchange of trial-related data and information with international partners been affected post-BREXIT?
4.VIIa In your organisation’s experience, have there been any challenges related to differences in patient populations across international sites in oncology trials?
4.VIIb If yes, please provide examples or instances where differences in patient populations posed challenges to collaborative efforts?
4.VIII How has the exchange of expertise and specialised resources with international collaborators been affected post-BREXIT?
4.IX From your organisation’s perspective, what strategies or initiatives could enhance international collaboration in oncology trials in the post-BREXIT era?
5.Ia Have you become aware of or experienced any challenges related to the alignment of data privacy and protection regulations in international oncology trials post-BREXIT?
5.Ib If yes, please elaborate on the specific challenges faced and any measures

Clinical Trials in Oncology.210324.docx

1. The total number of colonoscopies undertaken in Maidstone and Tunbridge Wells NHS Trust for the period
i) April 2019-March 2020
ii) April 2020-March 2021.
2. The total number of people diagnosed with colorectal cancer (or other clearly defined indications) within Maidstone and Tunbridge Wells NHS Trust for the period
i) April 2019-March 2020
ii) April 2020-March 2021.
3. The average adenoma detection rate (ADR) and post-colonoscopy colorectal cancer rate (PCCRC) for Maidstone and Tunbridge Wells NHS Trust for the period
i) April 2019-March 2020
ii) April 2020-March 2021
4. The total number of cancers detected, against cancer stage (e.g. 1,2,3 or 4), against colonoscopies performed in the prior three years within Maidstone and Tunbridge Wells NHS Trust in the period
i) April 2019-March 2020
ii) April 2020-March 2021

Colonoscopies and colorectal cancer. 160322.docx

In the past 3 months, how many patients have been treated for Colorectal Cancer [CRC] with the following regimens? If possible, please also provide the split of metastatic vs non-metastatic patients for each regimen.
Regimens
a. Capecitabine
b. CAPIRI
c. CAPOX
d. Cetuximab with FOLFIRI
e. Cetuximab with FOLFOX
f. Cetuximab as a single agent
g. Cetuximab with Encorafenib
h. Irinotecan as a single agent
i. FOLFIRI
j. FOLFOX
k. Fluorouracil (5FU) as a single agent
l. Oxaliplatin as a single agent
m. Nivolumab with Ipilimumab
n. Panitumumab with FOLFIRI
o. Panitumumab with FOLFOX
p. Panitumumab as a single agent
q. Pembrolizumab
r. Any other systemic anti-cancer therapy
s. Palliative care only

Colorectal Cancer.041223.docx

Q1. Within your health trust, how many patients have been treated in the past 3 months with the following agents for colorectal cancer [CRC]?
a. Aflibercept
b. Bevacizumab
c. Capecitabine
d. CAPIRI
e. CAPOX (XELOX)
f. Cetuximab in combination with FOLFIRI
g. Cetuximab in combination with FOLFOX
h. Cetuximab not in combination with FOLFIRI or FOLFOX
i. Irinotecan only
j. FOLFIRI
k. FOLFOX
l. Fluorouracil (5FU) only
m. Oxaliplatin only
n. Panitumumab in combination with FOLFIRI
o. Panitumumab in combination with FOLFOX
p. Panitumumab not in combination with FOLFIRI or FOLFOX
q. Pembrolizumab
r. Nivolumab
s. Raltitrexed
t. Ramucirumab
u. Regorafenib
v. Sorafenib
w. Other SACT
Q2. In the last 3 months, how many patients has your trust treated (for any condition) with the following treatments
a. Avatrombopag
b. Eltrombopag
c. Fostamatinib
d. Romiplostim
Q3. In the last 3 months, how many patients has your trust treated for Immune thrombocytopenia (ICD10 code D69.3)?
Q4. In the last 3 months, how many patients has your trust treated for Immune thrombocytopenia (ICD10 code D69.3) ONLY with the following treatments:
a. Avatrombopag
b. Mycophenolate mofetil
c. Rituximab
d. Surgery (splenectomy)

Colorectal cancer [CRC].160922.docx

All questions are shown as received by the Trust.
In the past 3 months, how many patients have been treated for Colorectal Cancer [CRC] with the following regimens? If possible, please also provide the split of metastatic vs non-metastatic patients for each regimen.
Regimens
Capecitabine
CAPIRI
CAPOX
Cetuximab with FOLFIRI
Cetuximab with FOLFOX
Cetuximab as a single agent
Cetuximab with Encorafenib
Irinotecan as a single agent
FOLFIRI
FOLFOX
Fluorouracil (5FU) as a single agent
Oxaliplatin as a single agent
Nivolumab with Ipilimumab
Panitumumab with FOLFIRI
Panitumumab with FOLFOX
Panitumumab as a single agent
Pembrolizumab
Any other systemic anti-cancer therapy
Palliative care only

Colorectal Cancer [CRC].180324.docx

All questions are shown as received by the Trust.
In the past 3 months, how many patients have been treated for Colorectal Cancer [CRC] with the following regimens?
Can you please provide the total number of patients treated for CRC with each product and the total number of Metastatic patients treated with each product for CRC in the table below.
Aflibercept plus chemotherapy
Bevacizumab plus fluoropyrimidine-based chemotherapy
Capecitabine
CAPIRI
CAPOX
Cetuximab with FOLFIRI
Cetuximab with FOLFOX
Cetuximab as a single agent
Cetuximab with Encorafenib
Irinotecan as a single agent
FOLFIRI
FOLFOX
Fluorouracil (5FU) as a single agent
Oxaliplatin as a single agent
Nivolumab with Ipilimumab
Panitumumab with FOLFIRI
Panitumumab with FOLFOX
Panitumumab as a single agent
Pembrolizumab
Any other systemic anti-cancer therapy
Palliative care only

Colorectal Cancer [CRC].250724.docx

Please could you provide me with a copy of the business case for the Trust’s Community Diagnostic Centre project, including the capital budget for the entire project.

Community Diagnostic Centre.080922.docx

I am writing to obtain information, under the Freedom of Information Act, about your Trust’s funding of Complementary and Alternative Medicine (CAM) services they provided.
To outline my query as clearly as possible, I am requesting:
1. How much the Trust has spent on CAM services for the following financial years:
a. 2019-20
b. 2020-21
c. 2021-22
This includes salaries for those employed to carry out these services, costs of medicine, equipment and any additional costs involved.
2. A list of all services provided under CAM.

Complementary and Alternative Medicine (CAM) services.101022.docx

All questions are shown as received by the Trust.
I kindly request that you provide the number of CT and MRI machines, categorised based on ownership (owned or rented) for the years 2019, 2020, 2021, 2022, and 2023, along with details regarding the age of the owned machinery for the year 2023 only.

CT and MRI machines.310124.docx

1) How many of each of the following machines do you have in use:
i) CT
ii) MRI
iii) X-ray
2) How many of each of the following machines are you using that are older than ten years old:
i) CT
ii) MRI
iii) X-ray
3) How old is your oldest in-use machine for each of:
i) CT
ii) MRI
iii) X-ray
4) How many of each of the following machines have you purchased in the past year:
i) CT
ii) MRI
iii) X-ray
5) How much did you spend repairing CT, MRI and X-ray machines in each of the past three years?

CT and MRI machines.311022.docx

1) The number of CT scanners in your Trust, where relevant please provide a number for each hospital.
2) The number of MRI scanners in your Trust, where relevant please provide a number for each hospital.
3) The number of ultrasound scanners in your Trust, where relevant please provide a number for each hospital.
4) The number of x-ray machines in your Trust, where relevant please provide a number for each hospital.
5) For each of the items 1-4, please also provide the number of machines that are more than 10 years old and if available the year that the machine was purchased.

Download response CT, MRI and Ultrasound Scanners and X-Ray machines. 170921.docx

Tab 1:
MES Contract
1. Supplier
2. Contract Start Date
3. Contract End Date
4. Initial Cost
5. Interest rates (%)
6. Consumables included?
7. Accessories included?
8. Maintenance included?
Tab 2:
Clinical Imaging Asset Details
1. Local Identifier
2. Modality
3. Equipment detail
4. Asset name
5. Manufacturer
6. Age
7. First in Service
8. Planned replacement date
9. Replacement schedule
10. Ownership structure
11. How is the ownership accounted for?
12. Capital purchase cost
13. Maintenance type (drop-down list)
14. Maintenance provider
15. Maintenance Service Contract Start Date
16. Maintenance Service Contract End Date
17. Maintenance Cost
Tab 3:
Clinical Imaging Accessories
1. Local Identifier
2. Modality
3. Equipment detail
4. Asset name
5. Manufacturer
6. Age
7. First in Service
8. Planned replacement date
9. Replacement schedule
10. Ownership structure
11. How is the ownership accounted for?
12. Capital purchase cost
13. Maintenance type (drop-down list)
14. Maintenance provider
15. Maintenance Service Contract Start Date
16. Maintenance Service Contract End Date
17. Maintenance Cost

CT, MRI, Nuclear Medicine and Ultrasound clinical imaging equipment.130324.docx

We are looking to produce a map of the CTCL (cutaneous T cell lymphoma) treatment centres in the UK.
To help with this, please could you provide the following:
1. Which centre/s in your NHS Trust offer treatment for CTCL, if any
2. The type of CTCL treatment these centres offer (TSEB or ECP)
3. A contact phone number for referrals for each centre

CTCL (cutaneous T cell lymphoma) treatment centres. 110322.docx

Please answer these questions relating to the usage of Dabrafenib + Trametinib in cancer treatment.
A) Over the previous 6 months, how many patients for the following diseases have been treated with a combination of Dabrafenib + Trametinib:
i) Metastatic Melanoma
ii) Adjuvant Melanoma
iii) BRAF mutated Lung Cancer

Dabrafenib + Trametinib.050722.docx

A) Over the previous 6 months, how many patients for the following diseases have been treated with a combination of Dabrafenib + Trametinib:
i) Metastatic Melanoma
ii) Adjuvant Melanoma
iii) BRAF mutated Lung Cancer

Dabrafenib + Trametinib.110423.docx

Please could you provide the figures for diagnoses of cancer within your hospital from January 2010 to date.
Please could you present these figures in a yearly format.

Diagnoses of cancer. 020822.docx

All questions are shown as received by the Trust.
1. How much has your trust spent on new diagnostic equipment in each of the past three financial years, e.g. x ray machines, CT scanners, MRIs etc?
2. How much has your trust spent on maintaining and repairing old equipment in the past three financial years?
3. How many diagnostic machines did you purchase in the last financial year?

Diagnostic equipment spend.251023.docx

All questions are shown as received by the Trust.
Q1. In the last 6 months, how many patients have been diagnosed with Diffuse Large B Cell Lymphoma (DLBCL)?
Q1a. Of these patients, how many commenced treatment at your trust within the last 6 months?
Q2. In the last 6 months, how many patients have you treated for Diffuse Large B Cell Lymphoma (DLBCL) with the following treatments:
a. R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone)
b. R-mini-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone)
c. Pola-BR (polatuzumab vedotin with rituximab and bendamustine)
d. Pola-R-CHP (Polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin hydrochloride, and prednisolone)
e. R-CODOX-M (rituximab, cyclophosphamide, vincristine, doxorubicin and methotrexate)
f. R-IVAC (rituximab, ifosfamide, etoposide and cytarabine)
g. Axicabtagene ciloleucel (Yescarta)
h. Tisagenlecleucel
i. Epcoritamab
j. Loncastuximab tesirine
k. Glofitamab
l. Any other SACT
m. Stem cell transplant or bone marrow transplant (autologous or allogeneic)
Q3. In the last 6 months, how many patients have received the following 2nd line treatments for Diffuse Large B Cell Lymphoma (DLBCL):
a. Axicabtagene ciloleucel (Yescarta)
b. Tisagenlecleucel
c. Pola-BR (polatuzumab vedotin with rituximab and bendamustine)
d. Stem cell transplant or bone marrow transplant (autologous or allogeneic)
e. Any other treatments
Q4. In the last 6 months, how many patients have you referred to other trusts for the treatment of Diffuse Large B Cell Lymphoma (DLBCL) for the following treatments:
a. CAR-T Therapy (E.g. Axicabtagene ciloleucel)
b. Stem cell transplant or bone marrow transplant (autologous or allogeneic)
c. Any other treatment
Q5. Do you participate in any active clinical trials for Diffuse Large B-Cell Lymphoma (DLBCL)? If so, can you please provide the name of each trial along with the number of patients taking part or enrolling?

Diffuse Large B Cell Lymphoma (DLBCL).06.08.24.docx

Q1. Does your trust treat patients with Diffuse Large B Cell Lymphoma (DLBCL)? If not, then which trust do you refer DLBCL patients to?
Q2. In the last 6 months, how many patients have you treated for Diffuse Large B Cell Lymphoma (DLBCL)?
Q3. In the last 6 months, how many patients have you treated for Diffuse Large B Cell Lymphoma (DLBCL) with the following treatments:
a. R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone)
b. R-mini-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone)
c. Other immuno-chemotherapy
d. Other chemotherapy
e. Stem cell transplant or bone marrow transplant (autologous or allogeneic)
f. Pola-BR (polatuzumab vedotin with rituximab and bendamustine) – any line of treatment
g. Pola-BR (polatuzumab vedotin with rituximab and bendamustine) – third-line treatment only
h. Tisagenlecleucel
i. Axicabtegene ciloleucel
j. Lisocabtagene maraleucel
Q4. In the last 6 months, how many Diffuse Large B Cell Lymphoma (DLBCL) patients have you referred to other trusts for:
a. Stem cell transplant or bone marrow transplant (autologous or allogeneic)
b. CAR-T therapy (Tisagenlecleucel, Axicabtegene ciloleucel, Lisocabtagene maraleucel)
Q5. Do you participate in any active clinical trials for Diffuse Large B-Cell Lymphoma (DLBCL)? If so, can you please provide the name of each trial along with the number of patients taking part?

Diffuse Large B Cell Lymphoma (DLBCL).270722.docx

Infrastructure:
1) Do you outsource your DXA scans? If Yes- please state the organisation providing this service and forward this FOI to your provider for completion (please continue to complete for any of the elements of the DXA pathway that are provided by your Trust/board)
2) In January 2023 how many DXA scanning machines did you have at your trust/board for clinical use?
a. n. Operational
b. n. not in use
c. n. accessible outside of Trust
3) What is the average weekly capacity for clinical scans? (N. of scans per week)
4) What was your average DNA rate over the last 3 months? (n. DNA/total n. scans booked)
5) What age range do you include in your clinical scans? Please tick all that apply
a. <20 years b. 20-40 years c. 40-60 years d. 60-75 years e. 75-80 years f. >80 years
6) What is the duration of your routine DXA appointment:
a. 15 minutes or less
b. 16-25 minutes
c. 26-30 minutes
d. >30 minutes
7) What was the average wait for clinical patients from referral to scan in January 2023?
a. <2 weeks (move to Q9) b. 2-6 weeks (move to Q9) c. 6-13 weeks d. >13 weeks
8) What are your perceived barriers to delivering DXA scans within 6 weeks from referral? Please tick all that apply
a. Scanner capacity (DXA equipment)
b. Clinical capacity (operator)
c. Other- please state
9) What was the average time from the scan to the report being available to the referrer in January 2023?
a. <3 weeks (move to Q11) b. 4-6 week c. 6-13 weeks d. >13 weeks
10) What are your perceived barriers to referrers receiving DXA scan reports within 3 weeks from scan? Please tick all that apply
a. Clerical- internal
b. Clinical- internal
c. Factors external to this service (please state)
d. Other (please state)
11) What hospital department is responsible for delivery of DXA scans:
a. Radiology
b. Medical physics
c. Nuclear medicine
d. Rheumatology
e. Other- please state
12) Which DXA examinations are included in routine protocols for the clinical service? Please tick all that apply
a. Lumbar spine
b. Proximal femur
c. Long femur (AFF assessment)
d. Total body
e. Vertebral fracture assessment (VFA)
f. Peripheral/forearm
13) What access facilities do you have available? Please tick all that apply
a. Overhead hoist
b. Portable hoist
c. Wheelchair transfers
d. Bed/trolley transfers
e. Changing room
f. Assistance for transfers
g. Other- please state
Workforce:
1)
i) What professional groups perform DXA scan measurements at your centre? (DXA operators)
a. Radiographer
b. DXA technician
c. Assistant practitioner
d. Clinical scientist
e. Nurse
f. Medical Dr- please state specialism
g. Other- please state
h. Unknown]
ii) Please indicate WTE for each group selected
2) What DXA-specific training (outside of professional training) have the DXA operators performing scans had?
a. In house
b. Manufacturers applications training
c. Recognized/accredited national training programme (please state the name of the training programme/provider)
d. Other- please state
e. Unknown
3) What professional groups report your DXA scans at your centre? ()
a. Radiographer – internal
b. Radiographer – external
c. DXA technician – internal
d. DXA technician – external
e. Assistant practitioner – internal
f. Assistant practitioner – external
g. Clinical scientist – internal
h. Clinical scientist – external
i. Nurse -internal
j. Nurse – external
k. Medical Dr – internal – please state specialism(s)
l. Medical Dr – external – please state specialism(s)
m. Other- please state
n. Reporting is outsourced
o. Unknown
4) What training (outside of professional training) have those reporting DXA scans had- specifically in DXA reporting?
a. In house
b. Manufacturers applications training
c. Recognized/accredited national training programme (please state the name of the training programme/provider)
d. Other- please state
e. Unknown
5) What professional group provides clinical leadership for your service?
a. Radiographer
b. DXA technician
c. Assistant practitioner
d. Clinical scientist
e. Nurse
f. Medical Dr- please state specialism(s)
g. Other- please state
h. Unknown
6) Please indicate how many (WTE) clinical vacancies in your DXA service do you have in January 2023? (Free text)
Quality:
1) Is your service accredited as part of a national programme?
a. ISAS
b. IOS
c. Other- please state
d. None
e. Unknown
2) What clinical audits do you routinely undertake? Please tick all that apply
a. DXA scan technique
b. Reporting (double reporting)
c. Reporting (clinical review)
d. Scanner QA review
e. Other- please state
f. Unknown
3) What IR(ME)R audits do you routinely undertake? Please tick all that apply
a. Patient pregnancy
b. DXA dose audit
c. Referrer entitlement
d. Scan justification
e. Other- please state
f. Unknown
4) What clinical protocols do you have in place? Please tick all that apply
a. Scan site
b. Scan mode
c. Reference data selection
d. Patient positioning
e. Scan analysis
f. Interpretation- T&Z-scores
g. Reporting
h. Other- please state
i. Unknown
5) Which of the following are routinely included in the DXA report issued to the PRIMARY CARE referrer? Please tick all that apply
A. Admin. details
i. Date of assessment
ii. Patient ID and demographics
iii. Reason for referral
iv. Reporter’s ID
B. BMD results for each measurement site
i. T score (after peak bone mass)
ii. Z score
iii. Rate of change for serial measurements
C. Comment on reliability of measurements
i. BMD results
ii. Documentation of excluded measurements eg. vertebrae
iii. Statistical significance of rate of change
iv. Clinical significance of rate of change
D. WHO diagnostic category (for adults after peak bone mass)
E. Results of additional investigations performed at DXA appointment
i. VFA
ii. X-ray or other imaging
iii. Laboratory tests
F. Summary of clinical risk factors for fracture
G. Summary of fracture history
H. Clinical interpretation to quantify absolute fracture risk
i. FRAX+BMD
ii. FRAX + TBS
iii. FRAX+BMD plus comment on additional adjustment
iv. Statement on level of risk based on clinical judgement (eg. low/moderate/high)
I. Management advice
i. Reference to national guideline (NICE/NOGG/ROS)
ii. Reference to local management guideline
iii. Individualised advice
J. Recommendations on:
i. Need for onward referral eg. falls assessment or additional investigation
ii. Timing of future scan
6) Which of the following are routinely included in the DXA report issued to the SECONDARY CARE referrer? Please tick all that apply
A. Admin. details
i. Date of assessment
ii. Patient ID and demographics
iii. Reason for referral
iv. Reporter’s ID
B. BMD results for each measurement site
i. T score (after peak bone mass)
ii. Z score
iii. Rate of change for serial measurements
C. Comment on reliability of measurements
i. BMD results
ii. Documentation of excluded measurements eg. vertebrae
iii. Statistical significance of rate of change
iv. Clinical significance of rate of change
D. WHO diagnostic category (for adults after peak bone mass)
E. Results of additional investigations performed at DXA appointment
i. VFA
ii. X-ray or other imaging
iii. Laboratory tests
F. Summary of clinical risk factors for fracture
G. Summary of fracture history
H. Clinical interpretation to quantify absolute fracture risk
i. FRAX+BMD
ii. FRAX + TBS
iii. FRAX+BMD plus comment on additional adjustment
iv. Statement on level of risk based on clinical judgement (eg. low/moderate/high)
I. Management advice
i. Reference to national guideline
ii. Reference to local management guideline
iii. Individualised advice
J. Recommendations on:
i. Need for onward referral eg. falls assessment or additional investigation
ii. Timing of future scan
K. The secondary care report is the same as the primary care report

DXA Facilities Audit.020323.docx

Q1. I am researching the usage of Pembrolizumab for the treatment of Melanoma. How many patients have you treated with Pembrolizumab in the three months from October to December 2022 for:
a. Melanoma – any stage
b. Melanoma – Stage IIb/IIc
c. Melanoma – Stage III
d. Melanoma – Metastatic
Q2. How many Stage IIb/IIc melanoma patients were on a “Watch and Wait” strategy in the three months from October to December 2022? These would be patients where a decision has been made to wait before commencing any treatment.

Early Melanoma.020323.docx

All questions are shown as received by the Trust.
1. Which hospitals in your Trust open elective theatres at the weekend? (please list the name of the hospital followed by a Y/N as to whether elective theatres are open at the weekend)
2. How many of the following scans has your Trust carried out in the last year, broken down by daily activity?
a. CT Scans
b. MRI Scans
c. X Rays

Elective theatres and scans.300124.docx

1. Does your trust provide SACT (systemic anti-cancer therapy) treatments for endometrial cancer? If not, which other trust do you refer endometrial cancer patients to for SACT treatments?
2. How many patients were treated for endometrial cancer in the past 6 months with the following treatments:
a. Dostarlimab
b. Hormone therapy (Progesterone or Letrozole)
c. Pembrolizumab monotherapy
d. Pembrolizumab in combination with Lenvatinib
e. Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide)
f. Any other SACT
3. How many endometrial cancer patients received the following therapies as 1st Line treatment in the past 6 months:
a. Hormone therapy (Progesterone or Letrozole)
b. Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide)
c. Any other SACT
4. Of the patients treated for endometrial cancer in the past 6 months with any SACT regimen, how many patients had high microsatellite instability (MSI-H) or mismatch repair deficiency (dMMR)?
5. Does your trust participate in any clinical trials for the treatment of endometrial cancer? If so, can you please provide the name of each trial and the number of patients taking part.

Endometrial Cancer.020623.docx

All questions are shown as received by the Trust.
Q1. Does your trust provide SACT (systemic anti-cancer therapy) treatments for endometrial cancer? If not, which other trust do you refer endometrial cancer patients to for SACT treatments?
Q2. How many patients were treated for endometrial cancer (any stage) in the past three months with the following treatments:
a. Dostarlimab (Jemperli)
b. Dostarlimab (Jemperli) AND Chemotherapy
c. Hormone therapy (Progesterone or Letrozole)
d. Pembrolizumab (Keytruda) monotherapy
e. Lenvatinib + Pembrolizumab (Lenvima +Keytruda)
f. Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide)
g. Any other SACT
Q3. In the past three months, how many patients were treated for recurrent endometrial cancer after having previously received platinum-based chemotherapy?
Q4. In the past three months, how many patients were treated for endometrial cancer with the following as first line treatments:
a. Dostarlimab (Jemperli) AND Chemotherapy
b. Hormone therapy (Progesterone or Letrozole)
c. Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide)
d. Any other SACT
Q5. Does your trust participate in any clinical trials for the treatment of endometrial cancer? If so, can you please provide the name of each trial and the number of patients taking part.

Endometrial Cancer.140824.docx

All questions are shown as received by the Trust.
Q1. Does your trust provide SACT (systemic anti-cancer therapy) treatments for endometrial cancer? If not, which other trust do you refer endometrial cancer patients to for SACT treatments?
Q2. How many patients were treated for endometrial cancer (any stage) in the past three months with the following treatments:
a. Dostarlimab (Jemperli)
b. Dostarlimab (Jemperli) AND Chemotherapy
c. Hormone therapy (Progesterone or Letrozole)
d. Pembrolizumab (Keytruda) monotherapy
e. Lenvatinib + Pembrolizumab (Lenvima +Keytruda)
f. Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide)
g. Any other SACT
h. Any other Chemotherapy
Q3. In the past three months, how many patients were treated for recurrent endometrial cancer after having previously received platinum-based chemotherapy?
Q4. In the past three months, how many patients were treated for endometrial cancer with the following as first line treatments:
a. Dostarlimab (Jemperli) AND Chemotherapy
b. Hormone therapy (Progesterone or Letrozole)
c. Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide)
d. Any other SACT
e. Any other chemotherapy
Q5. Does your trust participate in any clinical trials for the treatment of endometrial cancer? If so, can you please provide the name of each trial and the number of patients taking part.

Endometrial cancer.291124.docx

1. Please state what software/ systems the Trust utilises for managing medical equipment/ devices in order to be compliant with MHRA Guidance (see URL below) from the list below. If not listed, please specify:
a. EMAT
b. F2
c. RAM
d. e-Quip
e. Other – please specify
2. Please state the name and contact for the person responsible for ensuring compliance with the MHRA guidance quoted above.

Ensuring MHRA Compliance.190422.docx

Could you please tell me, do you have such services as ‘Flushing and locking of intravenous catheters’ in your clinic?

Flushing and locking of intravenous catheters.010722.docx

1 The manufacturer & model name of each gamma camera (Nuclear Medicine imaging system) installed in your Trust
2 The hospital name where each system is installed
3 The date that the current service/maintenance contract on each gamma camera started
4 The date that the current service/maintenance contract on each gamma camera expires

Gamma camera (Nuclear Medicine imaging system). 080422.docx

Q1. How many patients were treated in the past 3 months for gastric and gastro-oesophageal junction cancer (any stage) with:
a. CAPOX (Capecitabine with Oxaliplatin)
b. FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin)
c. Lonsurf (Trifluridine – tipiracil)
d. Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)
e. Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)
f. Any other systemic anti-cancer therapy
g. Palliative care only
Q2. How many patients were treated in the past 3 months for Oesophageal cancer (any stage) with:
a. Nivolumab monotherapy or combination with Ipilimumab
b. Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine)
c. Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine)
d. Platinum and Fluoropyrimidene based combination treatments (Cisplatin or Oxaliplatin with 5-Fluorouracil or Capecitabine)
e. Any other systemic anti-cancer therapy
f. Palliative care only
Q3. How many patients were treated in the past 3 months for ovarian cancer (any stage) with:
a. Paclitaxel in combination with a platinum-based compound
b. Platinum-based therapy alone (cisplatin or carboplatin)
c. Bevacizumab in combination with paclitaxel and carboplatin
d. Olaparib
e. Olaparib + Bevacizumab
f. Niraparib
g. Rucaparib
Q4. If data for HRD (homologous recombination deficiency) testing is available, please provide how many HRD positive ovarian cancer patients were treated in the last 3 months with:
a. Olaparib
b. Olaparib + Bevacizumab
c. Niraparib
d. Other treatments
Q5. Does your trust participate in any clinical trials for the treatment of ovarian cancer? If so, please provide the name of each trial along with the number of patients taking part.

Gastric Oesophageal cancer and Ovarian cancer.161123.docx

I am researching the use of certain types of drugs used in haematology. Could you please provide the number of patients treated (for any disease in the past 3 months with:
1. Aragam
2. Berinert
3. Cinryze
4. Cutaquig
5. Cuvitru
6. Firazyr
7. Flebogamma DIF
8. Gammagard
9. Gammanorm
10. Gammaplex
11. Gamunex
12. Hizentra
13. Hyqvia
14. Intratect
15. Iqymune
16. Kiovig
17. Octagam
18. Orladeyo
19. Panzyga
20. Privigen
21. Ruconest
22. Subgam
23. Takhzyro

Haematology.281222.docx

1. How many patients have been treated in the past 3 months for head and neck cancer (squamous cell carcinoma) with the following agents:
a. Carboplatin (monotherapy or in combination with 5-FU)
b. Cisplatin (monotherapy or in combination with 5-FU)
c. Cetuximab with/without chemotherapy
d. Cetuximab with radiotherapy
e. Pembrolizumab monotherapy
f. Pembrolizumab with chemotherapy
g. Nivolumab
h. Docetaxel (monotherapy or in combination with 5-FU)
i. Fluorouracil (5FU)
j. Radiotherapy only
k. Other
2. For the patients treated in the past 3 months for head and neck cancer (squamous cell carcinoma) with the therapies listed in the first question, please provide:
a. Total number of head and neck cancer patients
b. Number of locally advanced head and neck cancer patients
c. Number of unresectable recurrent and/or metastatic head and neck cancer patients
3. How many Urothelial cancer patients have been treated in the past 3 months with the following agents:
a. Avelumab
b. Atezolizumab
c. Carboplatin with Gemcitabine
d. Carboplatin single or in any other combination
e. Cisplatin with Gemcitabine
f. Cisplatin single or in any other combination
g. Nivolumab
h. Pembrolizumab
i. Any other regimen including Paclitaxel
j. Any other chemotherapy regimen
k. Other active systemic anti-cancer therapy [please state]
l. Palliative care only
4. Does your trust participate in any ongoing clinical trials for the treatment of head and neck cancer? If so, can you please provide the name of each trial along with the number of patients taking part?

Head and neck and urothelial cancer.030822.docx

1. How many patients have been treated in the past 3 months for head and neck cancer (squamous cell carcinoma) with the following agents:
a. Carboplatin (monotherapy or in combination with 5-FU)
b. Cisplatin (monotherapy or in combination with 5-FU)
c. Cetuximab with/without chemotherapy
d. Cetuximab with radiotherapy
e. Pembrolizumab monotherapy
f. Pembrolizumab with chemotherapy
g. Nivolumab
h. Docetaxel (monotherapy or in combination with 5-FU)
i. Fluorouracil (5FU)
j. Radiotherapy only
k. Other
2. For the patients treated in the past 3 months for head and neck cancer (squamous cell carcinoma) with the therapies listed in the first question, please provide:
a. Total number of head and neck cancer patients
b. Number of locally advanced head and neck cancer patients
c. Number of recurrent and/or metastatic head and neck cancer patients
3. How many Urothelial cancer patients have been treated in the past 3 months with the following agents:
a. Atezolizumab
b. Carboplatin with Gemcitabine
c. Carboplatin single or in any other combination
d. Cisplatin with Gemcitabine
e. Cisplatin single or in any other combination
f. Nivolumab
g. Pembrolizumab
h. Any other regimen including Paclitaxel
i. Any other chemotherapy regimen
j. Other active systemic anti-cancer therapy [please state]
k. Palliative care only
4. Does your trust participate in any ongoing clinical trials for the treatment of urothelial cancer? If so, can you please provide the name of each trial along with the number of patients taking part?

Head and Neck cancer (squamous cell carcinoma) and Urothelial cancer. 140422.docx

1. How many patients have been treated in the past 3 months for head and neck cancer (squamous cell carcinoma) with the following agents:
a. Carboplatin (monotherapy or in combination with 5-FU)
b. Cisplatin (monotherapy or in combination with 5-FU)
c. Cetuximab with/without chemotherapy
d. Cetuximab with radiotherapy
e. Pembrolizumab monotherapy
f. Pembrolizumab with chemotherapy
g. Nivolumab
h. Docetaxel (monotherapy or in combination with 5-FU)
i. Fluorouracil (5FU)
j. Radiotherapy only
k. Other
2. For the patients treated in the past 3 months for head and neck cancer (squamous cell carcinoma) with the therapies listed in the first question, please provide:
a. Total number of head and neck cancer patients
b. Number of locally advanced head and neck cancer patients
c. Number of unresectable recurrent and/or metastatic head and neck cancer patients
3. How many Urothelial cancer patients have been treated in the past 3 months with the following agents:
a. Avelumab
b. Atezolizumab
c. Carboplatin with Gemcitabine
d. Carboplatin single or in any other combination
e. Cisplatin with Gemcitabine
f. Cisplatin single or in any other combination
g. Nivolumab
h. Pembrolizumab
i. Any other regimen including Paclitaxel
j. Any other chemotherapy regimen
k. Other active systemic anti-cancer therapy [please state]
l. Palliative care only
4. Does your trust participate in any ongoing clinical trials for the treatment of head and neck cancer? If so, can you please provide the name of each trial along with the number of patients taking part?
5. Does your trust participate in any ongoing clinical trials for the treatment of urothelial cancer? If so, can you please provide the name of each trial along with the number of patients taking part?

Head & neck and urothelial cancer.281122.docx

1. Could you detail the quantity of helium that has been purchased each year for the last 5 years?
2. What are the main uses for helium within the Trust?
3. Could you outline the various grades/types of helium purchased?
4. What has the cost of helium been for each of those 5 years?
5. Who are your suppliers of helium and can you provide a copy of the supply contracts?
6. Can you detail your procurement process for obtaining helium and send any tender documents relating to helium?

Helium consumption.271022.docx

All questions are shown as received by the Trust.
1. The number of patients that are currently on the waiting list for this operation at this hospital?
2. What is the average waiting time for the operation from referral to the actual date of the operation.
3. Do the hospitals arrange for NHS patients to undergo this operation at a private hospitals?

HoLEP (Holmium Laser Enucleation of the Prostate) procedure.290524.docx

1. Please can you provide the following information for each piece of MRI scanners within the Trust or associated sites? (Please complete the attached spreadsheet)
a. Manufacturer
b. Model
c. Tesla – 0.5 to 1.4, 1.5, 3.0, 3.0 +
d. Location – Hospital Name or Site Name
e. Mobile / Static
f. Department equipment is primarily used in
g. Method of Finance at Procurement – Trust/Lease/MES/Charity/PFI
h. Initial cost of Equipment
i. Annual Maintenance cost
j. Acquisition Date
k. Planned Replacement Date
2. Please can you provide the following information for each CT scanners within the Trust or associated sites? (Please complete the attached spreadsheet)
a. Manufacturer
b. Model
c. Slices – 8, 16, 64, 128, 264
d. Location – Hospital Name or Site Name
e. Mobile / Static
f. Department equipment is primarily used in
g. Method of Finance at Procurement – Trust/Lease/MES/Charity/PFI
h. Initial cost of Equipment
i. Annual Maintenance cost
j. Acquisition Date
k. Planned Replacement Date
3. Please can you provide the following information for each Ultrasound scanner within the Trust or associated sites? (Please complete the attached spreadsheet)
a. Manufacturer
b. Model
c. Location – Hospital Name or Site Name
d. Department equipment is primarily used in
e. Method of Finance at Procurement – Trust/Lease/MES/Charity/PFI
f. Initial cost of Equipment
g. Annual Maintenance cost
h. Acquisition Date
i. Planned Replacement Date

Download response Imaging equipment. 230921.docx

Q1. How many patients has your trust treated (for any disease) in the last 6 months (or the latest 6 months data you have available) with the following treatments:
a. Revolade (eltrombopag)
b. Nplate (romiplostim)
c. Doptelet (avatrombopag)
d. Tavlesse (fostamatinib)
Q2. In the last 6 months (or the latest 6 months data you have available), how many patients has your trust treated for immune thrombocytopenia (ITP)?
Q3. Of the patients treated for immune thrombocytopenia (ITP) in the last 6 months (or the latest 6 months data you have available), how many were treated with:
a. rituximab
b. mycophenolate mofetil
c. surgery (splenectomy)
Q4. Does your trust participate in any ongoing clinical trials for immune thrombocytopenia (ITP)? If so, can you please provide the name of each trial along with the number of patients taking part?

Immune thrombocytopenia (ITP).031122.docx

1. Has your histopathology laboratory outsourced any cases for reporting in the past year?
2. If yes, approximately what percentage of your work is outsourced?
3. Does your histopathology laboratory use any form of digital pathology?
4. Can you name the supplier(s) of your digital pathology solution?
5. If the answer to question 3 is “no”, can you indicate if you are looking to procure a digital pathology solution in the next year?
6. How much funding does the Trust have to implement this?
7. What would you use digital pathology for?
a. Research
b. Training
c. Primary diagnosis
d. Second opinion
e. MDT preparation and review
(Tick all that apply)
8. What LIS does your department currently use?
9. How old is your current LIS?
10. Does your laboratory workflow incorporate a barcoded tracking system?
11. If yes, what tracking system do you use?
12. To reduce the initial capital outlay, would you favour a cost per scan pricing model?
13. Would you consider an insourcing model where the digital pathology solution is tailored to your needs with scanners placed on site and images stored and streamed to your consultant workforce for reporting on your LIS?
14. Would you use an outsourcing model where your slides are sent offsite for scanning and cases reported by an external consultant team with reports returned direct to your LIS?
15. Would you prefer to purchase your own scanners and IMS and work directly with a partner provider to handle, store, and report your own images?

Implementation of digital pathology in Histopathology. 240222.docx

Q1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:
a. Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) as a single agent
b. Abemaciclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole)
c. Abemaciclib + Fulvestrant
d. Anthracycline (e.g. doxorubicin or epirubicin) as a single agent
e. Atezolizumab +Nab-paclitaxel/Paclitaxel
f. Capecitabine as a single agent
g. Carboplatin or Cisplatin as a single agent
h. Eribulin as a single agent or in combination
i. Everolimus + Exemestane
j. Fulvestrant as a single agent
k. Lapatinib
l. Neratinib
m. Parp Inhibitors (Olaparib/Talazoparib)
n. Palbociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole)
o. Palbociclib + Fulvestrant
p. Pembrolizumab
q. Pertuzumab + Trastuzumab + Docetaxel
r. Ribociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole)
s. Ribociclib + Fulvestrant
t. Sacituzumab Govitecan
u. Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent
v. Trastuzumab as a single agent or in combination
w. Trastuzumab emtansine
x. Transtuzumab deruxtecan
y. Vinorelbine as a single agent
z. Any other active systemic anti-cancer therapy
Q2. In the past 3 months, how many early/locally advanced (Stages I to IIIc) breast cancer patients were treated with an Aromatase Inhibitor (anastrazole, exemestane, letrozole) as a single agent?

Incidence and treatment of breast cancer.110322.docx

Q1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:
a.Abemaciclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole)
b. Abemaciclib + Fulvestrant
c. Alpelisib + Fulvestrant
d. Anthracycline (e.g. doxorubicin or epirubicin) as a single agent
e. Atezolizumab +Nab-paclitaxel/Paclitaxel
f. Capecitabine as a single agent
g. Eribulin as a single agent or in combination
h. Everolimus + Exemestane
i. Fulvestrant as a single agent
j. Lapatinib
k. Neratinib
l. Parp Inhibitors (Olaparib/Talazoparib)
m. Palbociclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole)
n. Palbociclib + Fulvestrant
o. Pembrolizumab
p. Platinum (e.g. carboplatin or cisplatin) as a single agent
q. Ribociclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole)
r. Ribociclib + Fulvestrant
s. Sacituzumab Govitecan
t. Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent
u. Taxane and/or Anthracycline in combination
v. Trastuzumab as a single agent or in combination
w. Trastuzumab emtansine
x. Transtuzumab deruxtecan
y. Any other active systemic anti-cancer therapy
Q2. Does your trust participate in any clinical trials for breast cancer? If so, can you please provide the name of each trial and the number of patients taking part.

Incidence and treatment of breast cancer.311022.docx

Q1. How many patients has your trust treated in the past 3 months for the following conditions:
a. Chronic Lymphocytic Leukaemia (CLL)
b. Mantle Cell Lymphoma (MCL)
c. In case you do not treat either of the above conditions, please tell us which trust or hospital you refer patients to.
Q2. How many Chronic Lymphocytic Leukaemia (CLL) patients have been treated in the past 3 months with the following:
a. BR (bendamustine + rituximab)
b. Calquence (acalabrutinib)
c. FCR (fludarabine + cyclophosphamide + rituximab)
d. Gazyva (obinutuzumab) + chlorambucil
e. Imbruvica (ibrutinib)
f. Venclexta (venetoclax)
g. Venclexta (venetoclax) + Gazyva (obinutuzumab)
h. Venclexta (venetoclax) + rituximab
i. Zydelig (idelalisib) + rituximab
j. Any other systemic anti-cancer therapy
Q3. How many Mantle Cell Lymphoma (MCL) patients have been treated in the past 3 months with the following:
a. BR (bendamustine + rituximab)
b. Imbruvica (ibrutinib)
c. Imbruvica (ibrutinib) + rituximab
d. R-BAC (rituximab, bendamustine and cytarabine)
e. R-CHOP (rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone)
f. Nordic Protocol (rituximab, cyclophosphamide, doxorubicin, vincristine, cytarabine & prednisolone)
g. Velcade (bortezomib) + chemotherapy
h. Any other systemic anti-cancer therapy
i. Stem cell transplant
j. Tecartus (CAR-T) – Autologous anti-CD19-transduced CD3+ cells
Q4. Does your trust currently participate in any ongoing clinical trials for the treatment of Chronic Lymphocytic Leukaemia (CLL)? If so, can you please provide the name of each trial along with the number of patients taking part?
Q5. Does your trust currently participate in any ongoing clinical trials for the treatment of Mantle Cell Lymphoma (MCL)? If so, can you please provide the name of each trial along with the number of patients taking part?

Incidents of Chronic Lymphocytic Leukaemia (CLL) and Mantle Cell Lymphoma (MCL).170622.docx

1. Number and type of interventional radiology (IR) procedures performed by the radiology department (only) per each year in question.
2. Number of interventional radiologists currently in the unit.
3. Number of dedicated interventional Radiology nurses
4. What is the Consultant Interventional Radiology on call rota?
5. Are there interventional Radiology trainees in your units? If yes, how many?
6. Number of Interventional Radiology angiosuites?
7. Is there a day case unit in your radiology department and if so, how many beds?
8. Number of beds in the trust.

Interventional Radiology.031122.docx

1. The year of purchase of every LINAC machine in operation at your trust?
2. How many patients received SBRT or SABR at your Trust in 2020 and until the latest available in 2021 and for what indications?
3. How many individual business cases have been raised for new or replacement linear accelerators in 2020 and 2021.

LINAC machines and SBRT or SABR.170322.docx

Question 1
Does Maidstone and Tunbridge Wells NHS Trust have any local treatment guidelines/pathways/protocols/algorithms for the treatment of non-small cell lung cancer?
Question 2
Does Maidstone and Tunbridge Wells NHS Trust have protocols for the use of the following targeted drug therapies in the treatment of non-small cell lung cancer?
a. Sotorasib (Lumykras)
b. Entrectinib (Rozlytrek)
c. Larotrectinib (Vitrakvi)
d. Dabrafenib (Tafinlar)
e. Trametinib (Mekinist)
f. Capmatinib (Tabrecta)
g. Tepotinib (Tepmetko)
h. Bevacizumab (Avastin)
i. Ramucirumab (Cyramza)
j. Atezolizumab (Tecentriq)
k. Durvalumab (Imfinzi)
l. Cemiplimab- (Libtayo)
m. Nivolumab (Opdivo)
n. Pembrolizumab (Keytruda)
o. Ipilimumab (Yervoy)
p. Afatinib (Giotrif)
q. Dacomitinib (Vizimpro)
r. Erlotinib (Tarceva)
s. Gefitinib (Iressa)
t. Osimertinib (Tagrisso)
u. Amivantamab (Rybrevant)
v. Mobocertinib (Exkivity)
w. trastuzumab deruxtecan (Enhertu)
x. Alectinib (Alecensa)
y. Brigatinib (Alunbrig)
z. Ceritinib (Zykadia)
aa. Crizotinib (Xalkori)
bb. Lorlatinib (Lorviqua)
cc. Entrectinib (Rozlytrek)
dd. Pralsetinib (Gavreto)
ee. Selpercatinib (Retsevmo)
ff. Nintedanib (Vargatef®)
Question 3
If a local protocol for the use of Sotorasib (Lumykras) for the treatment of non-small cell lung cancer is available please could a copy be provided?
Question 4
Does Maidstone and Tunbridge Wells NHS Trust have any local pathways/protocols/guidelines for the use of molecular biomarker testing in diagnosis/treatment of non-small cell lung cancer?
Question 5
Is Maidstone and Tunbridge Wells NHS Trust part of a Cancer alliance or network, if so which ones?

Local Treatment Guidelines Non-Small Cell Lung Cancer.020823.docx

1. What was the longest a patient at your Trust waited (in weeks/days) for –
a) a first consultant appointment, following a GP urgent referral on the two week wait pathway;
b) being told they have cancer, or cancer being definitively excluded, following a GP urgent referral on the two week wait pathway;
c) a first treatment for cancer, following a GP urgent referral on the two week wait pathway;
d) a diagnostic test or procedure, following a GP urgent referral on the two week wait pathway
In each of the following calendar years – 2018, 2019, 2020, 2021, 2022?

Longest cancer waits.170323.docx

All questions are shown as received by the Trust.
1. The longest wait from an Urgent Suspected Cancer or Breast Symptomatic Referral, or Consultant Upgrade to a First Definitive Treatment for Cancer in the Trust in 2023/24 (so far)?
2. How many patients in your trust are currently waiting longer than 6 months (186 days) from an Urgent Suspected Cancer or Breast Symptomatic Referral, or Consultant Upgrade to a First Definitive Treatment for Cancer?

Longest Cancer Waits.210324.docx

1. Your Trusts longest wait time for a non-urgent X-ray in the past 12 months
2. Your Trusts longest wait time for a CT scan in the past 12 months
3. Your Trusts longest wait time for an MRI in the past 12 months
4. Your Trusts longest wait time for a PET scan in the past 12 months
5. Your Trusts longest wait time for an Ultrasound in the past 12 months
6. Your Trusts longest wait time for an Angiography in the past 12 months
7. Your Trusts longest wait time for an Electrocardiogram scan in the past 12 months
8. Your Trusts longest wait time for an Echocardiogram in the past 12 months

Longest wait time for scans and x-rays.270923.docx

All questions are shown as received by the Trust.
Q1. How many non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:
a. ALK Inhibitors (Alectinib, Brigatinib, Ceritinib, Crizotinib, Lorlatinib)
b. Amivantamab
c. Atezolizumab Monotherapy
d. Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel
e. Atezolizumab subcutaneous
f. Dabrafenib + Trametinib
g. Docetaxel monotherapy or in combination with Carboplatin/Cisplatin
h. Durvalumab
i. Gemcitabine
j. Nintedanib + Docetaxel
k. Nivolumab
l. Osimertinib
m. Other EGFR Inhibitors (Afatinib, Erlotinib, Gefitinib, Dacomitinib, Mobocertinib)
n. Paclitaxel
o. Pembrolizumab Monotherapy
p. Pembrolizumab + Paclitaxel + Platinum (Carboplatin/Cisplatin)
q. Pembrolizumab + Pemetrexed + Platinum (Carboplatin/Cisplatin)
r. Pemetrexed + Platinum (Carboplatin/Cisplatin)
s. RET Inhibitors (Pralsetinib, Selpercatinib)
t. Sotorasib
u. Tepotinib
v. Vinorelbine monotherapy or in combination with Carboplatin/Cisplatin
w. Other active systemic anti-cancer therapy
x. Palliative care only
Q2. How many patients were treated for Squamous non-small cell lung cancer (Sq NSCLC) ONLY in the past 3 months with:
a. Atezolizumab monotherapy
b. Durvalumab
c. Gemcitabine
d. Nivolumab
e. Osimertinib
f. Pembrolizumab Monotherapy
g. Pembrolizumab + Paclitaxel + Platinum (Carboplatin/Cisplatin)
h. Paclitaxel
i. Vinorelbine monotherapy or in combination with Carboplatin/Cisplatin
j. Other active systemic anti-cancer therapy (SACT)
k. Palliative care only

Lung cancer.201024.docx

Q1 – How many patients has your Trust treated in the past 3 months for:
a. Non-small cell lung cancer (NSCLC) – any treatment
b. Non-small cell lung cancer (NSCLC) – surgical treatment
c. Non-small cell lung cancer (NSCLC) – radiotherapy
d. Non-small cell lung cancer (NSCLC) – systemic anti-cancer treatment (SACT)
Q2 – How many Non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:
a. ALK Inhibitors (Alectinib, Brigatinib, Ceritinib, Crizotinib, Lorlatinib)
b. Amivantamab
c. Atezolizumab monotherapy
d. Atezolizumab with chemotherapy
e. Dabrafenib + Trametinib
f. Durvalumab
g. Gemcitabine
h. Nitendanib + Docetaxel
i. Nivolumab
j. Osimertinib
k. Other EGFR Inhibitors (Afatinib, Erlotinib, Gefitinib, Dacomitinib, Mobocertinib)
l. Paclitaxel
m. Pembrolizumab monotherapy
n. Pembrolizumab with chemotherapy
o. Pemetrexed with carboplatin/cisplatin
p. RET Inhibitors (Pralsetinib, Selpercatinib)
q. Sotorasib
r. Tepotinib
s. Vinorelbine monotherapy or combination with Carboplatin/Cisplatin
t. Other active systemic anti-cancer therapy [please state]
u. Palliative care only
Q3 – Of the NSCLC patients treated with Nivolumab in the past 3 months, how many patients received (surgery) or are scheduled to receive surgical treatment after commencement of the treatment with Nivolumab?

Lung cancer.230623.docx

All questions are shown as received by the Trust.
Q1. How many non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:
a. ALK Inhibitors (Alectinib, Brigatinib, Ceritinib, Crizotinib, Lorlatinib)
b. Amivantamab
c. Atezolizumab Monotherapy
d. Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel
e. Dabrafenib + Trametinib
f. Docetaxel monotherapy or in combination with Carboplatin/Cisplatin
g. Durvalumab
h. Gemcitabine
i. Nitedanib + Docetaxel
j. Nivolumab
k. Osimertinib
l. Other EGFR Inhibitors (Afatinib, Erlotinib, Gefitinib, Dacomitinib, Mobocertinib)
m. Paclitaxel
n. Pembrolizumab Monotherapy
o. Pembrolizumab + Paclitaxel + Platinum (Carboplatin/Cisplatin)
p. Pembrolizumab + Pemetrexed + Platinum (Carboplatin/Cisplatin)
q. Pemetrexed + Platinum (Carboplatin/Cisplatin)
r. RET Inhibitors (Pralsetinib, Selpercatinib)
s. Sotorasib
t. Tepotinib
u. Vinorelbine monotherapy or in combination with Carboplatin/Cisplatin
v. Other active systemic anti-cancer therapy
w. Palliative care only
Q2. How many patients were treated for Squamous non-small cell lung cancer (Sq NSCLC) ONLY in the past 3 months with:
a. Atezolizumab monotherapy
b. Durvalumab
c. Gemcitabine
d. Nivolumab
e. Osimertinib
f. Pembrolizumab (Keytruda) Mono
g. Pembrolizumab + Paclitaxel + Platinum (Carboplatin/Cisplatin)
h. Paclitaxel
i. Vinorelbine monotherapy or in combination with Carboplatin/Cisplatin
j. Other active systemic anti-cancer therapy (SACT)
k. Palliative care only

Lung cancer.250624.docx

Q1. In the past 3 months, how many non-small cell lung cancer (NSCLC) patients were treated with:
a. Afatinib
b. Alectinib
c. Amivantamab
d. Atezolizumab monotherapy
e. Atezolizumab with chemotherapy
f. Brigatinib
g. Ceritinib
h. Crizotinib
i. Dacomitinib
j. Dabrafenib with Trametinib
k. Durvalumab
l. Erlotinib
m. Gefitinib
n. Lorlatinib
o. Mobocertinib
p. Nintedanib with Docetaxel
q. Nivolumab
r. Osimertinib
s. Pembrolizumab monotherapy
t. Pembrolizumab with chemotherapy
u. Pemetrexed with Carboplatin/Cisplatin
v. Sotorasib
w. Tepotinib
x. Vinorelbine with Carboplatin/Cisplatin
y. Any other active systemic anti-cancer therapy (SACT)
z. Palliative care only
Q2. In the past 3 months, how many patients were treated for Squamous non-small cell lung cancer (Sq NSCLC) ONLY with the following drugs:
a. Atezolizumab monotherapy
b. Atezolizumab with chemotherapy
c. Durvalumab
d. Nivolumab
e. Osimertinib
f. Pembrolizumab (Keytruda) Mono
g. Pembrolizumab (Keytruda) with Chemotherapy
h. Tepotinib
i. Other active systemic anti-cancer therapy (SACT)
j. Palliative care only

Lung cancer.270622.docx

All questions are shown as received by the Trust.
Q1. How many Non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:
a. ALK Inhibitors (Alectinib, Brigatinib, Ceritinib, Crizotinib, Lorlatinib)
b. Amivantamab
c. Atezolizumab Monotherapy
d. Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel
e. Dabrafenib + Trametinib
f. Docetaxel monotherapy or in combination with Carboplatin/Cisplatin
g. Durvalumab
h. Gemcitabine
i. Nitedanib + Docetaxel
j. Nivolumab
k. Osimertinib
l. Other EGFR Inhibitors (Afatinib, Erlotinib, Gefitinib, Dacomitinib, Mobocertinib)
m. Paclitaxel
n. Pembrolizumab Monotherapy
o. Pembrolizumab + Paclitaxel + Platinum (Carboplatin/Cisplatin)
p. Pembrolizumab + Pemetrexed + Platinum (Carboplatin/Cisplatin)
q. Pemetrexed + Platinum (Carboplatin/Cisplatin)
r. RET Inhibitors (Pralsetinib, Selpercatinib)
s. Sotorasib
t. Tepotinib
u. Vinorelbine monotherapy or in combination with Carboplatin/Cisplatin
v. Other active systemic anti-cancer therapy
w. Palliative care only
Q2. Of all the NSCLC patients treated with nivolumab in the past 3 months, how many patients received (surgery) or are scheduled to receive surgical treatment after commencement of the treatment with nivolumab?
Q3. Does your trust/health board participate in any clinical trials for non-small cell lung cancer (NSCLC)? If so, could you please provide the name of each active trial and the number of patients taking part.

Lung cancer.271023.docx

All questions are shown as received by the Trust.
Q1. How many non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:
a. ALK Inhibitors (Alectinib, Brigatinib, Ceritinib, Crizotinib, Lorlatinib)
b. Amivantamab
c. Atezolizumab Monotherapy
d. Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel
e. Dabrafenib + Trametinib
f. Docetaxel monotherapy or in combination with Carboplatin/Cisplatin
g. Durvalumab
h. Gemcitabine
i. Nitedanib + Docetaxel
j. Nivolumab
k. Osimertinib
l. Other EGFR Inhibitors (Afatinib, Erlotinib, Gefitinib, Dacomitinib, Mobocertinib)
m. Paclitaxel
n. Pembrolizumab Monotherapy
o. Pembrolizumab + Paclitaxel + Platinum (Carboplatin/Cisplatin)
p. Pembrolizumab + Pemetrexed + Platinum (Carboplatin/Cisplatin)
q. Pemetrexed + Platinum (Carboplatin/Cisplatin)
r. RET Inhibitors (Pralsetinib, Selpercatinib)
s. Sotorasib
t. Tepotinib
u. Vinorelbine monotherapy or in combination with Carboplatin/Cisplatin
v. Other active systemic anti-cancer therapy
w. Palliative care only
Q2. How many patients were treated for Squamous non-small cell lung cancer (Sq NSCLC) ONLY in the past 3 months with:
a. Atezolizumab monotherapy
b. Durvalumab
c. Gemcitabine
d. Nivolumab
e. Osimertinib
f. Pembrolizumab (Keytruda) Mono
g. Pembrolizumab + Paclitaxel + Platinum (Carboplatin/Cisplatin)
h. Paclitaxel
i. Vinorelbine monotherapy or in combination with Carboplatin/Cisplatin
j. Other active systemic anti-cancer therapy (SACT)
k. Palliative care only

Lung Cancer.280224.docx

1. Who provides the maintenance and/or repair of the Trust’s surgical power tool inventory? If more than one, please provide all.
2. When is the expiry date of the existing maintenance contract for the Trust’s surgical power tool inventory? If more than one, please provide all.

Maintenance contract for the Trust’s surgical power tool inventory.181022.docx

Could you please provide me with the name, telephone number & email address of whom we need to contact at the Trust to be considered for the maintenance contract on the GE Discovery 670 gamma camera systems when the current contracts expire in March 23?

Maintenance contract on the GE Discovery 670 gamma camera systems.141122.docx

1. Approximately how many medical devices/EBME devices does the trust own?
2. Approximately how many patient beds does the Trust have?
3. Does the trust subcontract the maintenance of medical/EBME devices to an outside provider(s) or does it maintain the devices using internal engineers?
3a. If an external provider(s) is used, what is the name of the company(s)?
3b. If an external provider(s) is used, what was the value of the contract when awarded?
3c. If an external provider(s) is used, what is the contract type – PPM/ Fully-Comprehensive / Ad-hoc support?
3d. If an external provider(s) is used, what is the contract renewal date(s)?
4. Please provide the name, email address of the role responsible for managing medical devices within the trust
5. If medical device maintenance is managed internally, how many clinical engineers are employed by the Trust?
6. What is the current % of assets ‘within service date’ – i.e., the date by which a device must be serviced has not expired? (This will be a standard KPI)

Medical devices.021222.docx

1. The name of the person within your Trust that is responsible for Medical Devices e.g. Medical Device Manager.
2. The email address of the person that holds this responsibility.
3. The name of the person within your Trust that holds the job title EMBE Manager
4. The email address of the Trusts EBME Manager

Medical Devices.050722.docx

A list of the current medical imaging equipment held by the Trust across all hospital sites, providing the following information:
Q1: What is the contract value for each imaging modality requested below:
a) Computed Tomography (CT)
b) Magnetic Resonance Imaging (MRI)
c) Ultrasound
d) Fluoroscopy
e) Mammography
f) Nuclear
g) Mobile X-ray
h) Static X-ray
Q2: A list of the current modalities held by the Trust across all hospital sites for each of the following:
a) Supplier name
b) Product name
c) Contract start date
d) Contract expiry date
e) Number of devices
f) Age of product
Q3: What percentage of your imaging equipment has an element of Artificial Intelligence?

Medical Imaging Equipment.110522.docx

All questions are shown as received by the Trust.
Q1. How many patients have been treated in the past 3 months with the following agents for melanoma (any stage) :
a. Cobimetinib
b. Dabrafenib
c. Dabrafenib + Trametinib
d. Dacarbazine
e. Denosumab
f. Encorafenib + Binimetinib
g. Ipilimumab monotherapy
h. Ipilimumab + Nivolumab
i. Nivolumab monotherapy
j. Nivolumab + Relatlimab
k. Pembrolizumab
l. Trametinib
m. Vemurafenib
n. Vemurafenib + Cobimetinib
o. Other active systemic anti-cancer therapy
p. Palliative care only
Q2. If possible, could you please provide the patients treated in the past 3 months with the following agents for metastatic melanoma ONLY:
a. Ipilimumab monotherapy
b. Ipilimumab + Nivolumab
c. Nivolumab monotherapy
d. Nivolumab + Relatlimab
e. Pembrolizumab
f. Any Targeted Therapy (Dabrafenib /Dabrafenib AND Trametinib /Encorafenib AND Binimetinib /Trametinib /Vemurafenib /Vemurafenib AND Cobimetinib)
g. Other active systemic anti-cancer therapy
h. Palliative care only
Q3. In the last 3 months, how many patients have been initiated* on the following agents for treatment for melanoma?
a. Ipilimumab (monotherapy)
b. Nivolumab (monotherapy)
c. Nivolumab AND Ipilimumab (combination)
d. Nivolumab AND Relatlimab
e. Pembrolizumab
f. Any Targeted Therapy (Dabrafenib /Dabrafenib AND Trametinib /Encorafenib AND Binimetinib /Trametinib /Vemurafenib /Vemurafenib AND Cobimetinib)
g. Other active systemic anti-cancer therapy

Melanoma.250624.docx

All questions are shown as received by the Trust.
Q1. How many patients have been treated in the past 3 months with the following agents for melanoma (any stage) :
a. Cobimetinib
b. Dabrafenib
c. Dabrafenib + Trametinib
d. Dacarbazine
e. Denosumab
f. Encorafenib + Binimetinib
g. Ipilimumab monotherapy
h. Ipilimumab + Nivolumab
i. Nivolumab monotherapy
j. Nivolumab + Relatlimab
k. Pembrolizumab
l. Trametinib
m. Vemurafenib
n. Vemurafenib + Cobimetinib
o. Other active systemic anti-cancer therapy
p. Palliative care only
Q2. If possible, could you please provide the patients treated in the past 3 months with the following agents for metastatic melanoma ONLY:
a. Ipilimumab monotherapy
b. Ipilimumab + Nivolumab
c. Nivolumab monotherapy
d. Nivolumab + Relatlimab
e. Pembrolizumab
f. Any Targeted Therapy (Dabrafenib /Dabrafenib AND Trametinib /Encorafenib AND Binimetinib /Trametinib /Vemurafenib /Vemurafenib AND Cobimetinib)
g. Other active systemic anti-cancer therapy
h. Palliative care only
Q3. In the last 3 months, how many patients have been initiated* on the following agents for treatment for melanoma?
a. Ipilimumab (monotherapy)
b. Nivolumab (monotherapy)
c. Nivolumab AND Ipilimumab (combination)
d. Nivolumab AND Relatlimab
e. Pembrolizumab
f. Any Targeted Therapy (Dabrafenib /Dabrafenib AND Trametinib /Encorafenib AND Binimetinib /Trametinib /Vemurafenib /Vemurafenib AND Cobimetinib)
g. Other active systemic anti-cancer therapy
*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.

Melanoma.251024.docx

Q1. In the past 3 months (or the latest 3 months data you have available), how many melanoma patients were treated with:
a. Bevacizumab (Avastin)
b. Dacarbazine (DTIC)
c. Trametinib (Mekinist)
d. Dabrafenib (Tafinlar)
e. Ipilimumab (Yervoy)
f. Vemurafenib (Zelboraf)
g. Nivolumab (Opdivo)
h. Nivolumab + Ipilimumab (Opdivo + Yervoy)
i. Pembrolizumab (Keytruda)
j. Vemurafenib + cobimetinib (Zelboraf + Cotellic)
k. Dabrafenib + Trametinib (Tafinlar + Mekinist)
l. Braftovi (encorafenib) in combination with Mektovi (binimetinib) for BRAF V600 patients
m. Other active systemic anti-cancer therapy [please state]
n. Palliative care only
Q2. In the past 3 months (or the latest 3 months data you have available), how many metastatic melanoma patients were treated with the following:
a. Ipilimumab
b. Ipilimumab AND Nivolumab
c. Nivolumab
d. Pembrolizumab
e. Dabrafenib AND Trametinib
f. Any Other Targeted Therapy (Dabrafenib /Encorafenib AND Binimetinib /Trametinib /Vemurafenib /Vemurafenib AND Cobimetinib)
g. Other active systemic anti-cancer therapy
h. Palliative care only

Melanoma.290922.docx

Q1. In the past 3 months (or the latest 3 months data you have available), how many melanoma patients were treated with:
a. Bevacizumab (Avastin)
b. Dacarbazine (DTIC)
c. Trametinib (Mekinist)
d. Dabrafenib (Tafinlar)
e. Ipilimumab (Yervoy)
f. Vemurafenib (Zelboraf)
g. Nivolumab (Opdivo)
h. Nivolumab + Ipilimumab (Opdivo + Yervoy)
i. Pembrolizumab (Keytruda)
j. Vemurafenib + cobimetinib (Zelboraf + Cotellic)
k. Dabrafenib + Trametinib (Tafinlar + Mekinist)
l. Braftovi (encorafenib) in combination with Mektovi (binimetinib) for BRAF V600 patients
m. Other active systemic anti-cancer therapy [please state]
n. Palliative care only
Q2. In the past 3 months (or the latest 3 months data you have available), how many metastatic melanoma patients were treated with the following:
a. Ipilimumab
b. Ipilimumab AND Nivolumab
c. Nivolumab
d. Pembrolizumab
e. Dabrafenib AND Trametinib
f. Any Other Targeted Therapy (Dabrafenib /Encorafenib AND Binimetinib /Trametinib /Vemurafenib /Vemurafenib AND Cobimetinib)
g. Other active systemic anti-cancer therapy
h. Palliative care only

Melanoma.290922.docx

All questions are shown as received by the Trust.
1. Please detail the standard follow-up regime for newly diagnosed melanoma patients (Stages IA-IIB) within your Trust, indicating the frequency of appointments and duration of follow-up (1-5 years) as per your clinical protocols.
2. Which of the following Melanoma NICE guidelines do you currently implement at your Trust/Health Board/other:
a. Pre-27th July 2022 NICE guidelines titled ‘NG14: Melanoma: assessment and management’ Yes or No
b. Latest NICE guidelines title ‘NG14: Melanoma: assessment and management’ released on the 27th July 2022. Yes or No
c. Using own Melanoma guideline for the Trust. Yes or No
i. If yes, please provide document in PDF format.
3. What is your current waiting time for sentinel lymph node biopsy for those confirmed with any stage melanoma? Please provide measure (Weeks, months etc, but please identify..)
4. In the last 12 months for stage 2Bs melanoma only, what proportion of them had Pembrolizumab.
5. Is ultrasound used in any of the follow up pathways for the stages of Melanoma below for patients in your Trust, please answer Yes or No:
– IA Yes or No
– IB Yes or No
– IIA Yes or No
– IIB Yes or No
6. For the following NHS financial year dates, how many melanoma cases per year have been newly diagnosed in your Trust
a. 2020/21, 2021/22 and 2022/23
7. Could you please confirm for your Trust in 2022/23 the following numbers of newly diagnosed Melanoma skin cancer patients and the number of these who have received a subsequent Sentinel Lymph Node biopsy by Melanoma Stage?

Melanoma Cancer Care Protocols and Patient Management Details.130324.docx

All questions are shown as received by the Trust.
Q1. How many patients have you treated with Pembrolizumab in the three months from May 2023 to July 2023 for:

• Melanoma – any stage
• Stage IIb/IIc Melanoma
• Stage III Melanoma
• Metastatic Melanoma

Q2. How many Stage IIb/IIc melanoma patients were on a “Watch and Wait” strategy in the three months from May 2023 to July 2023? These would be patients where a decision has been made to wait before commencing any treatment.

Melanoma Treatment.250823.docx

Please tell me with respect to the financial year 2022/23:
1) How many incidents were reported by your Trust on the Datix incident reporting system under the category ‘MRI safety’?
2) How many of these MRI safety Datix incident reports were listed under the division, ‘MRI Non Declared Internal Passive Metallic Implant’?
3) How many of these MRI safety Datix incident reports were under the division ‘MRI Non Declared Internal Active Metallic Implant’?

For all of the incidents captured under 2 and 3 above in 2022/23, can you please provide a verbatim copy of the description of the adverse event?
Please do a search based on relevant words and then review to ensure they meet the criteria outlined above of non-declared passive and active metal implant incidents in MRI scans.

Another alternative, if your Trust lacks the Datix system, could be to search for safety incidents logged under the location ‘MRI’.

Metallic implants in MRI scans – 2022-23.310723.docx

Q1. In the past 3 months (or the latest 3 months data you have available), how many metastatic non-small cell lung cancer (NSCLC) patients were treated with any of the following:
a. Afatinib
b. Alectinib
c. Atezolizumab monotherapy
d. Atezolizumab in combination
e. Bevacizumab
f. Brigatinib
g. Capmatenib
h. Ceritinib
i. Crizotinib
j. Dacomitinib
k. Dabrafenib with Trametinib
l. Docetaxel monotherapy
m. Durvalumab
n. Erlotinib
o. Gefitinib
p. Gemcitabine
q. Nintedanib with Docetaxel
r. Nivolumab
s. Osimertinib
t. Paclitaxel
u. Pembrolizumab monotherapy
v. Pembrolizumab in combination
w. Pemetrexed with Carboplatin/Cisplatin
x. Tepotinib
y. Vinorelbine with Cisplatin/Carboplatin
z. Any other SACT
aa. Palliative care only

Metastatic non-small cell lung cancer (NSCLC).270422.docx

Q1. In the past 3 months (or the latest 3 months data you have available), how many Metastatic/advanced Breast cancer patients were treated with:
a. Abemaciclib (Verzenios) + aromatase inhibitor *
b. Abemaciclib (Verzenios) + Fulvestrant (Faslodex)
c. Alpelisib (Piqray) + Fulvestrant (Faslodex)
d. Atezolizumab (Tecentriq)**
e. Bevacizumab (Avastin)
f. Eribulin (Halaven)
g. Everolimus (Afinitor) + Exemestane
h. Fulvestrant (Faslodex) as a single agent
i. Gemcitabine + paclitaxel
j. Herceptin (Trastuzumab) + paclitaxel
k. Herceptin (Trastuzumab) as a single agent
l. Lapatinib (Tyverb)
m. Neratinib (Nerlynx)
n. Olaparib (Lynparza)
o. Palbociclib (Ibrance) + aromatase inhibitor*
p. Palbociclib (Ibrance) + Fulvestrant (Faslodex)
q. Pertuzumab (Perjeta) + trastuzumab + docetaxel
r. Ribociclib (Kisqali) + aromatase inhibitor*
s. Ribociclib (Kisqali) + Fulvestrant (Faslodex)
t. Talazoparib (Talzenna)
u. Trastuzumab emtansine (Kadcyla)
v. Other active systemic anti-cancer therapy **
*aromatase inhibitor e.g. Anastrozole, Exemestane or Letrozole
**e.g. docetaxel, vinorelbine or capecitabine as a single agent
Q2. For the above patients, how many of these received their first ever dose for each product line?

Metastatic or advanced Breast cancer. 140422.docx

All questions are shown as received by the Trust.
1. Do you use IMDC (International Metastatic Renal Cell Carcinoma Database Consortium) criteria for classifying Metastatic Renal Cell Carcinoma patients? (Yes or No)
2. If Yes, for the patients treated for Metastatic Renal Cell Carcinoma during the time period January through to March 2024, how many patients were classified as:
a. Favourable risk
b. Intermediate risk
c. Poor risk

Metastatic Renal Cell Carcinoma.190424.docx

All questions are shown as received by the Trust.
1. Details of the current mobile MRI and CT contracts held by your Trust, including:
a. Contract value(s)
b. Duration of the current contract(s)
c. Date(s) when the contract(s) are scheduled for renewal
2. Information on the frameworks through which these contracts were procured, including:
a. Name(s) of the framework(s) utilized
b. Any relevant framework reference numbers
3 – Contact details for the Radiology Managers and Procurement Managers responsible for overseeing these contracts, including:
a. Name(s)
b. Job title(s)
c. Trust Email address(es)
d. Trust Telephone number(s)

Mobile MRI and CT Contracts.070824.docx

All questions are shown as received by the Trust.
• The number of oral cancer referrals received by hospitals in your Trust between January 2017 and the most recent completed month that is available (most likely June 2024). I also request this data be presented as monthly figures.

Mouth Cancer.260724.docx

1. Which Hospitals use post-processing Cardiac MRI software? Please discriminate per hospital and department. To help you identify whether any Cardiac MRI software (MRI cardiovascular post-processing software) is in use, please see some examples below (please note this is not a comprehensive list) and note that Cardiac MRI Software is a software that allows dedicated cardiac visualization, analysis, and reporting:
Based on Q1 can you please provide for each hospital the following:
2. Name of Supplier: Software provider for each contract?
3. The brand of the software: Actual name of the software. Please do not provide the supplier name again please provide the actual software name.
4. Description of the contract: Can you please provide detailed information about this contract and please state if upgrade, maintenance and support is included. Please also list the software modules included in these contracts.
5. What is the value of the contract? (please detail what the initial up-front cost of the software platform is, and detail annual or recurring costs in perpetuity i.e. support and maintenance, and professional services invoiced for, be it with the vendor directly and or a third-party)
6. Number of Users/Licenses: What is the total number of user/licenses for this contract?
7. Contract Duration: What is the duration of the contract please include any available extensions within the contract.
8. Contract Start Date: What is the start date of this contract? Please include month and year of the contract. DD-MM-YY or MM-YY.
9. Contract Expiry: What is the expiry date of this contract? Please include month and year of the contract. DD-MM-YY or MM-YY.
10. Contact Details: Contact details of the person within the organisation responsible for this particular software contract (name, job title, email, contact number).

MRI cardiovascular post-processing software. 160322.docx

All questions are shown as received by the Trust.
1. For the calendar year of 2023, please could you tell me how many individual MRI examinations were performed overall?
2. For the calendar year of 2023, please could you give a breakdown of the individual MRI examinations performed into body part/area? For instance, how many brain scans, spine scans etc. I am happy with whichever body part description is input in the PACS system.
3. As of the start of 2024, what would the waiting time be (in weeks) for a routine MRI scan (for example how long would a patient have to wait if they were referred for a routine MRI scan of their knee)?
4. How much money was paid to private companies during the calendar year 2023 for the outsourcing of MRI either to mobile MRI units, private hospitals or private companies staffing hospital scanners to scan NHS patients?
5. From question 4 which companies were used and how many patients were scanned?
6. How many MRI scanners does the Trust own?
7. From question 6 could I please have the manufacturer, model, and date of install of the MRI scanners?

MRI imaging.300124.docx

Please tell me in the financial years a) 2020/21 and b) 2021/22
1) How many incidents were reported by your Trust on the Datix incident reporting system under the category ‘MRI safety’?
2) How many of these MRI safety Datix incident reports were listed under the division, ‘MRI Non Declared Internal Passive Metallic Implant’?
3) How many of these MRI safety Datix incident reports were under the division ‘MRI Non Declared Internal Active Metallic Implant’?
For all of the incidents captured under 2 and 3 above in 2020/21 and 2021/22, can you please provide a verbatim copy of the description of the adverse event? To avoid running into Section 40 exemptions, please redact any person identifiable information.
Note: The above is based on the understanding of MRI reporting procedures I derived from reading the following webpage: https://www.mriphysics.scot.nhs.uk/reporting-incidents-and-near-misses/. If the terminology used by your Trust is slightly different, please give me the nearest equivalent.
4a) Finally, can you please tell me if MRI scanner(s) at your Trust have at any point needed to be temporarily left out of service due to supply chain issues impacting access to helium in 2021/22? If the answer to this question is YES, please also tell me
4b) How many machines were affected by the helium shortage?
4c) In which hospitals/buildings do those machine(s) operate?
4d) How long were the machine(s) out of action as a result of the helium shortage?
4e) How many patients were affected by the MRI scanner outage?

MRI safety and helium supply.281022.docx

1. For the calendar year of 2021, please could you tell me how many individual MRI examinations were performed overall?
2. For the calendar year of 2021, please could you give a breakdown of the individual MRI examinations performed into body part/area? For instance, how many brain scans, spine scans etc. I am happy with whichever body part description is input in the PACS system.
3. As of the start of 2022, what would the waiting time be (in weeks) for a routine MRI scan (for example how long would a patient have to wait if they were referred for a routine MRI scan of their knee)?
4. How much money was paid to private companies during the calendar year 2021 for the outsourcing of MRI either to mobile MRI units, private hospitals or private companies staffing hospital scanners to scan NHS patients?
5. From question 4 which companies were used and how many patients were scanned?
6. How many MRI scanners does the Trust own?
7. From question 6 could I please have the manufacturer, model, and date of install of the MRI scanners?

MRI services.240222.docx

I am investigating the use of targeted therapies in blood-related cancers.
1. Could you please tell me how many patients have you treated in the last 3 months for Multiple Myeloma?
2. Further, how many have received the following treatments?
Treatment:
Bortezomib [Velcade] and Dexamethasone
Bortezomib [Velcade], Thalidomide and Dexamethasone [known as VTD]
Bortezomib [Velcade], Cyclophosphamide/Melphalan and Dexamethasone/Prednisolone [known as VCD or VMP]
Lenalidomide [Revlimid] monotherapy
Lenalidomide [Revlimid] and Dexamethasone
Lenalidomide [Revlimid], Bortezomib [Velcade] and Dexamethasone
Lenalidomide [Revlimid], Melphalan and Prednisolone
Thalidomide, Cyclophosphamide/Melphalan, and Dexamethasone/Prednisolone [known as MPT or CTD]
Bortezomib [Velcade] monotherapy
Carfilzomib [Kyprolis] and Dexamethasone
Carfilzomib [Kyprolis], Lenalidomide [Revlimid], and Dexamethasone [known as KRD]
Daratumumab [Darzalex], Velcade [Bortezomib] and Dexamethasone [known as DVD]
Daratumumab [Darzalex], Velcade [Botezomib], Thalidomide and Dexamethasone [known as Dara-VTd]
Daratumumab [Darzalex], Lenalidomide [Revlimid] and Dexamethasone
Daratumumab [Darzalex], Pomalidomide [Imnovid] and Dexamethasone (DaraPd)
Daratumumab [Darzalex] monotherapy
Isatuximab [Sarclisa], Pomalidomide [Imnovid] and Dexamethasone [known as IsaPd]
Isatuximab [Sarclisa], Carfilzomib [Kyprolis] and Dexamethasone [known as IsaKd]
Ixazomib [Ninlaro], Lenalidomide [Revlimid] and Dexamethasone [known as IRD]
Pomalidomide [Imnovid] and Dexamethasone
Panobinostat [Farydak], Bortezomib [Velcade] and Dexamethasone
Any other systemic anti-cancer treatment

Multiple Myeloma. 140322.docx

Q1. Over the past 6 months, how many adult multiple myeloma [MM] patients have you treated? If you refer your multiple myeloma patients to another centre, please state which.
Q2. Of the multiple myeloma patients over the past 6 months, how many were treated with the following:
a. Belantamab Mafodotin [Blenrep]
b. Bortezomib [Velcade] monotherapy or with dexamethasone
c. Bortezomib, thalidomide and dexamethasone [VTD]
d. Bortezomib [Velcade], Melphalan/Cyclophosphamide and prednisolone/dexamethasone (VMp or VCd)
e. Carfilzomib [Kyprolis] and dexamethasone
f. Carfilzomib [Kyprolis], Lenalidomide [Revlmid] and dexamethasone
g. Daratumumab [Darzalex] monotherapy
h. Daratumumab [Darzalex], Bortezomib [Velcade] and dexamethasone (known as DVd or DBd)
i. Daratumumab [Darzalex], Bortezomib [Velcade], thalidomide and dexamethasone (known as Dara-VTd)
j. Elranatamab
k. Idecabtagene vicleucel [Abecma]
l. Isatuximab [Sarclisa], Pomalidomide [Imnovid] and dexamethasone (known as IsaPd)
m. Ixazomib [Ninlaro], Lenalidomide [Revlmid] and dexamethasone (known as IRd)
n. Lenalidomide [Revlmid] monotherapy
o. Lenalidomide [Revlimid] and dexamethasone
p. Pomalidomide [Imnovid] and dexamethasone
q. Selinexor and dexamethasone
r. Talquetamab
s. Teclistamab [Tecvayli]
t. Any other systemic anti-cancer therapy

Multiple Myeloma.200723.docx

All questions are shown as received by the Trust.
Q1. Over the past 6 months, how many adult multiple myeloma [MM] patients have you treated? If you refer your multiple myeloma patients to another centre, please state which.
Q2. Of the multiple myeloma patients over the past 6 months, how many were treated with the following:
a. Belantamab Mafodotin [Blenrep]
b. Bortezomib [Velcade] monotherapy or with dexamethasone
c. Bortezomib, thalidomide and dexamethasone [VTD]
d. Bortezomib [Velcade], Melphalan/Cyclophosphamide and prednisolone/dexamethasone (VMp or VCd)
e. Carfilzomib [Kyprolis] and dexamethasone
f. Carfilzomib [Kyprolis], Lenalidomide [Revlmid] and dexamethasone
g. Daratumumab [Darzalex] monotherapy
h. Daratumumab [Darzalex], Bortezomib [Velcade] and dexamethasone (known as DVd or DBd)
i. Daratumumab [Darzalex], Bortezomib [Velcade], thalidomide and dexamethasone (known as Dara-VTd)
j. Daratamumab [Darzalex] with Lenalidomide [Revlimid] and dexamethasone
k. Elranatamab
l. Idecabtagene vicleucel [Abecma]
m. Isatuximab [Sarclisa], Pomalidomide [Imnovid] and dexamethasone (known as IsaPd)
n. Ixazomib [Ninlaro], Lenalidomide [Revlmid] and dexamethasone (known as IRd)
o. Lenalidomide [Revlmid] monotherapy
p. Lenalidomide [Revlimid] and dexamethasone
q. Pomalidomide [Imnovid] and dexamethasone
r. Selinexor and dexamethasone
s. Talquetamab
t. Teclistamab [Tecvayli]
u. Any other systemic anti-cancer therapy

Multiple Myeloma.240424.docx

All questions are shown as received by the Trust.
Q1. Over the past 6 months, how many adult multiple myeloma [MM] patients have you treated? If you refer your multiple myeloma patients to another centre, please state which.
Q2. Of the multiple myeloma patients over the past 6 month, how many were treated with the following:
a. Bortezomib [Velcade], Melphalan/Cyclophosphamide and prednisolone/dexamethasone (VMp or VCd)
b. Bortezomib, thalidomide and dexamethasone [VTD]
c. Daratamumab [Darzalex] with Lenalidomide [Revlimid] and dexamethasone
d. Daratumumab [Darzalex], Bortezomib [Velcade], thalidomide and dexamethasone (known as Dara-VTd)
e. Selinexor, Bortexomiv [Velcade] and dexamethasone
f. Carfilzomib [Kyprolis] and dexamethasone
g. Bortezomib [Velcade] monotherapy or with dexamethasone
h. Daratumumab [Darzalex], Bortezomib [Velcade] and dexamethasone (known as DVd or DBd)
i. Carfilzomib [Kyprolis], Lenalidomide [Revlmid] and dexamethasone
j. Belantamab Mafodotin [Blenrep]
k. Idecabtagene vicleucel [Abecma]
l. Isatuximab [Sarclisa], Pomalidomide [Imnovid] and dexamethasone (known as IsaPd)
m. Elranatamab
n. Daratumumab [Darzalex] monotherapy
o. Ixazomib [Ninlaro], Lenalidomide [Revlmid] and dexamethasone (known as IRd)
p. Lenalidomide [Revlimid] and dexamethasone
q. Lenalidomide [Revlmid] monotherapy
r. Pomalidomide [Imnovid] and dexamethasone
s. Selinexor and dexamethasone
t. Talquetamab
u. Teclistamab [Tecvayli]
v. Any other systemic anti-cancer therapy

Multiple myeloma [MM].221124.docx

1. Could you please provide a copy of the Trusts/entity “New Medical Device policy?”
2. Could you please provide a copy of the Trusts/entity “Medical Devices and Procurement Review Group policy?”
3. Could you please provide a copy of the Trusts/entity “Business case template for new medical devices or technology” for new medical/diagnostic device approval?
4. Could you please provide a list of all approved medical devices in your Trusts/entity? Excel format, word or PDF is fine.
5. Could you please provide a copy of the policy which supports “medical devices on trial requirements”.
6. Could you please provide the policy for including a new pathology test within the Trusts/entity?
7. Could you please provide the policy for the “New medical Product Selection Group”
8. Could you please confirm how often new medical device review meetings take place?
9. Could you please provide me the name of the staff member responsible for finances of new medical devices and their email address.
10. Could you please provide me the name of the staff member responsible for procurement of new medical devices and their email address.
11. Lastly, could you please supply a copy of the last 3 ‘New Medical Device meeting’ minutes and also the location of where they are published on your website?

New medical device policy.101022.docx

Q1. In the last 3 months, how many patients have been initiated* on the following agents for the treatment of melanoma?
a. Ipilimumab (monotherapy)
b. Nivolumab (monotherapy)
c. Nivolumab AND Ipilimumab (combination)
d. Pembrolizumab
e. Any Targeted Therapy (Dabrafenib /Dabrafenib AND Trametinib /Encorafenib AND Binimetinib /Trametinib /Vemurafenib /Vemurafenib AND Cobimetinib)
f. Other active systemic anti-cancer therapy
*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.

Q2. In the last 3 months, how many patients have been initiated* on the following agents for the treatment of renal cell carcinoma?
a. Nivolumab (monotherapy)
b. Nivolumab + Ipilimumab
c. Nivolumab + Cabozantinib
d. Avelumab + Axitinib
*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.

Q3. In the past 3 months, how many patients have been initiated* on the following agents for the treatment of gastric, gastro-oesophageal junction or oesophageal cancer:
a. Nivolumab monotherapy or in combination with Ipilimumab
b. Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine)
c. Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine)
*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.

Nivolumab.020823.docx

Q1. In the last 3 months, how many patients have been initiated* on the following agents for the treatment of melanoma?
a. Ipilimumab (monotherapy)
b. Nivolumab (monotherapy)
c. Nivolumab AND Ipilimumab (combination)
d. Pembrolizumab
e. Any Targeted Therapy (Dabrafenib /Dabrafenib AND Trametinib /Encorafenib AND Binimetinib /Trametinib /Vemurafenib /Vemurafenib AND Cobimetinib)
f. Other active systemic anti-cancer therapy
*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.
Q2. In the last 3 months, how many patients have been initiated* on the following agents for the treatment of Renal Cell Carcinoma?
a. Nivolumab (monotherapy)
b. Nivolumab + Ipilimumab
c. Nivolumab + Cabozantinib
d. Avelumab + Axitinib
*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.
Q3. In the past 3 months, how many patients have been initiated* on the following agents for treatment of Oesophageal Cancer:
a. Nivolumab monotherapy or in combination with Ipilimumab
b. Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine)
c. Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine)
*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.

Nivolumab.170423.docx

All questions are shown as received by the Trust.
Q1. In the last 3 months, how many patients have been initiated* on the following agents for the treatment of melanoma?
a. Ipilimumab (monotherapy)
b. Nivolumab (monotherapy)
c. Nivolumab AND Ipilimumab (combination)
d. Pembrolizumab
e. Any Targeted Therapy (Dabrafenib /Dabrafenib AND Trametinib /Encorafenib AND Binimetinib /Trametinib /Vemurafenib /Vemurafenib AND Cobimetinib)
f. Other active systemic anti-cancer therapy
*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.
Q2. In the last 3 months, how many patients have been initiated* on the following agents for the treatment of Renal cell carcinoma?
a. Nivolumab (monotherapy)
b. Nivolumab + Ipilimumab
c. Nivolumab + Cabozantinib
d. Avelumab + Axitinib
*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.
Q3. In the past 3 months, how many patients have been initiated* on the following agents for treatment for Advanced/Metastatic Oesophageal Cancer:
a. Nivolumab monotherapy or in combination with Ipilimumab
b. Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)
c. Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)
*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.

Nivolumab.271223.docx

In the past 3 months, how many early-stage (non-metastatic or Stages 1-3) Non-small cell lung cancer patients received the following treatments:
1. Atezolizumab
2. Durvalumab
3. Nivolumab
4. Pembrolizumab
5. Chemotherapy (Platinum, Taxane, Vinorelbine, Gemcitabine, Pemetrexed) only
6. Radiotherapy only
7. Chemotherapy + radiotherapy

Non-small cell lung cancer.280723.docx

Q1. In the past 3 months, how many non-small cell lung cancer (NSCLC) patients were treated with:
a. Afatinib
b. Alectinib
c. Amivantamab
d. Atezolizumab monotherapy
e. Atezolizumab with chemotherapy
f. Brigatinib
g. Ceritinib
h. Crizotinib
i. Dacomitinib
j. Dabrafenib with Trametinib
k. Durvalumab
l. Erlotinib
m. Gefitinib
n. Lorlatinib
o. Mobocertinib
p. Nintedanib with Docetaxel
q. Nivolumab
r. Osimertinib
s. Pembrolizumab monotherapy
t. Pembrolizumab with chemotherapy
u. Pemetrexed with Carboplatin/Cisplatin
v. Pralsetinib
w. Selpercatinib
x. Sotorasib
y. Tepotinib
z. Vinorelbine with Carboplatin/Cisplatin
aa. Any other active systemic anti-cancer therapy (SACT)
bb. Palliative care only
Q2. In the past 3 months, how many patients were treated for Squamous non-small cell lung cancer (Sq NSCLC) ONLY with the following drugs:
a. Atezolizumab monotherapy
b. Atezolizumab with chemotherapy
c. Durvalumab
d. Nivolumab
e. Osimertinib
f. Pembrolizumab (Keytruda) Mono
g. Pembrolizumab (Keytruda) with Chemotherapy
h. Tepotinib
i. Other active systemic anti-cancer therapy (SACT)
j. Palliative care only
Non-small cell lung cancer (NSCLC).020323.docx

Q1. In the past 3 months, how many non-small cell lung cancer (NSCLC) patients were treated with:
a. Afatinib
b. Alectinib
c. Atezolizumab monotherapy
d. Atezolizumab with chemotherapy
e. Bevacizumab
f. Brigatinib
g. Ceritinib
h. Crizotinib
i. Dacomitinib
j. Dabrafenib with Trametinib
k. Docetaxel monotherapy or combination with Carboplatin/Cisplatin
l. Durvalumab
m. Erlotinib
n. Gefitinib
o. Gemcitabine
p. Lorlatinib
q. Nintedanib with Docetaxel
r. Nivolumab
s. Osimertinib
t. Paclitaxel
u. Pembrolizumab monotherapy
v. Pembrolizumab with chemotherapy
w. Pemetrexed with Carboplatin/Cisplatin
x. Vinorelbine with Carboplatin/Cisplatin
y. Any other active systemic anti-cancer therapy (SACT)
z. Palliative care only
Q2. In the past 3 months, how many patients were treated for Squamous non-small cell lung cancer (Sq NSCLC) ONLY with the following drugs:
a. Atezolizumab monotherapy
b. Atezolizumab with chemotherapy
c. Durvalumab
d. Gemcitabine
e. Nivolumab
f. Osimertinib
g. Paclitaxel
h. Pembrolizumab (Keytruda) Mono
i. Pembrolizumab (Keytruda) with Chemotherapy
j. Other active systemic anti-cancer therapy (SACT)
k. Palliative care only
Q3. Does your trust participate in any ongoing clinical trials for the treatment of non-small cell lung cancer (NSCLC)? If so, can you please provide the name of each trial along with the number of patients taking part?

Download response Non-small cell lung cancer (NSCLC). 041121.docx

Q1. In the past 3 months, how many non-small cell lung cancer (NSCLC) patients were treated with:
a. Afatinib
b. Alectinib
c. Atezolizumab monotherapy
d. Atezolizumab with chemotherapy
e. Bevacizumab
f. Brigatinib
g. Ceritinib
h. Crizotinib
i. Dacomitinib
j. Dabrafenib with Trametinib
k. Docetaxel monotherapy or combination with Carboplatin/Cisplatin
l. Durvalumab
m. Erlotinib
n. Gefitinib
o. Gemcitabine
p. Lorlatinib
q. Nintedanib with Docetaxel
r. Nivolumab
s. Osimertinib
t. Paclitaxel
u. Pembrolizumab monotherapy
v. Pembrolizumab with chemotherapy
w. Pemetrexed with Carboplatin/Cisplatin
x. Tepotinib
y. Vinorelbine with Carboplatin/Cisplatin
z. Any other active systemic anti-cancer therapy (SACT)
aa. Palliative care only
Q2. In the past 3 months, how many patients were treated for Squamous non-small cell lung cancer (Sq NSCLC) ONLY with the following drugs:
a. Atezolizumab monotherapy
b. Atezolizumab with chemotherapy
c. Durvalumab
d. Gemcitabine
e. Nivolumab
f. Osimertinib
g. Paclitaxel
h. Pembrolizumab (Keytruda) Mono
i. Pembrolizumab (Keytruda) with Chemotherapy
j. Other active systemic anti-cancer therapy (SACT)
k. Palliative care only

Non-small cell lung cancer (NSCLC). 220222.docx

Q1. In the past 3 months, how many non-small cell lung cancer (NSCLC) patients were treated with:
a. Afatinib
b. Alectinib
c. Amivantamab
d. Atezolizumab monotherapy
e. Atezolizumab with chemotherapy
f. Brigatinib
g. Ceritinib
h. Crizotinib
i. Dacomitinib
j. Dabrafenib with Trametinib
k. Durvalumab
l. Erlotinib
m. Gefitinib
n. Lorlatinib
o. Mobocertinib
p. Nintedanib with Docetaxel
q. Nivolumab
r. Osimertinib
s. Pembrolizumab monotherapy
t. Pembrolizumab with chemotherapy
u. Pemetrexed with Carboplatin/Cisplatin
v. Pralsetinib
w. Selpercatinib
x. Sotorasib
y. Tepotinib
z. Vinorelbine with Carboplatin/Cisplatin
aa. Any other active systemic anti-cancer therapy (SACT)
bb. Palliative care only
Q2. In the past 3 months, how many patients were treated for Squamous non-small cell lung cancer (Sq NSCLC) ONLY with the following drugs:
a. Atezolizumab monotherapy
b. Atezolizumab with chemotherapy
c. Durvalumab
d. Nivolumab
e. Osimertinib
f. Pembrolizumab (Keytruda) Mono
g. Pembrolizumab (Keytruda) with Chemotherapy
h. Tepotinib
i. Other active systemic anti-cancer therapy (SACT)
j. Palliative care only
Q3. Do you participate in any clinical trials for non-small cell lung cancer (NSCLC)? If so, could you please provide the name of each trial and the number of patients taking part.

Non-small cell lung cancer (NSCLC).311022.docx

Q1. How many patients were treated in the past 3 months for gastric and gastro-oesophageal junction cancer (any stage) with:
a. CAPOX (Capecitabine with Oxaliplatin)
b. FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin)
c. Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)
d. Any other systemic anti-cancer therapy
e. Palliative care only
Q2. How many patients were treated in the past 3 months for Oesophageal cancer (any stage) with:
a. Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)
b. Platinum and Fluoropyrimidine based combination treatments (Cisplatin or Oxaliplatin with 5-Fluorouracil or Capecitabine)
c. Nivolumab monotherapy
d. Nivolumab and Ipilimumab
e. Any other systemic anti-cancer therapy
f. Palliative care only
Q3. Does your trust participate in any active clinical trials for the treatment of gastric cancer or cancer of the gastro-oesophageal junction? If so, can you please provide the name of each trial and the number of patients taking part.
Q4. Does your trust participate in any active clinical trials for the treatment of oesophageal cancer? If so, can you please provide the name of each trial and the number of patients taking part.

Oesophageal and Gastric Cancer.210422.docx

Q1. Please provide the total number of patients treated in the last 3 months with any systemic anti-cancer therapy for:
a. Oesophageal cancer (any type or stage)
b. Oesophageal adenocarcinoma (any stage)
c. Oesophageal squamous cell carcinoma (any stage)
d. Gastric cancer (any type or stage)
e. Cancer of the gastro-oesophageal junction (any stage)
Q2. How many patients were treated in the past 3 months for gastric and gastro-oesophageal junction cancer (any stage) with:
a. CAPOX (Capecitabine with Oxaliplatin)
b. FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin)
c. Lonsurf (Trifluridine – tipiracil)
d. Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)
e. Any other systemic anti-cancer therapy
f. Palliative care only
Q3. How many patients were treated in the past 3 months for Oesophageal cancer (any stage) with:
a. Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine)
b. Platinum and Fluoropyrimidene based combination treatments (Cisplatin or Oxaliplatin with 5-Fluorouracil or Capecitabine)
c. Nivolumab monotherapy
d. Nivolumab and Ipilimumab
e. Any other systemic anti-cancer therapy
f. Palliative care only

Oesophageal and Gastric Cancer.251122.docx

Q1. How many patients were treated in the past 3 months for gastric and gastro-oesophageal junction cancer (any stage) with:
a. CAPOX (Capecitabine with Oxaliplatin)
b. FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin)
c. Lonsurf (Trifluridine – tipiracil)
d. Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)
e. Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)
f. Any other systemic anti-cancer therapy
g. Palliative care only
Q2. How many patients were treated in the past 3 months for Oesophageal cancer (any stage) with:
a. Nivolumab monotherapy or combination with Ipilimumab
b. Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine)
c. Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine)
d. Platinum and Fluoropyrimidene based combination treatments (Cisplatin or Oxaliplatin with 5-Fluorouracil or Capecitabine)
e. Any other systemic anti-cancer therapy
f. Palliative care only
Q3. How many patients were treated in the past 3 months for advanced/metastatic resected oesophageal cancer ONLY with:
a. Nivolumab monotherapy or combination with Ipilimumab
b. Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine)
c. Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine)
d. Platinum and Fluoropyrimidene based combination treatments (Cisplatin or Oxaliplatin with 5-Fluorouracil or Capecitabine)
e. Any other systemic anti-cancer therapy
f. Palliative care only
Q4. In the past 3 months, how many patients have been initiated* on the following agents for treatment for gastric, gastro-oesophageal junction or Oesophageal cancer:
a. Nivolumab monotherapy or in combination with Ipilimumab
b. Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine)
c. Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine)
*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.
Q5. Does your trust participate in any clinical trials for gastric cancer? If so, please provide the name of each trial and the number of patients taking part.
Q6. Does your trust participate in any clinical trials for oesophageal cancer? If so, please provide the name of each trial and the number of patients taking part.
Oesophageal and gastric cancer.260723.docx

Q1. How many patients were treated in the past 3 months for gastric and gastro-oesophageal junction cancer (any stage) with:
a. CAPOX (Capecitabine with Oxaliplatin)
b. FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin)
c. Lonsurf (Trifluridine – tipiracil)
d. Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)
e. Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)
f. Any other systemic anti-cancer therapy
g. Palliative care only
Q2. How many patients were treated in the past 3 months for Oesophageal cancer (any stage) with:
a. Platinum and Fluoropyrimidene based combination treatments (Cisplatin or Oxaliplatin with 5-Fluorouracil or Capecitabine)
b. Nivolumab monotherapy
c. Nivolumab and Ipilimumab
d. Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)
e. Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine)
f. Any other systemic anti-cancer therapy
g. Palliative care only
Q3. Does your trust participate in any clinical trials for gastric cancer? If so, please provide the name of each trial and the number of patients taking part.
Q4. Does your trust participate in any clinical trials for oesophageal cancer? If so, please provide the name of each trial and the number of patients taking part.

Oesophageal and Gastric cancer.270323.docx

Q1. How many patients were treated in the past 3 months for gastric and gastro-oesophageal junction cancer (any stage) with:
a. CAPOX (Capecitabine with Oxaliplatin)
b. FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin)
c. Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)
d. Any other systemic anti-cancer therapy
e. Palliative care only
Q2. How many patients were treated in the past 3 months for Oesophageal cancer (any stage) with:
a. Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine)
b. Platinum and Fluoropyrimidene based combination treatments (Cisplatin or Oxaliplatin with 5-Fluorouracil or Capecitabine)
c. Nivolumab monotherapy
d. Nivolumab and Ipilimumab
e. Any other systemic anti-cancer therapy
f. Palliative care only
Q3. Please provide the total number of patients treated in the last 3 months with any systemic anti-cancer therapy for:
a. Oesophageal cancer (any type or stage)
b. Oesophageal adenocarcinoma (any stage)
c. Oesophageal squamous cell carcinoma (any stage)
d. Gastric cancer (any type or stage)
e. Cancer of the gastro-oesophageal junction (any stage)

Oesophageal and Gastric cancer.270722.docx

All questions are shown as received by the Trust.
Q1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:
a. Abemaciclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole)
b. Abemaciclib + Fulvestrant
c. Alpelisib + Fulvestrant
d. Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide
e. Aromatase Inhibitor as a single agent
f. Atezolizumab
g. Capecitabine as a single agent
h. Carboplatin + Paclitaxel
i. Eribulin as a single agent or in combination
j. Everolimus + Exemestane
k. Fulvestrant as a single agent
l. Palbociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole)
m. Palbociclib + Fulvestrant
n. Parp Inhibitors (Olaparib/Talazoparib)
o. Pembrolizumab
p. Ribociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole)
q. Ribociclib + Fulvestrant
r. Sacituzumab Govitecan
s. Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent
t. Transtuzumab deruxtecan
u. Trastuzumab as a single agent or in combination
v. Trastuzumab emtansine
w. Any other active systemic anti-cancer therapy
Q2. If breast cancer is not treated at or within the Trust, where are patients referred?

Oncology Breast Cancer.240624.docx

All questions are shown as received by the Trust.
1. The number of oncology patients awaiting a Harm Review from the trust.
2. Does the trust have a dedicated IT system to support the harm review process?
a. If so, what is the name of this system?
b. When was this system implemented?

Oncology Harm Review.300524.docx

All questions are shown as received by the Trust.
Q1. How many patients were treated in the past 3 months for gastric and gastro-oesophageal junction cancer (any stage) with:
a. CAPOX (Capecitabine with Oxaliplatin)
b. FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin)
c. Lonsurf (Trifluridine – tipiracil)
d. Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)
e. Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)
f. Any other systemic anti-cancer therapy
g. Palliative care only
Q2. How many early-stage (non-metastatic or Stages 1-3) non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:
a. Atezolizumab (Tecentriq)
b. Durvalumab (Imfinzi)
c. Nivolumab (Opdivo)
d. Pembrolizumab (Keytruda)
e. Chemotherapy
f. Radiotherapy
g. Chemotherapy AND Radiotherapy
Q3. In the past three months, how many advanced renal cell carcinoma patients received the following first-line treatments:
a. Avelumab + Axitinib (Bavencio + Inlyta)
b. Cabozantinib (Cometriq)
c. Nivolumab (Opdivo)
d. Nivolumab + Cabozantinib (Opdivo + Cometriq)
e. Nivolumab + Ipilimumab (Opdivo + Yervoy)
f. Pembrolizumab + Lenvatinib (Keytruda + Kisplyx)

Oncology treatments.180324.docx

Please could you provide an answer to the question below.
Are node positive breast cancer patients in your trust undergoing Oncotype testing?
A yes/no response is fine, so this query should only use a few moments of your oncology team’s time.

Oncotype use for breast cancer.250822.docx

All questions are shown as received by the Trust.
1. The number of referrals for Open MRIs for patient size (not claustrophobia) authorised by your Trust in 2017, 2018, 2019, 2020, 2021, 2022, 2023 and until June 1, 2024.
2. Total remuneration for open MRI scans for patient size including staffing and MFF for the same time frame as above.
3. A single total figure for how much the Trust has spent on specialist bariatric equipment for the same time frame as above.

Open MRI scans.030724.docx

The number of oral cancer referrals received by hospitals in your Trust between January 2017 and the most recent completed month that is available (most likely July or August 2022). I also request this data be presented as monthly figures.

Oral cancer referrals.290922.docx

All questions are shown as received by the Trust.
1. Please provide information for the following financial years, 2017/18, 2018/19, 2019/20, 2020/21, 2021/22, 2022/, for the respective diagnostic imaging data:
a. Volumes of CT, MRI and PET CT scans, split by scan type performed
b. The volume MRI, CT and PET CT scans, split by scan type and which providers you outsource the scans too
c. Please provide outsourcing price per scan split by CT, MRI and PET CT
2. Can you please provide details of all the current CT, MRI and PET CT outsourcing contracts you currently have in place, can you please include the following data where possible:
a. Scan modality
b. Contract length
c. Agreed pricing and volumes
d. KPI or performance metrics and any data on how they are performing

Outsourced Diagnostic Imaging.070923.docx

Split into each hospital within the Trust:
1. Does the Trust make use of outsourced tele-radiology reporting services for routine radiology reporting?
2. If you do make use of tele-radiology reporting, please provide the names of the providers of each service (on-call and elective separately please)?
3. If you do make use of tele-radiology reporting services, please provide the annual volumes for both 2021 and for 2022 sent to each provider, broken into the following:
a. Overnight on-call
b. Elective Reporting (MRI, CT)
c. Plain Film Reporting
4. Start date, duration and end date of any contracts with tele-radiology providers?
5. Was the contract procured via a framework (direct award, which framework?), mini-tender, or ITT procurement process?
6. Who is the senior officer (outside of procurement) responsible for this contract?
7. Who is the non-clinical manager/service manager that is responsible for this contract?

Outsourced Radiology Reporting Services.181122.docx

1. Does the Trust use outsourced teleradiology reporting services for any of the following?
i. Overnight on-call (/urgent)
ii. Elective reporting (MRI/CT)
iii. Plain film/X-ray reporting
2. Please provide the names of the teleradiology providers you use for each service (on-call and elective separately, if applicable) (e.g. Medica, Everlight, 4ways, TMC)
3. What is the start date, duration and end date of any current contracts with teleradiology providers?
4. What is the annual spend on teleradiology providers in financial years 2019, 2020 and 2021 (or as available) by each provider?
i. Medica
ii. Everlight
iii. 4ways
iv. TMC
v. Other
5. Please provide the annual volumes sent to teleradiology providers for full financial year 2019, 2020, 2021, and year to date 2022 (or as available) sent to each provider split by the following
i. Overnight on-call (/urgent)
ii. Elective reporting (MRI/CT)
iii. Plain film/X-ray reporting
6. Please provide the annual total scans performed by the trust full financial year 2019, 2020, 2021, and year to date 2022 (or as available) by the following
i. Overnight on-call (/urgent)
ii. Elective reporting (MRI/CT)
iii. Plain film/X-ray reporting
7. How does the trust expect its usage of teleradiology services to change in the next three years (please select one)?
a. Increase
b. Stay the same
c. Decrease
8. Does the trust have any strategic plans to invest in technologies to enhance productivity of radiology reporting (e.g. Artificial Intelligence) (please select one)?
a. Yes
b. No
c. Unsure

Outsourced teleradiology reporting services.141122.docx

Q1. How many patients have been treated for advanced (FIGO Stages III and IV) ovarian (epithelial ovarian, fallopian tube or primary peritoneal) cancer over the last 3 months? If none, do you refer advanced ovarian cancer patients to another trust, and if so which one?
Q2. How many ovarian cancer patients (any stage) have been treated in the last 3 months with:
a. Paclitaxel in combination with a platinum-based compound
b. Platinum-based therapy alone (cisplatin or carboplatin)
c. Bevacizumab in combination with paclitaxel and carboplatin
d. Olaparib
e. Olaparib + Bevacizumab
f. Niraparib
g. Rucaparib
Q3. Does your trust participate in any clinical trials for the treatment of ovarian cancer? If so, please provide the name of each trial along with the number of patients taking part.
Q4. If data for HRD (homologous recombination deficiency) testing is available, please provide how many HRD positive patients were treated in the last 3 months with:
a. Olaparib
b. Olaparib + Bevacizumab
c. Niraparib
d. Other treatments
Q5. If data for HRD (homologous recombination deficiency) and BRCA testing is available, please provide how many HRD positive BRCA mutated patients were treated in the last 3 months with:
a. Olaparib
b. Olaparib + Bevacizumab
c. Niraparib
d. Other treatments

Ovarian cancer.230623.docx

1. How many patients have been treated for advanced (FIGO Stages III and IV) high-grade ovarian (epithelial ovarian, fallopian tube or primary peritoneal) cancer over the last 3 months? If none, do you refer ovarian cancer patients to another trust, if so which one?
2. How many ovarian cancer patients (any stage) have been treated in the last 3 months with:
a. Paclitaxel in combination with a platinum-based compound
b. Platinum-based therapy alone (cisplatin or carboplatin)
c. Bevacizumab in combination with paclitaxel and carboplatin
d. Olaparib
e. Olaparib + Bevacizumab
f. Niraparib
g. Rucaparib
3. Of the ovarian cancer patients (any stage) treated over the last 3 months, how many patients:
a. Received HRD (homologous recombination deficiency) testing
b. Received BRCA testing
c. Tested HRD positive
d. Tested BRCA positive (BRCAm)
4. If data for HRD testing is available, please provide how many HRD positive patients were treated in the last 3 months with:
a. Olaparib
b. Olaparib + Bevacizumab
c. Niraparib
d. Other treatments
5. If data for HRD and BRCA testing is available, please provide how many HRD positive-BRCA positive patients were treated in the last 3 months with:
a. Olaparib
b. Olaparib + Bevacizumab
c. Niraparib
d. Other treatments

Download response Ovarian cancer. 311221.docx

The number of diagnoses for pancreatic cancer at your hospital trust.
I would like this information for each of the last 5 calendar years as follows: 2017, 2018, 2019, 2020, 2021.

Pancreatic cancer. 130422.docx

1. A copy of the Trust’s parking policy
2. Details of the price of car parking per hospital site within the Trust
3. Confirmation of how the Trust has implemented both the mandatory and voluntary elements of the “NHS car parking guidance 2022 for NHS trusts and NHS foundation trusts”, including;
a. whether parents and/or carers of children and young people (up to age 25) with cancer are offered free parking/parking exemptions
b. whether parents and/or carers of children and young people (up to age 25) with cancer are offered parking concessions and details of the financial value of these
c. whether young people (17-25) with cancer are offered free parking/parking exemptions
d. whether young people (17-25) with cancer are offered parking concessions and details of the financial value of these
e. whether any free parking/parking exemptions or concessions apply to inpatient/active treatment visits, visits to attend follow-up appointments (i.e. not undergoing active treatment), or both
4. If yes to any items in point 3, how many parents and/or carers of children and young people (up to age 25) with cancer and/or young people (17-25) with cancer have been offered free parking/parking exemptions or concessions, provided per category (free parking/exemption, concession);
a. per financial year since 2017 (2017/18, 2018/19, 2019/20, 2020/21, 2021/22, and 2022/23 to date)
b. per hospital site within the Trust
5. Details of how the Trust shares, communicates and displays information about free parking/parking exemptions and/or concessions, their eligibility, how to access them and their financial value
6. Confirmation whether car parking within the Trust is owned and managed by the Trust or is owned and managed by a private company, and if so what company
7. Details of how many complaints the Trust has received from parents and/or carers of children and young people (up to age 25) with cancer and/or young people (17-25) with cancer regarding car parking charges or regarding the information the Trust provides about car parking charges;
a. per financial year since 2017 (2017/18, 2018/19, 2019/20, 2020/21, 2021/22, and 2022/23 to date)
b. per hospital site within the NHS Trust or NHS Foundation Trust
8. Details of any other travel-related support provided by the Trust which is available to parents and/or carers of children and young people (up to age 25) with cancer and/or young people with cancer, including;
a. how children and young people and their parents or carers are informed of the support that is available to them
b. how the support is accessed/applied for
c. the financial value of the support and whether this is provided up-front or requires a claim to be paid back to the recipient
d. the duration of the support and type of care this applies to (e.g. inpatient/active treatment, follow-up/outpatient etc.)

Parking for Children and Young People with Cancer.200623.docx

Q1. In the last 3 months, how many patients have been initiated* on the following agents for treatment for melanoma?
a. Nivolumab (monotherapy)
b. Nivolumab AND Ipilimumab (combination)
*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.
Q2. In the last 3 months, how many patients have been initiated* on the following agents for treatment for Renal Cell Carcinoma?
a. Nivolumab (monotherapy)
b. Nivolumab + Ipilimumab
c. Nivolumab + Cabozantinib
d. Avelumab + Axitinib
*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.
Q3. In the past 3 months, how many patients have been initiated* on the following agents for treatment for Advanced/Metastatic Oesophageal Cancer:
a. Nivolumab (monotherapy)
b. Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine)
*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.

Patient treatment with Nivolumab. 130422.docx

All questions are shown as received by the Trust.
The number of patients who died whilst on your trusts waiting list to start cancer treatment for each of the years a) 2019, b) 2020, c) 2021, d) 2022, e) 2023 so far.

Please could you provide this information by email, preferably in a spreadsheet.

Patients who died while on the cancer waiting list.251023.docx

1. Does your trust/HB have access to PET-CT for the investigation of suspected biochemical recurrence in prostate cancer patients?
a. Yes
b. Not on site, but we refer patients elsewhere (please state the trust/HB patients are referred to, if possible:)
c. No
2. If you answered “No” to question 1. Would you use PET-CT for the investigation of suspected biochemical recurrence in prostate cancer patients if it were available?
a. Yes
b. No
c. N/A – We already have access to PET-CT.
3. In 2020-21, how many patients do you estimate were investigated for suspected biochemical recurrence of prostate cancer at your trust/HB?
4. What percentage of patients with suspected biochemical recurrence do you estimate are referred for PET-CT at your trust/HB?
5. Of patients with suspected biochemical recurrence referred for PET-CT, what % of scans do you estimate use a PSMA tracer (either Ga-PSMA or F-PSMA)?
6. Are there any exclusion criteria for referral for PET-CT for suspected biochemical recurrence of prostate cancer? If so, what are they? E.g. Upper and lower PSA limits, age, life expectancy, ECOG score.
7. What do you estimate is the average waiting time for the PET-CT scans for investigation of suspected biochemical recurrence of prostate cancer?
8. What do you estimate is the average time it takes to report PET-CT scans for investigation of suspected biochemical recurrence of prostate cancer?

Download response PET-CT Access. 131021.docx

1. Please provide information for the following financial years (2017/18, 2018/19, 2019/20, 2020/21, 2021/22, 2022/23) for the following:
a. How many PET CT scans in total were performed each year?
b. How many of the PET CT scans performed were outsourced to a third party provider? Please can you split volumes by each provider if you use more than one.
c. The average price per PET CT scan for each year

PET CT scans.170423.docx

1. In the most recent 12 months of data which you have access to, how many patients have been diagnosed with the following stages of prostate cancer:
A) Stage 1 and stage 2 – localised prostate cancer
B) Stage 3 cancer that has not spread to other parts of the body – locally advanced prostate cancer
C) Stage 4 cancer which has spread to other parts of the body – metastatic prostate cancer.
2. In reference to the answer for question 1:
A) what number, for each stage, received novel imaging?
B) what was the average, for each stage, time post diagnosis for them to receive the novel imaging?
3. In the most recent 12 months of data which you have access to, how many patients in total initially sat within the urology department, but were referred to the oncology department before they develop metastases?
4. In reference to the answer for question 3, what number of these patients developed metastases prior to being referred to the oncology department.
5. For all patients who have received darolutamide, what is the average duration of treatment?

Prostate Cancer.

I’d like to request data of the following for the last 5 years 2017, 2018, 2019, 2020 and 2021, however if this exceeds the FOI time limit please provide the data for 2021 only:
1) How many people were diagnosed with prostate cancer within your trust
2) How many people that were diagnosed with prostate cancer had Brachytherapy
3) The average cost of undergoing Brachytherapy

Prostate cancer. 130422.docx

1. Please provide the total number of patients treated in the last 3 months with any systemic anti-cancer treatment for:
a. Prostate cancer (any stage)
b. Metastatic prostate cancer
2. How many patients were treated for prostate cancer (any stage) in the past 3 months with:
a. Androgen Deprivation Therapy (ADT) standalone
b. Abiraterone (Zytiga) in combination with any ADT
c. Abiraterone (Zytiga) – no ADT
d. Enzalutamide (Xtandi) in combination with any ADT
e. Enzalutamide (Xtandi) – no ADT
f. Apalutamide (Erleada) in combination with any ADT
g. Darolutamide (Nubeqa) in combination with any ADT
h. Cabazitaxel (Jevtana)
i. Docetaxel in combination with any ADT
j. Docetaxel – no ADT
k. Degarelix (Firmagon)
l. Olaparib (Lynparza)
3. How many metastatic prostate cancer patients were treated in the past 3 months with:
a. Androgen Deprivation Therapy (ADT) standalone
b. Apalutamide (Erleada) in combination with any ADT
c. Docetaxel in combination with any ADT
d. Docetaxel – no ADT

Prostate Cancer.210422.docx

We should be grateful if you could provide us with a copy of the protocols in place for patient selection for thrombectomy beyond 6 hours by using CT perfusion imaging to look for salvageable brain tissue, applicable in July 2020.

Download response Protocols in place for patient selection for thrombectomy beyond 6 hours by using CT perfusion imaging to look for salvageable brain tissue, applicable in July 2020. 311221.docx

All questions are shown as received by the Trust.
1. Does your Trust have a Standard Operating Procedure – also referred to as a PSFU Protocol – that covers the PSFU pathway for breast cancer?
If yes, please share your current, or most recent, version of this Standard Operating Procedure/PSFU Protocol.
2. Are all hospitals that form part of your Trust following the processes set out in the Standard Operating Procedure/PFSU Protocol for breast cancer?
If no, please send the breast cancer related Standard Operating Procedure/PSFU Protocol of each hospital in the Trust
3. At the end of hospital-based treatment do you provide primary breast cancer patients with information about the signs and symptoms of primary breast cancer?
If yes- please provide a copy of the information provided or a link to the information if it is available online. If this information is part of a longer document please provide the full document.
4. At the end of hospital-based treatment, do you provide primary breast cancer patients with information about the signs and symptoms of secondary breast cancer?
If yes- please provide a copy of the information provided or a link to the information if it is available online. If this information is part of a longer document please provide the full document.
5. How many patients did you treat for primary breast cancer that finished their hospital-based treatment in each of the Financial Years 2022-23 and 2023- 2024?
6. For each of the Financial Years 2022-23 and 2023-24, of the primary breast cancer patients that completed hospital-based treatment, please provide an estimate of what proportion were stratified to each follow up pathway?
a) A PIFU pathway
b) A Routine Follow Up pathway
If you can provide the figures spilt between the age under 45 category and age 45 and over category that would be useful but if the information is not readily available by age, please provide for all ages combined.
% of patients
2022-2023 2023-24
Under 45
45 and over
All ages
PIFU
Routine Follow Up
7. At the end of hospital-based treatment, is there a set period of time during which all patients in the Trust receive Routine Follow Up, with the decision between a Routine Follow Up pathway and a PIFU pathway being taken at a later date?
If yes, which hospitals offer this and for each hospital how long is the set period of time?
Description of the pathway
8. If a patient wants to raise a concern about a breast cancer sign or symptom (either primary breast cancer or secondary breast cancer) while on a PIFU pathway, what are the options for them to do so (please tick all that apply):
A telephone service
Email contact
Drop in clinics
Other- please detail
9. Are all breast cancer patients on a PIFU pathway logged and tracked on the organisation’s IT system?
All are logged
All are logged and tracked
Some are logged
Some are logged and tracked
No
10. Is there a standard time limit on how long PSFU pathways are available to breast cancer patients e.g. 5 years?
If yes, what is the standard time limit?
If yes, how frequently is the standard time limit applied?
Always Most of the time
Sometimes
Rarely
If any patients have a difference to the standard time limit, please detail and explain in what circumstances this occurs and the range of time limits?
11. When it is time for a breast cancer patient to be discharged from PSFU, do they receive any notification of this, e.g. by letter or phone call?
If yes, please explain how they receive this notification and provide a copy of the standardised information they would receive at that point, if it is in written form.
We are keen to discuss in more detail the answers to this FOI with a small number of Trusts. If this is something you would consider, please let us know and we will follow up if needed.
If yes, the person to contact is:

PSFU pathway for primary breast cancer patients.241024.docx

1. Which CM is and volume is used for brain imaging within MRI and is a power injector used for this?
2. Which CM and volume is used for Prostate within MRI and is a power injector used for this?
3. Which CM and volume is used for Breast within MRI and is a power injector used for this?
4. Which CM and volume is used for Liver within MRI and is a power injector used for this?
5. What CM and volume is used for Gynaecological scans within MRI at both hospitals and is a power injector used for this?
6. Are you able to provide the number of neuro scans performed with contrast media within MRI at both hospitals and in 2021?
7. Are you able to provide the number of Prostate scans performed with contrast media within MRI at both hospitals and in 2021 (MPLVPC, MPELVC)?
8. Are you able to provide the number of breast scans performed with contrast media within MRI at both hospitals in 2021?
9. Are you able to provide the annual figure of liver scans performed with contrast media within MRI at both hospitals and in 2021 (Codes MLIVEC, MLIVHC, MABDOC)?
10. Are you able to provide the annual figure of Gynaecological scans performed with contrast media within MRI at both hospitals and in 2021 (Code MPELVC)?

Radiology.011122.docx

Could you please let me know the patient numbers for the following procedure codes and where applicable the hospital within your trust that carries them out?
Please also break these down for 2020, 2021 and ytd 2022 or by months should that be simpler.
Procedure code Description
XCEMB Contrast enhanced spectral mammography Both
XCEML Contrast enhanced spectral mammography Lt
XCEMR Contrast enhanced spectral mammography Rt

Radiology.151222.docx

All questions are shown as received by the Trust.
Radiotherapy Treatment Planning System
1. Does your Trust use Radiotherapy Treatment Planning System?
2. If so, what is the cost of this service per annum? Ideally, for the last 3 financial years
3. What Radiotherapy Treatment Planning System do you utilise?
Artificial Intelligence in Radiotherapy
4. Does your Trust use any artificial intelligence software in Radiotherapy?
5. If so, what is the cost of this service per annum?
6. What Radiotherapy Artificial Intelligence Software do you utilise?
Contact
7. Please provide names and contact details for the trust’s
a. Lead for Radiotherapy Treatment Planning System
b. Radiotherapy Artificial Intelligence Lead

Radiotherapy.190624.docx

I made a request to the integrated care board about the ages of the Radiotherapy machines in use in the Maidstone and Tonbridge Wells NHS Cancer department.

Radiotherapy machines.140923.docx

All questions are shown as received by the Trust.
Q1. How many patients have been treated in the past 3 months with the following agents for renal cell carcinoma (any stage) :

a. Avelumab + Axitinib
b. Axinitib
c. Cabozantinib
d. Everolimus
e. Lenvatinib + Everolimus
f. Lenvatinib + Pembrolizumab
g. Nivolumab monotherapy
h. Nivolumab + Cabozantinib
i. Nivolumab + Ipilimumab
j. Pazopanib
k. Pembrolizumab monotherapy
l. Pembrolizumab + Axitinib
m. Radiotherapy only
n. Sunitinib
o. Temsirolimus
p. Tivozanib
q. Other active systemic anti-cancer therapy
r. Palliative care only

Q2. In the last 3 months, how many patients have undergone full or partial nephrectomy (any of the following OPCS codes M02.1, M02.2, M02.3,M02.4, M02.5, M03.1, M03.9, M04.2, M10.1 or M10.4)?

Q3. In the last 3 months, how many patients have been initiated* on the following agents for treatment for Renal Cell Carcinoma?

a. Nivolumab (monotherapy)
b. Nivolumab + Ipilimumab
c. Nivolumab + Cabozantinib
d. Avelumab + Axitinib

*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.

Q4. Does you trust participate in any clinical trials for the treatment of renal cell carcinoma? If so please provide the name of each trial and number of patients that are taking part?

Renal cell carcinoma. 171024.docx

All questions are shown as received by the Trust.
Q1. How many patients have been treated in the past 3 months with the following agents for renal cell carcinoma (any stage):
a. Avelumab + Axitinib
b. Axinitib
c. Cabozantinib
d. Everolimus
e. Lenvatinib + Everolimus
f. Lenvatinib + Pembrolizumab
g. Nivolumab monotherapy
h. Nivolumab + Cabozantinib
i. Nivolumab + Ipilimumab
j. Pazopanib
k. Pembrolizumab monotherapy
l. Pembrolizumab + Axitinib
m. Radiotherapy only
n. Sunitinib
o. Temsirolimus
p. Tivozanib
q. Other active systemic anti-cancer therapy
r. Palliative care only
Q2. In the last 3 months, how many patients have undergone full or partial nephrectomy (any of the following OPCS codes M02.1, M02.2, M02.3,M02.4, M02.5, M03.1, M03.9, M04.2, M10.1 or M10.4)?
Q3. In the last 3 months, how many patients have been initiated* on the following agents for treatment for Renal Cell Carcinoma?
a. Nivolumab (monotherapy)
b. Nivolumab + Ipilimumab
c. Nivolumab + Cabozantinib
d. Lenvatinib + Pembrolizumab
e. Avelumab + Axitinib
*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.
Q4. Does your trust participate in any clinical trials for the treatment of renal cell carcinoma? If so please provide the name of each trial and number of patients that are taking part?

Renal cell carcinoma.260624.docx

Q1. How many patients have been treated in the past 3 months with the following agents for renal cell carcinoma:
a. Avelumab + Axitinib
b. Axinitib
c. Cabozantinib
d. Everolimus
e. Lenvatinib + Everolimus
f. Nivolumab
g. Nivolumab + Cabozantinib
h. Nivolumab + Ipilimumab
i. Pazopanib
j. Pembrolizumab + Axitinib
k. Pembrolizumab + Lenvatinib
l. Pembrolizumab monotherapy
m. Radiotherapy only
n. Sunitinib
o. Temsirolimus
p. Tivozanib
q. Other active systemic anti-cancer therapy
r. Palliative care only
Q2. How many patients have been treated in the past 3 months with the following agents for melanoma (any stage):
a. Cobimetinib
b. Dabrafenib
c. Dabrafenib AND Trametinib
d. Dacarbazine
e. Encorafenib AND Binimetinib
f. Ipilimumab
g. Ipilimumab AND Nivolumab
h. Nivolumab
i. Pembrolizumab
j. Trametinib
k. Vemurafenib
l. Vemurafenib AND Cobimetinib
m. Other active systemic anti-cancer therapy
n. Palliative care only
Q3. If possible, could you please provide the patients treated in the past 3 months with the following agents for metastatic melanoma ONLY:
a. Cobimetinib
b. Dabrafenib
c. Dabrafenib AND Trametinib
d. Dacarbazine
e. Encorafenib AND Binimetinib
f. Ipilimumab
g. Ipilimumab AND Nivolumab
h. Nivolumab
i. Pembrolizumab
j. Trametinib
k. Vemurafenib
l. Vemurafenib AND Cobimetinib
m. Other active systemic anti-cancer therapy
n. Palliative care only
Q4. In the last 3 months, how many patients have undergone full or partial nephrectomy (any of the following OPCS codes M02.1, M02.2, M02.3, M02.4, M02.5, M03.1, M03.9, M04.2, M10.1 or M10.4)?

Renal cell carcinoma and melanoma.020323.docx

Q1. How many patients have been treated in the past 3 months with the following agents for renal cell carcinoma:
a. Avelumab + Axitinib
b. Axinitib
c. Cabozantinib
d. Everolimus
e. Lenvantinib + Everolimus
f. Nivolumab
g. Nivolumab + Ipilimumab
h. Pazopanib
i. Pembrolizumab + Axitinib
j. Sunitinib
k. Temsirolimus
l. Tivozanib
m. Other
Q2. How many patients have been treated in the past 3 months with the following agents for melanoma (any stage):
a. Cobimetinib
b. Dabrafenib
c. Dabrafenib AND Trametinib
d. Encorafenib AND Binimetinib
e. Ipilimumab
f. Ipilimumab AND Nivolumab
g. Nivolumab
h. Pembrolizumab
i. Trametinib
j. Vemurafenib
k. Vemurafenib AND Cobimetinib
l. Other active systemic anti-cancer therapy
m. Palliative care only
Q3. If possible, could you please provide the patients treated in the past 3 months with the following agents for metastatic melanoma ONLY:
a. Cobimetinib
b. Dabrafenib
c. Dabrafenib AND Trametinib
d. Encorafenib AND Binimetinib
e. Ipilimumab
f. Ipilimumab AND Nivolumab
g. Nivolumab
h. Pembrolizumab
i. Trametinib
j. Vemurafenib
k. Vemurafenib AND Cobimetinib
l. Other active systemic anti-cancer therapy
m. Palliative care only
Q4. In the last 3 months, how many patients have undergone full or partial nephrectomy (any of the following OPCS codes M02.1, M02.2, M02.3, M02.4, M02.5, M03.1, M03.9, M04.2, M10.1 or M10.4)?

Download response Renal cell carcinoma and melanoma. 081121.docx

Q1. How many patients have been treated in the past 3 months with the following agents for renal cell carcinoma:
a. Avelumab + Axitinib
b. Axinitib
c. Cabozantinib
d. Everolimus
e. Lenvatinib + Everolimus
f. Nivolumab
g. Nivolumab + Cabozantinib
h. Nivolumab + Ipilimumab
i. Pazopanib
j. Pembrolizumab monotherapy
k. Pembrolizumab + Axitinib
l. Pembrolizumab + Lenvatinib
m. Sunitinib
n. Temsirolimus
o. Tivozanib
p. Other active systemic anti-cancer therapy
Q2. How many patients have been treated in the past 3 months with the following agents for melanoma (any stage):
a. Cobimetinib
b. Dabrafenib
c. Dabrafenib AND Trametinib
d. Dacarbazine
e. Encorafenib AND Binimetinib
f. Ipilimumab
g. Ipilimumab AND Nivolumab
h. Nivolumab
i. Pembrolizumab
j. Trametinib
k. Vemurafenib
l. Vemurafenib AND Cobimetinib
m. Other active systemic anti-cancer therapy
n. Palliative care only
Q3. If possible, could you please provide the patients treated in the past 3 months with the following agents for metastatic melanoma ONLY:
a. Cobimetinib
b. Dabrafenib
c. Dabrafenib AND Trametinib
d. Encorafenib AND Binimetinib
e. Ipilimumab
f. Ipilimumab AND Nivolumab
g. Nivolumab
h. Pembrolizumab
i. Trametinib
j. Vemurafenib
k. Vemurafenib AND Cobimetinib
l. Other active systemic anti-cancer therapy
m. Palliative care only
Q4. In the last 3 months, how many patients have undergone full or partial nephrectomy (any of the following OPCS codes M02.1, M02.2, M02.3, M02.4, M02.5, M03.1, M03.9, M04.2, M10.1 or M10.4)?

Renal cell carcinoma and melanoma.110722.docx

Q1. How many patients have been treated in the past 3 months with the following agents for renal cell carcinoma:
a. Avelumab + Axitinib
b. Axinitib
c. Cabozantinib
d. Everolimus
e. Lenvantinib + Everolimus
f. Nivolumab
g. Nivolumab + Ipilimumab
h. Pazopanib
i. Pembrolizumab + Axitinib
j. Pembrolizumab monotherapy
k. Sunitinib
l. Temsirolimus
m. Tivozanib
n. Other active systemic anti-cancer therapy
Q2. How many patients have been treated in the past 3 months with the following agents for melanoma (any stage):
a. Cobimetinib
b. Dabrafenib
c. Dabrafenib AND Trametinib
d. Encorafenib AND Binimetinib
e. Ipilimumab
f. Ipilimumab AND Nivolumab
g. Nivolumab
h. Pembrolizumab
i. Trametinib
j. Vemurafenib
k. Vemurafenib AND Cobimetinib
l. Other active systemic anti-cancer therapy
m. Palliative care only
Q3. If possible, could you please provide the patients treated in the past 3 months with the following agents for metastatic melanoma ONLY:
a. Cobimetinib
b. Dabrafenib
c. Dabrafenib AND Trametinib
d. Encorafenib AND Binimetinib
e. Ipilimumab
f. Ipilimumab AND Nivolumab
g. Nivolumab
h. Pembrolizumab
i. Trametinib
j. Vemurafenib
k. Vemurafenib AND Cobimetinib
l. Other active systemic anti-cancer therapy
m. Palliative care only
Q4. In the last 3 months, how many patients have undergone full or partial nephrectomy (any of the following OPCS codes M02.1, M02.2, M02.3, M02.4, M02.5, M03.1, M03.9, M04.2, M10.1 or M10.4)?

Renal cell carcinoma and melanoma. 140422.docx

Q1. How many patients have been treated in the past 3 months with the following agents for renal cell carcinoma (any stage):
a. Avelumab + Axitinib
b. Axinitib
c. Cabozantinib
d. Everolimus
e. Lenvantinib + Everolimus
f. Nivolumab monotherapy
g. Nivolumab + Cabozantinib
h. Nivolumab + Ipilimumab
i. Pazopanib
j. Pembrolizumab monotherapy
k. Pembrolizumab + Axitinib
l. Pembrolizumab + Lenvatinib
m. Radiotherapy only
n. Sunitinib
o. Temsirolimus
p. Tivozanib
q. Other active systemic anti-cancer therapy
r. Palliative care only
Q2. How many patients have been treated in the past 3 months with the following agents for melanoma (any stage) :
a. Cobimetinib
b. Dabrafenib
c. Dabrafenib AND Trametinib
d. Dacarbazine
e. Denosumab
f. Encorafenib AND Binimetinib
g. Ipilimumab
h. Ipilimumab AND Nivolumab
i. Nivolumab
j. Pembrolizumab
k. Trametinib
l. Vemurafenib
m. Vemurafenib AND Cobimetinib
n. Other active systemic anti-cancer therapy
o. Palliative care only
Q3. Does you trust participate in any clinical trials for the treatment of renal cell carcinoma? If so please provide the name of each trial and number of patients that are taking part?

Renal cell carcinoma and melanoma.271023.docx

Q1. How many patients have been treated in the past 3 months with the following agents for renal cell carcinoma (any stage):
a. Avelumab + Axitinib
b. Axinitib
c. Cabozantinib
d. Everolimus
e. Lenvantinib + Everolimus
f. Nivolumab monotherapy
g. Nivolumab + Cabozantinib
h. Nivolumab + Ipilimumab
i. Pazopanib
j. Pembrolizumab monotherapy
k. Pembrolizumab + Lenvatinib
l. Pembrolizumab + Axitinib
m. Radiotherapy only
n. Sunitinib
o. Temsirolimus
p. Tivozanib
q. Other active systemic anti-cancer therapy
r. Palliative care only
Q2. How many patients have been treated in the past 3 months with the following agents for melanoma (any stage):
a. Cobimetinib
b. Dabrafenib
c. Dabrafenib + Trametinib
d. Dacarbazine
e. Denosumab
f. Encorafenib + Binimetinib
g. Ipilimumab monotherapy
h. Ipilimumab + Nivolumab
i. Nivolumab monotherapy
j. Nivolumab + Relatlimab
k. Pembrolizumab
l. Trametinib
m. Vemurafenib
n. Vemurafenib + Cobimetinib
o. Other active systemic anti-cancer therapy
p. Palliative care only
Q3. Does you trust participate in any clinical trials for the treatment of melanoma? If so please provide the name of each trial and number of patients that are taking part?

Renal cell carcinoma and melanoma.280224.docx

Q1. How many patients have been treated in the past 3 months with the following agents for renal cell carcinoma:
a. Avelumab + Axitinib
b. Axinitib
c. Cabozantinib
d. Everolimus
e. Ipilimumab montherapy
f. Lenvantinib + Everolimus
g. Nivolumab monotherapy
h. Nivolumab + Cabozantinib
i. Nivolumab + Ipilimumab
j. Pazopanib
k. Pembrolizumab + Axitinib
l. Pembrolizumab + Lenvatinib
m. Pembrolizumab monotherapy
n. Radiotherapy only
o. Sunitinib
p. Temsirolimus
q. Tivozanib
r. Other active systemic anti-cancer therapy
s. Palliative care only
Q2. How many patients have been treated in the past 3 months with the following agents for melanoma (any stage):
a. Cobimetinib
b. Dabrafenib
c. Dabrafenib AND Trametinib
d. Dacarbazine
e. Encorafenib AND Binimetinib
f. Ipilimumab
g. Ipilimumab AND Nivolumab
h. Nivolumab
i. Pembrolizumab
j. Trametinib
k. Vemurafenib
l. Vemurafenib AND Cobimetinib
m. Other active systemic anti-cancer therapy
n. Palliative care only
Q3. If possible, could you please provide the patients treated in the past 3 months with the following agents for metastatic melanoma ONLY:
a. Ipilimumab
b. Ipilimumab AND Nivolumab
c. Nivolumab
d. Pembrolizumab
e. Any Targeted Therapy (Dabrafenib /Dabrafenib AND Trametinib /Encorafenib AND Binimetinib /Trametinib /Vemurafenib /Vemurafenib AND Cobimetinib)
f. Other active systemic anti-cancer therapy
g. Palliative care only
Q4. In the last 3 months, how many patients have undergone full or partial nephrectomy (any of the following OPCS codes M02.1, M02.2, M02.3, M02.4, M02.5, M03.1, M03.9, M04.2, M10.1 or M10.4)?

Renal cell carcinoma and melanoma.300623.docx

Q1. How many patients have been treated in the past 3 months with the following agents for renal cell carcinoma:
a. Avelumab + Axitinib
b. Axinitib
c. Cabozantinib
d. Everolimus
e. Lenvatinib + Everolimus
f. Nivolumab
g. Nivolumab + Cabozantinib
h. Nivolumab + Ipilimumab
i. Pazopanib
j. Pembrolizumab + Axitinib
k. Pembrolizumab + Lenvatinib
l. Pembrolizumab monotherapy
m. Radiotherapy only
n. Sunitinib
o. Temsirolimus
p. Tivozanib
q. Other active systemic anti-cancer therapy
r. Palliative care only
Q2. How many patients have been treated in the past 3 months with the following agents for melanoma (any stage):
a. Cobimetinib
b. Dabrafenib
c. Dabrafenib AND Trametinib
d. Dacarbazine
e. Encorafenib AND Binimetinib
f. Ipilimumab
g. Ipilimumab AND Nivolumab
h. Nivolumab
i. Pembrolizumab
j. Trametinib
k. Vemurafenib
l. Vemurafenib AND Cobimetinib
m. Other active systemic anti-cancer therapy
n. Palliative care only
Q3. If possible, could you please provide the patients treated in the past 3 months with the following agents for metastatic melanoma ONLY:
a. Cobimetinib
b. Dabrafenib
c. Dabrafenib AND Trametinib
d. Dacarbazine
e. Encorafenib AND Binimetinib
f. Ipilimumab
g. Ipilimumab AND Nivolumab
h. Nivolumab
i. Pembrolizumab
j. Trametinib
k. Vemurafenib
l. Vemurafenib AND Cobimetinib
m. Other active systemic anti-cancer therapy
n. Palliative care only
Q4. In the last 3 months, how many patients have undergone full or partial nephrectomy (any of the following OPCS codes M02.1, M02.2, M02.3, M02.4, M02.5, M03.1, M03.9, M04.2, M10.1 or M10.4)?

Renal cell carcinoma and melanoma.311022.docx

All questions are shown as received by the Trust.
Please can you confirm the number of Sentinel Lymph Node Biopsies undertaken in the 2023 calendar year?

Sentinel Lymph Node biopsies undertaken in the 2023 calendar year.231024.docx

I am writing to you under the Freedom of Information Act 2000 to request the following information from NAME OF TRUST, separated by the hospitals within your trust:
• A list of Single Chamber and Double Chamber CRM devices purchased in 2021

Single Chamber and Double Chamber CRM devices.150722.docx

1. What are your current skin cancer patient clinical pathway guidelines e.g., from initial patient symptoms in a GP setting to specialist referral as well as treatment and follow-up procedures and protocol.
2. Does your skin cancer pathway include remote patient-clinic interactions (as opposed to face-to-face interactions), Yes or No and if yes, elaborate what they are and what stage in the pathway they’re used e.g., teledermatology (the use of digital photography to assess patient lesions) at the GP stage.
3. What were your latest skin cancer pathway guidelines in 2019/2020 prior to the COVID-19 pandemic (announced as a pandemic by WHO on 11 March 2020).

Skin Cancer Pathway Management.270223.docx

All questions are shown as received by the Trust.
1. The number of patients who were on a waiting list at your Trust to start treatment following an urgent referral for any type of skin cancer for the each of the following financial years a) 2019/2020, b) 2020/21, c) 2021/22, d) 2022/2023 e) 2023/24

2. The number of patients who were on a waiting list at your Trust following an urgent referral for any type of skin cancer who waited longer than i) 62-days, ii) six-months, iii) 12-months to start treatment for the each of the following financial years a) 2019/2020, b) 2020/21, c) 2021/22, d) 2022/2023 e) 2023/24

3. The longest a patient waited who was on a waiting list at your Trust following an urgent referral for any type of skin cancer to start treatment in the financial year 2023/24

Skin cancer treatment times.240524.docx

I am researching Skin MDTs with regards to how they run, their efficacy and costs across the UK.
I am writing to your team for the following information by FOI request:
1. Venue
2. All staff present based on attendance records
3. Time spent by each team member in preparing for the SSMDT meeting
4. Time spent by team coordinator preparing for and disseminating SSMDT outcome
5. Running time in minutes of the SSMDT
6. Overheads as a percentage of total operating costs from the most recent financial year
7. Number of new cases discussed
8. Number of re-discussions discussed (re-discussion defined as any patient discussed at the same point in their pathway but following an additional test or any patient brought back to MDT for re-discussion of the same test results)
9. Were any videoconferencing facilities used across sites?

Skin MDT.310123.docx

Please note the questionnaire refers only to day patient chemotherapy units treating ADULTS with cancer. Please exclude answers for any units only treating children or non-cancer conditions.
1) Does your trust host one or more day patient chemotherapy unit (s)?
Yes / No (delete as appropriate)
If No, please return the questionnaire at this stage – no further questions need to be answered.
If Yes, how many day patient chemotherapy units does your trust host, and on how many sites?
i) Number of day patient chemotherapy units = (insert here)
ii) Number of different hospital sites within the trust that provide day patient chemotherapy = (insert here)
For each separate chemotherapy unit (service), please answer the following questions about the CURRENT situation at your Trust (please copy the template in order to respond for each unit separately):
2. For each chemotherapy unit please indicate the following:
a) Is it a static or mobile unit? (delete as appropriate) Mobile / Static
b) How many treatment chairs are there in the unit? (insert number)
c) What are the opening hours of the unit for patients (insert NA if not applicable)?
d) How many registered nurses are rostered to be on duty each day? (insert target number of staff per shift- fill in as appropriate for unit’s shift pattern)
e) How many Clinical Support Workers are rostered to be on duty each day? (insert target number of staff- fill in as appropriate for unit’s shift pattern)
f) How many patients have received SACT (chemotherapy and biological therapy) in the 12 month period to 31st August 2021?
3. For each chemotherapy unit, how many Whole Time Equivalent (WTE) members of staff are currently employed SPECIFICALLY in the chemotherapy unit in the following roles (please exclude any vacant positions from the number of WTE but include the number in vacancies column)?

Download response Staffing in Chemotherapy Units. 011121.docx

Please note the questionnaire refers only to day patient chemotherapy units treating ADULTS with cancer. Please exclude answers for any units only treating children or non-cancer conditions.
1) Does your trust host one or more day patient chemotherapy unit (s)?
Yes / No (delete as appropriate)
If No, please return the questionnaire at this stage – no further questions need to be answered.
If Yes, how many day patient chemotherapy units does your trust host, and on how many sites?
i) Number of day patient chemotherapy units =
ii) Number of different hospital sites within the trust that provide day patient chemotherapy =
For each separate chemotherapy unit (service), please answer the following questions about the CURRENT situation at your trust
2. For each chemotherapy unit please indicate the following:
a) Is it a static or mobile unit? (delete as appropriate) Mobile / Static
b) How many treatment chairs are there in the unit? (insert number)
c) What are the opening hours of the unit for patients (insert NA if not applicable)?
d) What services are provided within the unit? (delete as appropriate)
i) Group introductory sessions
ii) Individual introductory sessions
iii) Pre-chemotherapy assessments
iv) Peripherally inserted central catheter (PICC) insertion clinic
v) Phlebotomy
vi) Central line flush
vii) Non-medical or medical prescribing
viii) Supportive therapies (e.g. blood transfusions, IV fluids, bisphosphonates etc.)
ix) External chemotherapy administration services (e.g. homecare)
x) Clinical trial management
xi) Other services (please describe any additional services provided in the day unit by its staff)
e) How many registered nurses are rostered to be on duty each day? (insert target number of staff per shift- as appropriate for unit)
f) How many Clinical Support Workers are rostered to be on duty each day? (insert target number of staff)
g) How many patients have received SACT (chemotherapy and biological therapy) in the 12-month period to 31st August 2021?
h) How many SACT appointments were attended in the 12-month period to 31st August 2021?
3. For each chemotherapy unit, how many Working Time Equivalent (WTE) members of staff are currently employed SPECIFICALLY in the chemotherapy unit in the following roles (please exclude any vacant positions from the number of WTE but include the number of vacancies in brackets afterwards)?
Staff type
Registered nursing
Registered nursing associate
Clinical support staff
Medical staff
Operational management (non-nursing) (please describe)
Administration support (e.g. receptionist, scheduling) (please describe)
Pharmacist (please describe)
Non-clinical support staff (please describe)
Other (please describe)

Download response Staffing in Chemotherapy Units. 121021.docx

1. What is the name of the manufacturer of the Trust’s surgical power tool inventory? If more than one, please provide all.
2. Please provide the name of the maintenance and/or repair provider of the Trust’s surgical power tool inventory? If more than one, please provide all.
3. Please provide the expiry date of the existing maintenance contract for the Trust’s surgical power tool inventory? If more than one, please provide all.

Surgical power tool inventory. 240222.docx

Teleradiology.

You asked: All questions are shown as received by the Trust.
1. Please provide the names of the providers of each service (on-call and elective separately please)?
2. Start date, duration and end date of any contracts with teleradiology providers?
3. Can the contract be extended and how long for?
4. When do you start looking at the contract before expires?
5. Which framework do you use for teleradiology services?
o NHS supply chain
o Shared Business Services (SBS)
o Health Trust Europe (HTE)
o East of England NHS CPH (EOECPH)
o North of England CPC
o Other
6. What is the usual procurement process for teleradiology services, and is it typically carried out as part of an Integrated Care System (ICS) or through the respective Trust?
7. Who deals with the procurement of contracts for teleradiology?
8. Please provide the name and contact details of the Clinical Director for Radiology
9. Please provide the name and contact details of the General Manager for Radiology
10. Please provide the name and contact details of the Service manager for Radiology

Teleradiology.160823.docx

1. We would be grateful if you could send me a copy of the most recent Transfusion policy document for the Maidstone Trust.

2. Also would you be so kind to confirm whether the trust has operating cell salvage machines and have trained personnel familiar with it?

Transfusion policy and cell salvage machines. 120422.docx

Q1. How many patients has your trust treated (for any disease) in the last 6 months with the following treatments:
a. Doptelet (avatrombopag)
b. Jakavi (ruxolitinib)
c. Nplate (romiplostim)
d. Revolade (eltrombopag)
e. Tavlesse (fostamatinib)
f. Hydroxycarbamide
Q2. In the last 6 months, how many patients has your trust treated for:
a. Immune thrombocytopenia (ICD10 code D69.3)
b. Myelofibrosis (ICD10 code D47.4)
c. Myelofibrosis (ICD10 code D47.4) – patients over the age 65
Q3. Of the patients treated for immune thrombocytopenia (ICD10 code D69.3) in the last 6 months, how many were treated with:
a. Mycophenolate mofetil
b. Rituximab
c. Surgery (splenectomy)
Q4. How many myelofibrosis (ICD10 code D47.4) patients has your trust diagnosed in the past 3 years?
a. Of the myelofibrosis patients diagnosed in the last 3 years, how many were treated in the past 6 months with Hydroxycarbamide?
b. Of the myelofibrosis patients diagnosed in the last 3 years, how many have received no active treatment in the past 6 months?
Q5. Does your trust participate in any ongoing clinical trials for immune thrombocytopenia (ITP)? If so, can you please provide the name of each trial along with the number of patients taking part?
Q6. Does your trust participate in any ongoing clinical trials for myelofibrosis? If so, can you please provide the name of each trial along with the number of patients taking part?

Download response Treatment of blood disorders. 281021.docx

All questions are shown as received by the Trust.
1) In the past 6 months, at your trust how many patients were treated with a combination of Dabrafenib + Trametinib for the following conditions:
A) Metastatic Melanoma
B) Adjuvant Melanoma
C) BRAF mutated Lung Cancer

2) In the past 6 months, at your trust how many patients were treated with a combination of Encorafenib (Braftovi) + Binimetnib (Mektovi) for the following conditions:
A) Metastatic Melanoma
B) Colorectal Cancer

Treatment of Cancer using a Specific Combination of Drugs.251024.docx

All questions are shown as received by the Trust.
Q1. How many early-stage (non-metastatic or Stages 1-3) non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:
a. Atezolizumab (Tecentriq)
b. Durvalumab (Imfinzi)
c. Nivolumab (Opdivo)
d. Pembrolizumab (Keytruda)
e. Chemotherapy
f. Radiotherapy
g. Chemotherapy AND Radiotherapy
h. Osimertinib
Q2. How many patients were treated in the past 3 months for gastric and gastro-oesophageal junction cancer (any stage) with:
a. CAPOX (Capecitabine with Oxaliplatin)
b. FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin)
c. Lonsurf (Trifluridine – tipiracil)
d. Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)
e. Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)
f. Any other systemic anti-cancer therapy
g. Palliative care only
h. Zolbetuximab (Vyloy)

Treatment of certain types of cancer. 291124.docx

Over the latest 12 months of data that you have access to, how many patients who were diagnosed with HR+ adjuvant breast cancer received trastuzumab monotherapy?

Treatment of HR+ adjuvant breast cancer.091222.docx

Q1. In the past 3 months (or the latest 3 months data you have available), how many metastatic non-small cell lung cancer (NSCLC) patients were treated with any of the following:
a. Afatinib
b. Alectinib
c. Atezolizumab monotherapy
d. Atezolizumab in combination
e. Bevacizumab
f. Brigatinib
g. Capmatenib
h. Ceritinib
i. Crizotinib
j. Dacomitinib
k. Dabrafenib with Trametinib
l. Docetaxel monotherapy
m. Durvalumab
n. Erlotinib
o. Gefitinib
p. Gemcitabine
q. Nintedanib with Docetaxel
r. Nivolumab
s. Osimertinib
t. Paclitaxel
u. Pembrolizumab monotherapy
v. Pembrolizumab in combination
w. Pemetrexed with Carboplatin/Cisplatin
x. Tepotinib
y. Vinorelbine with Cisplatin/Carboplatin
z. Any other SACT
aa. Palliative care only

Treatments for Lung Cancer.080922.docx

Question 1 – In the past three months, how many patients were treated for Triple-Negative Breast Cancer with the following:
a) Anthracycline (e.g. doxorubicin) as a single agent
b) Atezolizumab + nab-paclitaxel or paclitaxel
c) Capecitabine as a single agent
d) Eribulin as a single agent
e) Eribulin + other chemotherapy
f) PARP inhibitor (e.g. Olaparib)
g) Platinum (e.g. carboplatin, cisplatin) as a single agent
h) Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent
i) Other single agent chemotherapy
j) Other chemotherapy combination
k) Other immunotherapy containing regimen
l) Other active systemic anti-cancer therapy
Question 2 – How many of these Triple-Negative Breast Cancer patients treated in the last three months received treatment that was:
a) Privately funded
b) Part of clinical trial
c) Part of an early access scheme

Download response Triple-Negative Breast Cancer. 261021.docx

Could you please tell me how many patients you have treated for Triple Negative breast cancer in the last 3 months with the following systemic anti-cancer therapies:
a) Anthracycline (e.g. doxorubicin) as single agent
b) Atezolizumab + nab-paclitaxel or paclitaxel
c) Capecitabine as a single agent
d) Eribulin as a single agent or in combination
e) PARP inhibitor (e.g. Olaparib)
f) Pembrolizumab + chemotherapy
g) Platinum (e.g. carboplatin, cisplatin) as a single agent
h) Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent
i) Taxane + Anthracycline based combinations
j) Vinorelbine as a single agent
k) Other active systemic anti-cancer therapy

Triple-Negative (ER negative, PR negative and HER2 negative) breast cancer. 110322.docx

1. Would you be able to clarify what devices are used within the Trophon machines?
2. In what areas the machines are located?
3. What product(s) are currently being used to pre-clean and high level disinfect the cable/plug?

Download response Trophon machines. 011221.docx

1. Please can you provide the most recent data available that details the total number of urological cancer referrals in 2021
2. Please can you provide data showing the total number of urological cancer referrals in 2020
3. Please can you provide data showing the total number of urological cancer referrals in 2019
4. Please can you provide data showing the total number of urological cancer referrals in 2018
5. Please can you provide data showing the total number of urological cancer referrals in 2017

Urological cancer referrals. 130422.docx

1. In the past 3 months, how many patients have been treated for urothelial cancer with the following agents?

a. Avelumab
b. Atezolizumab
c. Carboplatin with Gemcitabine
d. Carboplatin single or in any other combination
e. Cisplatin with Gemcitabine
f. Cisplatin single or in any other combination
g. Nivolumab
h. Pembrolizumab
i. Any other systemic anti-cancer therapy
j. Palliative care only

2. Does your trust participate in any ongoing clinical trials for the treatment of urothelial cancer? If so, can you please provide the name of each trial along with the number of patients taking part?

3. In the past 3 months, how many patients have been treated for colorectal cancer [CRC] with the following agents?

a. Aflibercept
b. Bevacizumab
c. Capecitabine
d. CAPIRI
e. CAPOX (XELOX)
f. Cetuximab in combination with FOLFIRI/FOLFOX
g. Cetuximab not in combination with FOLFIRI or FOLFOX
h. Irinotecan only
i. FOLFIRI
j. FOLFOX
k. Fluorouracil (5FU) only
l. Oxaliplatin only
m. Nivolumab
n. Panitumumab in combination with FOLFIRI/FOLFOX
o. Panitumumab not in combination with FOLFIRI or FOLFOX
p. Pembrolizumab
q. Raltitrexed
r. Ramucirumab
s. Regorafenib
t. Tegafur + Uracil
u. Any other systemic anti-cancer therapy
v. Palliative care only

Urothelial and Colorectal Cancer.270723.docx

Q1. How many urothelial cancer patients have been treated in the past 3 months with the following agents:
a. Avelumab
b. Atezolizumab
c. Carboplatin with Gemcitabine
d. Carboplatin single or in any other combination
e. Cisplatin with Gemcitabine
f. Cisplatin single or in any other combination
g. Nivolumab
h. Pembrolizumab
i. Any other regimen including Paclitaxel
j. Any other chemotherapy regimen
k. Other active systemic anti-cancer therapy
l. Palliative care only
Q2. How many colorectal cancer [CRC] patients have been treated in the past 3 months with the following agents:
a. Aflibercept
b. Bevacizumab
c. Capecitabine
d. CAPIRI
e. CAPOX (XELOX)
f. Cetuximab in combination with FOLFIRI
g. Cetuximab in combination with FOLFOX
h. Cetuximab not in combination with FOLFIRI or FOLFOX
i. Irinotecan only
j. FOLFIRI
k. FOLFOX
l. Fluorouracil (5FU) only
m. Oxaliplatin only
n. Panitumumab in combination with FOLFIRI
o. Panitumumab in combination with FOLFOX
p. Panitumumab not in combination with FOLFIRI or FOLFOX
q. Pembrolizumab
r. Nivolumab
s. Raltitrexed
t. Ramucirumab
u. Regorafenib
v. Sorafenib
w. Other active systemic anti-cancer therapy
x. Palliative care only

Urothelial and Colorectal Cancer.280323.docx

All questions are shown as received by the Trust.
Q1. Do you treat patients for Urothelial cancer (Yes or No)? If No, where do you refer patients for treatment
Q2. How many patients were treated for Urothelial cancer (any stage) in the past 3 months with the following treatments:
a. Atezolizumab (Tecentriq)
b. Avelumab (Bavencio)
c. Carboplatin single agent or in any other combination
d. Carboplatin with Gemcitabine
e. Carboplatin with Paclitaxel
f. Cisplatin single agent or in any other combination
g. Cisplatin with Gemcitabine
h. Cisplatin with Gemcitabine + Nivolumab (Opdivo)
i. Enfortumab Vedotin + Pembrolizumab (Padcev + Keytruda)
j. Nivolumab (Opdivo)
k. Pembrolizumab (Keytruda)
l. Other active systemic anti-cancer therapy
m. Palliative care only
Q3. Does your trust participate in any ongoing clinical trials for the treatment of urothelial cancer? If so, can you please provide the name of each trial along with the number of patients taking part?
Q4. How many early-stage (non-metastatic or Stages 1-3) non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:
a. Atezolizumab (Tecentriq)
b. Durvalumab (Imfinzi)
c. Nivolumab (Opdivo)
d. Pembrolizumab (Keytruda)
e. Chemotherapy
f. Radiotherapy
g. Chemotherapy AND Radiotherapy

Urothelial cancer and non-small cell lung cancer (NSCLC).160824.docx

All questions are shown as received by the Trust.
1. How many patients were treated for Urothelial cancer (any stage) in the past 3 months with the following treatments:
a. Atezolizumab (Tecentriq)
b. Avelumab (Bavencio)
c. Carboplatin single agent or in any other combination
d. Carboplatin with Gemcitabine
e. Carboplatin with Paclitaxel
f. Cisplatin single agent or in any other combination
g. Cisplatin with Gemcitabine
h. Cisplatin with Gemcitabine + Nivolumab (Opdivo)
i. Enfortumab Vedotin + Pembrolizumab (Padcev + Keytruda)
j. Nivolumab (Opdivo)
k. Pembrolizumab (Keytruda)
l. Other active systemic anti-cancer therapy
m. Palliative care only
2. Does your trust participate in any ongoing clinical trials for the treatment of urothelial cancer? If so, can you please provide the name of each trial along with the number of patients taking part?

Urothelial cancer (any stage).201124.docx

1. Do you have a Virtual Ward?
If yes,
a. For what specialities and care pathway have you implemented Virtual Wards?
b. How many Virtual Ward beds do you have?
c. Do you know how many Virtual Ward beds you need? If so, how many?
d. Who is your Virtual ward provider(s)?
If no,
e. Do you intend to implement a Virtual Ward?
f. If yes, have you identified and engaged a Virtual Ward provider?
g. Do you know how many Virtual Ward beds you need? If so, how many?
h. Do you have an internal Virtual Ward lead?

Virtual wards.260423.docx

Please enter ‘No System Installed’ or ‘No Department’ under supplier name if your trust does not use the system or have the department:
1. System type – Vendor Neutral Archive
2. Supplier name
3. System name –
4. Date installed –
5. Contract expiration –
6. Is this contract annually renewed? – Yes/No
7. Do you currently have plans to replace this system? – Yes/No
8. Procurement framework –
9. Other systems it integrates with? –
10. Total value of contract (£) –
11. Notes – e.g. we are currently out to tender

VNA Systems query (Vendor Neutral Archive – A picture archiving and communications system is used for diagnostic images.)270723.docx

1. Your Trusts current waiting list for a non-urgent x-ray and the waiting list for a non-urgent X-ray in July 2022
2. Your Trusts current waiting list for a CT scan and the waiting list for a CT scan in July 2022
3. Your Trusts current waiting list for an MRI and the waiting list for an MRI in July 2022
4. Your Trusts current waiting list for a PET scan and the waiting list for a PET scan in July 2022
5. Your Trusts current waiting list for an Ultrasound and the waiting list for an Ultrasound scan in July 2022
6. Your Trusts current waiting list for an Angiography and the waiting list for an Angiography scan in July 2022
7. Your Trusts current waiting list for an Electrocardiogram and the waiting list for an Electrocardiogram in July 2022
8. Your Trusts current waiting list for an Echocardiogram scan and the waiting list for an Echocardiogram in July 2022

Waiting list for scans and X-rays.060224.docx

1. Please can you provide the following information for each Mobile X-ray Systems within the Trust or associated sites? (Please complete the attached spreadsheet)
a. Manufacturer
b. Model
c. Location – Hospital Name or Site Name
d. Department equipment is primarily used in
e. Method of Finance at Procurement – Trust/Lease/MES/Charity/PFI
f. Initial cost of Equipment
g. Annual Maintenance cost
h. Acquisition Date
i. Planned Replacement Date
2. Please can you provide the following information for each Fixed X-ray Rooms within the Trust or associated sites? (Please complete the attached spreadsheet)
a. Manufacturer
b. Model
c. Digital / Analogue
d. Location – Hospital Name or Site Name
e. Department equipment is primarily used in
f. Method of Finance at Procurement – Trust/Lease/MES/Charity/PFI
g. Initial cost of Equipment
h. Annual Maintenance cost
i. Acquisition Date
j. Planned Replacement Date
3. Please can you provide the following information for each Mammography system within the Trust or associated sites? (Please complete the attached spreadsheet)
a. Manufacturer
b. Model
c. Screening / Symptomatic
d. Location – Hospital Name or Site Name
e. Mobile / Static
f. Department equipment is primarily used in (e.g. Radiology, Surgery, A&E)
g. Method of Finance at Procurement – Trust/Lease/MES/Charity/PFI
h. Initial cost of Equipment
i. Annual Maintenance cost
j. Acquisition Date
k. Planned Replacement Date
FOI Imaging Equipment Request
4. Please can you provide the following information for each Dental / OPG X-ray equipment within the Trust or associated sites? (Please complete the attached spreadsheet)
a. Manufacturer
b. Model
c. Digital / Analogue
d. Location – Hospital Name or Site Name
e. Department equipment is primarily used in
f. Method of Finance at Procurement – Trust/Lease/MES/Charity/PFI
g. Initial cost of Equipment
h. Annual Maintenance cost
i. Acquisition Date
j. Planned Replacement Date
5. Please can you provide the following information for each Cone Beam CT X-ray equipment within the Trust or associated sites? (Please complete the attached spreadsheet)
a. Manufacturer
b. Model
c. Digital / Analogue
d. Location – Hospital Name or Site Name
e. Department equipment is primarily used in
f. Method of Finance at Procurement – Trust/Lease/MES/Charity/PFI
g. Initial cost of Equipment
h. Annual Maintenance cost
i. Acquisition Date
j. Planned Replacement Date

Download response X-ray equipment. 131021.docx

1. What are the contractual performance KPI’s for this contract?
2. Suppliers who applied for inclusion on each framework/contract and were successful & not successful at the PQQ & ITT stages
3. Actual spend on this contract/framework (and any sub lots), from the start of the contract to the current date
4. Start date & duration of framework/contract?
5. Could you please provide a copy of the service/product specification given to all bidders for when this contract was last advertised?
6. Is there an extension clause in the framework(s)/contract(s) and, if so, the duration of the extension?
7. Has a decision been made yet on whether the framework(s)/contract(s) are being either extended or renewed?
8. Who is the senior officer (outside of procurement) responsible for this contract?

Car park management contract.140923.docx

Based on your latest available data,
1. How many fines have been handed out to members of staff at your Trust over the past five years for issues related to car parking? This could include parking in the wrong area, not having a permit etc.
2. How many staff does your Trust currently have
3. How many of these currently have a car parking permit?
4. How many are on the waiting list to receive a permit?
If possible, please provide data broken down by year by calendar year. Spreadsheet format preferred if possible.

Car parking.110324.docx

All questions are shown as received by the Trust.
1. a list of all of the measurements you record to understand parking demand and availability
2. the data for those measurements for the past 5 years.
3. a copy of the any plans you have in respect of parking improvement

Car parking.140224.docx

All questions are shown as received by the Trust.
1) How much money the trust made from car parking charges in 2022/23 (i.e the year ending March 2023) and in 2023/24 (i.e. the year ending March 2024).
For both years, could you please give:
a) the overall total
b) if possible, separate figures for staff and visitor/patient parking
2) How much money was made from car parking fines in 2022/23 and 2023/24.
For both years, could you please give:
a) the overall total
b) if possible, separate figures for staff and visitor/patient parking
3a) Did you increase the cost of parking in your car parks from 2022/23 to 2023/24?
b) If yes, please provide a breakdown of the increase(s)
4) Did you charge for disabled parking in 2023/24?
5a) Were any of your car parks managed by a private firm in 2023/24?
b) If yes, what proportion of revenue from parking income did the firm take?
c) What proportion of revenue from parking fines did the firm take?

Car parking.270624.docx

Can you please confirm if you planning to extend the current contract with APCOA or extend, if so could you please confirm for how long?

Download response Car parking contract. 051021.docx

1. Could you please advise me if you manage the car parking facilities on your own, or do you employ a private operator/contractor to manage the facilities for you i.e., ANPR, POFs and PCNs etc?
2. If you use a private operator/contractor, can you please advise me who they are and when their existing contract with yourselves expires?

Car parking facilities.180123.docx

All questions are shown as received by the Trust.
1. Financial Revenue and Distribution:
How much revenue was generated from parking fees charged to NHS staff for the last financial year?
a. Of this revenue, what percentage or amount was paid to private parking management companies?
2. Private Companies Profiting:
Can you provide a list of the private parking companies that have benefited from these arrangements within the last financial year?
3. Revenue Breakdown:
Please provide a breakdown of the revenue generated from parking fees and fines, per hospital or area within your trust, for the last financial year.

Financial Details and Operations of Private Parking Arrangements for NHS Staff.050624.docx

1. Do you provide free parking for NHS staff and/or patients?
2. If not, how much do you charge staff to park?
3. how long does it take for staff to be issued a permit when joining your trust?

Free NHS Staff Parking.220722.docx

All questions are shown as received by the Trust.
1. The total number of parking charge notices issued within the last 2 calendar years (2022 and 2023) and the year-to-date for 2024 at all hospitals operated by your NHS Trust.
2. The total revenue generated from these parking charge notices for the last 2 calendar years (2022 and 2023) and the year-to-date for 2024, broken down by each individual hospital operated by your NHS Trust.
3. The current pricing structure for parking at each hospital operated by your NHS Trust, including the cost for different lengths of stay (e.g. 0-1 hour, 1-2 hours, 2-3 hours, daily rate, etc.).

Hospital parking.050924.docx

All questions are shown as received by the Trust.
Please could I be given any information the hospital has on plans to improve the parking at the hospital? (Either though price scheme – or to build more capacity)

Parking at Maidstone Hospital.120224.docx

1. How much money was generated by your hospital trust through parking charges in the hospital car parks during 2017-18, 2018-19, 2019-20, 2020-21, 2021-22 and 2022-23 to date?
2. Can you please break this down – revenue generated through public parking and revenue generated through staff parking?
3. How many parking fines were issued for parking infringements in the car parks during the years stated above?
4. How many parking fines were written off during the years stated above?

Parking charges.150722.docx

Please confirm how many complaints you have received regarding the number of spaces, over the last 3 years, on a monthly basis. Please regard that as a request under the freedom of information act.

Parking complaints for Tunbridge Wells Hospital.270223.docx

1. Who currently manages the car parks run for/by the trust?
2. Do you outsource the parking management to a 3rd party. If so, to who?
3. How many parking related complaints have you received over the last 12 months, split per hospital within the trust?
4. Do you use Automatic Number Plate Recognition for parking enforcement at any of the hospitals, and if so, at which ones?
5. How much money was raised through people paying to park at the trust, split per hospital over the last 12 months?
6. When were the existing payment machines installed, and can people pay using a credit/debit card at all machines?
7. Can users pay to park using a mobile phone-based APP, if so, which one?
8. How many parking charge notices (PCN’s) were issued during the last 12-month period?
9. How much money was generated for the trust by people paying enforcement notices, split per hospital over the last 12 months?

Parking operations, impact, and parking charge notices.110823.docx

1. Who is responsible for the parking management? (Job title)
2. Do you outsource your current parking services management?
1. If you DO outsource:
1. What is the total size of the contract in terms of costs paid? (If this is broken down into smaller parts of the contract, please provide details)
2. What contract type do you currently have? Management (i.e. site is owned by you but managed by a third-party) or Concession (site is owned and managed by third-party)
1. What services are required as part of the contract? (e.g. wardens/revenue collection, security staff, backend services)
2. Is there future potential for capacity increase or the addition of further services?
3. Who is your current parking provider?
4. Which other providers have you used in the last 20 years, if any? (Please provide details of recent contracts and providers, with dates)
5. When did your current contract start? When does the contract end? Is there an extension period, and if so how long is it?
1. When going out to tender, do you use a framework or is it an open tender?
2. Do you usually engage with the market before the tender? If so, how?
2. If you DO NOT outsource:
1. Would you consider outsourcing the parking asset management to an external provider in the future?
2. If so, in what circumstances would you do this?

Parking services management arrangements.180523.docx

1. How much is an annual parking permit for a full-time member of nursing staff?
2. How much is a monthly parking permit for a full-time member of nursing staff?
3. If there is more than one hospital site at your trust, are the permit charges the same for each site? If they differ, please specify.
4. How much does it cost for a member of staff without a permit to park at the trust for 12 hours? How much to park beyond 12 hours?
5. Is the annual/monthly cost of a parking permit the same price for all members of staff, or determined by pay band?
6. Are nursing students on placements able to apply for a permit? Or are they exempt from parking charges?
7. Does the trust supply its own parking services or is it contracted out to a company? If so, who?

Staff parking charges.190123.docx

All questions are shown as received by the Trust.
1. The longest time it took for a person aged 18 and under to be seen after arriving at your Trust’s Accident and Emergency department broken down by each of the years a) 2018, b) 2019, c) 2020, d) 2021, e) 2022, g) 2023 so far
2. The number of people aged 18 and under waiting more than four hours to be seen after arriving at your Trust’s Accident and Emergency department broken down by each of the years a) 2018, b) 2019, c) 2020, d) 2021, e) 2022, g) 2023 so far
3. The number of people under the aged 18 and under waiting more than twelve hours to be seen after arriving at your Trust’s Accident and Emergency department broken down by each of the years a) 2018, b) 2019, c) 2020, d) 2021, e) 2022, g) 2023 so far
4. The number of people aged 18 and under seen by your Trust’s Accident and Emergency department broken down by each of the years a) 2018, b) 2019, c) 2020, d) 2021, e) 2022, g) 2023 so far.

Accident and emergency delays for children.170724.docx

All questions are shown as received by the Trust.
1. The longest time it took for a person aged 18 and under to be seen after arriving at your Trust’s Accident and Emergency department broken down by each of the years a) 2018, b) 2019, c) 2020, d) 2021, e) 2022, g) 2023 so far
2. The number of people aged 18 and under waiting more than four hours to be seen after arriving at your Trust’s Accident and Emergency department broken down by each of the years a) 2018, b) 2019, c) 2020, d) 2021, e) 2022, g) 2023 so far
3. The number of people under the aged 18 and under waiting more than twelve hours to be seen after arriving at your Trust’s Accident and Emergency department broken down by each of the years a) 2018, b) 2019, c) 2020, d) 2021, e) 2022, g) 2023 so far
4. The number of people aged 18 and under seen by your Trust’s Accident and Emergency department broken down by each of the years a) 2018, b) 2019, c) 2020, d) 2021, e) 2022, g) 2023 so far.

Accident and emergency delays for children.170724.docx

QUESTION 1
A. How many children are currently waiting to receive a first assessment appointment?
B. What is the average wait time for these children, starting from the point of initial referral?
C. How many of these children have been waiting longer than 13 weeks?
D. What are the longest three wait times for these children?
QUESTION 2
A. How many children are currently waiting to receive a second assessment appointment?
B. What is the average wait time for these children to receive a second appointment, since their first appointment?
C. What are the longest three wait times for these children, since their first appointment?
QUESTION 3
A. How many children are currently waiting to receive a diagnosis (ie. waiting for an assessment outcome to find out whether they do or do not have ASD)?
B. What is the average wait time, since the point of initial referral?
C. What are the longest three wait times for these children, since their initial referral?
QUESTION 4
A. In the year up to 31 March 2022, how many children with suspected autism received a first assessment appointment?
B. What was the average wait time for these children to receive a first assessment appointment, since their initial referral?
C. What were the longest three wait times for these children to receive a first diagnostic appointment, since their initial referral??
QUESTION 5
A. In the year up to 31 March 2022, how many children with suspected autism received a second assessment appointment?
B. What was the average wait time for these children to receive a second diagnostic appointment, since their first appointment?
C. What were the longest three wait times for these children to receive a second assessment appointment, since their first appointment?
QUESTION 6
A. In the year up to 31 March 2022, how many children with suspected autism received an ASD diagnosis?
B. What was the average wait time for these children to receive an ASD diagnosis, since their initial referral?
C. What were the longest three wait times for these children to receive an ASD diagnosis, since their initial referral?
QUESTION 7
A. In the year up to 31 March 2021, how many children with suspected autism received a first assessment appointment?
B. What was the average wait time for these children to receive a first assessment appointment, since their initial referral?
QUESTION 8
A. In the year up to 31 March 2021, how many children with suspected autism received a second assessment appointment?
B. What was the average wait time for these children to receive a second diagnostic appointment, since their first appointment?
QUESTION 9
A. In the year up to 31 March 2021, how many children with suspected autism received an ASD diagnosis?
B. What was the average wait time for these children to receive an ASD diagnosis, since their initial referral?
QUESTION 10
A. In the year up to 31 March 2020, how many children with suspected autism received a first assessment appointment?
B. What was the average wait time for these children to receive a first assessment appointment, since their initial referral?
QUESTION 11
A. In the year up to 31 March 2020, how many children with suspected autism received a second assessment appointment?
B. What was the average wait time for these children to receive a second diagnostic appointment, since their first appointment?
QUESTION 12
A. In the year up to 31 March 2019, how many children with suspected autism received an ASD diagnosis?
B. What was the average wait time for these children to receive an ASD diagnosis, since their initial referral?
QUESTION 13
A. In the year up to 31 March 2020, how many children with suspected autism received an ASD diagnosis?
B. What was the average wait time for these children to receive an ASD diagnosis, since their initial referral?
QUESTION 14
A. In the year up to 31 March 2019, how many children with suspected autism received a first assessment appointment?
B. What was the average wait time for these children to receive a first assessment appointment, since their initial referral?
QUESTION 15
A. In the year up to 31 March 2019, how many children with suspected autism received a second assessment appointment?
B. What was the average wait time for these children to receive a second diagnostic appointment, since their first appointment?